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Chapter 1: 
General introduction. Circulating versus tissue renin 
angiotensin system: on the origin of prorenin
Based on:
Krop M, Danser AHJ. Circulating versus tissue renin-angiotensin system: on the 
origin of (pro)renin. Current Hypertension report. 2008 Apr; 10(2):112-8. 
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ABSTRACT
Angiotensin synthesis at tissue sites is well-established, and interference with tissue 
angiotensin is now believed to underlie the beneficial effects of renin-angiotensin system 
blockers. At first it was thought that the renin required to synthesize angiotensin at tissue 
sites was also synthesized locally. Recent studies show, however, that this is not the case at 
important cardiovascular sites like the heart and vessel wall. Moreover, extrarenal sites that 
do express the renin gene release prorenin, the inactive precursor of renin, instead of renin. 
This chapter provides an update on the sources of (pro)renin in the body, lists the known 
stimulants and inhibitors of its production, and discusses the concept that prorenin rather 
than renin determines tissue angiotensin generation. 
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 INTRODUCTION
Angiotensin (Ang) production at tissue sites is now well-established.1 Such local production 
efficiently allows Ang II to stimulate its receptors,2 with little Ang II spillover to blood. 
Yet, in contrast to what was originally believed, not all components required to generate 
Ang II locally are actually synthesized at tissue sites. In particular, renin is not expressed 
locally at important cardiovascular tissue sites like the heart and vessel wall.3, 4 Since renin 
is indispensable for angiotensin generation, this implies that such tissues must sequestrate 
renin from blood. Alternatively, these tissues might sequester prorenin, particularly because 
the levels of this inactive renin precursor are much higher than those of renin.5 To allow 
prorenin to contribute to angiotensin generation, it should be converted locally to renin. 
 Remarkably, it is prorenin, and not renin, that remains detectable in blood following 
a bilateral nephrectomy, although its levels are lower than in normal subjects. This suggests 
that the kidney is the main, if not the only, source of renin in the body, but that there are 
other tissues releasing prorenin into the circulation. Extrarenal prorenin might contribute to 
tissue angiotensin generation in the absence of renin/prorenin release from juxtaglomerular 
(JG) cells. This chapter provides an update on the sources of (pro)renin, lists the known 
stimulants and inhibitors of its production, and discusses the concept of prorenin activation 
at tissue sites. 
KIDNEY
Juxtaglomerular cells
The JG epithelioid cells, located in the walls of renal afferent arterioles at the entrance of the 
glomerular capillary network, are the main source of renin in the body. Renin is synthesized 
as preprorenin. Preprorenin is converted to prorenin on insertion into the endoplasmatic 
reticulum. The majority (75%) of prorenin is secreted constitutively, while the remainder is 
targeted to dense core secretory granules. In the secretory granules, an acidic pH is created 
by vacuolar H+-ATPases to optimize the activity of the proteases (cathepsin B, prohormone 
convertases) that cleave off the 43-amino acid prosegment to yield renin.6 Glycosylation 
affects the amount of prorenin trafficking to dense core secretory vesicles.7 Acute stimulation 
of renin release leads to an increase in the release of mature renin secretory granules that 
contain only renin, while chronic stimulation leads to an increased release of both renin and 
prorenin. This is due to activation of the renin synthetic pathway and/or the recruitment of 
new juxtaglomerular cells. The granular volume and the number of granules per cell usually 
remain the same. Yet, chronic stimulation causes more prorenin to be converted to renin, 
leading to an increased renin/prorenin ratio in plasma.5
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 Well-known stimulants of renin secretion are the sympathetic nervous system 
(via β1-adrenoceptor stimulation), low renal perfusion pressure and sodium depletion. 
Stimulation of Ang II type 1 (AT
1
) receptors receptors inhibits renin release, and thus, 
during renin-angiotensin system (RAS) blockade, renin levels will rise. β
1
-adrenoceptors 
activate adenylyl cyclase, inducing exocytosis of the renin-containing granules via increased 
cAMP levels. Other adenylyl cyclase activators, like prostaglandin E
2
, prostaglandin 
I
2
, adrenomedullin, dopamine and calcitonin gene-related peptide also stimulate renin 
release. Nitric oxide (NO), through activation of soluble guanylyl cyclase, induces the 
generation of cGMP, which, by blocking phosphodiesterase, indirectly increases the levels 
of cAMP. Thus, NO also stimulates renin secretion. Conversely, activation of particular 
guanylate cyclases by natriuretic peptides inhibits renin secretion, possibly via a process 
involving cGMP-dependent protein kinase II. Paradoxically, calcium inhibits exocytosis, 
and therefore, calcium-mobilizing hormones like Ang II, endothelin and vasopressin, as 
well as α
1
-adrenoceptor agonists, will block renin secretion. Recent studies have provided 
the molecular basis of this phenomenon: Ca2+ directly reduces the cAMP levels through 
interference with the calcium-sensitive isoforms of adenylyl cyclase (AC5 and AC6) that are 
expressed in the JG cells.8 
Collecting duct
The principal cells of the collecting duct synthesize renin, and remarkably, Ang II 
stimulates renin expression at this site,9 as opposed to its inhibitory effects in JG cells. Using 
angiotensinogen from proximal tubule cells as a substrate, collecting duct-derived renin 
may contribute to the generation of Ang II that acts in the proximal and distal tubulus. This 
Ang II augments H+ secretion and Na+ absorption, possibly by interfering with vacuolar 
H+-ATPase activity .10 Kang et al.11 recently suggested that prorenin is stored in the collecting 
duct, and that such prorenin is the source of the elevated prorenin levels found in diabetic 
subjects.     
ADRENAL
The adrenal gland contains the highest renin concentration next to the kidney, and the adrenal 
renin-angiotensin system (RAS) is a well-known regulator of aldosterone production. Renin 
protein and renin mRNA occur predominantly (>90%) in the steroid-producing cells of the 
zona glomerulosa.12 A low-sodium diet increases, whereas a high-sodium diet decreases the 
adrenal renin content. Adrenocorticotrophic hormone (ACTH), cAMP and high potassium all 
stimulate adrenal renin, and the strongest stimulus of adrenal renin is nephrectomy, possibly 
because ACTH and potassium increase post-nephrectomy. Cultured zona glomerulosa cells 
predominantly contain renin, but release prorenin. Ang II has a dual effect in glomerulosa 
cells: it weakly increases (pro)renin synthesis and release, but simultaneously it blocks the 
ACTH-induced stimulatory effects on (pro)renin production.13
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 Analysis of adrenal RNA revealed the existence of 2 renin transcripts in the 
adrenal: the known full-length transcript, and a transcript lacking exon 1.14 Translation of 
this second mRNA results in a truncated prorenin, lacking the endoplasmatic reticulum 
signal and part of the prosegment. Such prorenin will remain in the cell, and might display 
catalytic activity. Possibly, it accumulates in the mitochondria,14 i.e., the site of aldosterone 
synthesis. Its function, if any, is not known.
EYE
As discussed above, chronic stimulation of the RAS generally increases renal prorenin to 
renin conversion, thereby decreasing the relative amount of prorenin in the circulation. There 
are some exceptions to this rule. A very striking example is diabetes mellitus complicated 
by retinopathy and nephropathy.15 Prorenin levels increase with the severity of retinopathy, 
and it has therefore been speculated that this prorenin originates, at least in part, in the 
eye.16, 17 Indeed, the prorenin levels in ocular fluids are up to 100 times higher than expected 
on the basis of the plasma protein content of these fluids, and prorenin was higher in vitreous 
fluid from eyes with proliferative diabetic retinopathy, than in eyes of non-diabetic subjects 
with spontaneous retinal detachment.16 Renin in ocular fluids was low or undetectable. 
Furthermore, human retina and pigment epithelium-choroid contained renin mRNA,18 
whereas renin synthesis was subsequently confined to the macroglial Müller cells in the 
rat eye.19 The endfeet of these cells make numerous contacts with retinal blood vessels, 
thereby suggesting that ocular prorenin is involved in neovascularization. Whether prorenin 
is released from ocular tissue sites into the blood remains to be proven. Based on the existing 
prorenin levels in the eye,16, 17 it seems impossible however, given the low ocular blood flow, 
that the eye is a major contributant to the rise in prorenin in diabetics with retinopathy.  
MAST CELLS
Silver et al.20 discovered that in the rat heart, renin co-stained with mast cells. Also, when 
culturing the human mastocytoma cell line HMC-1, stimulation with a mast cell degranulator 
released Ang I-generating activity. Mackins et al. subsequently showed that the coronary 
effluent of the isolated perfused guinea pig heart contained Ang I-generating activity after 
exposure of the heart to the mast cell degranulator compound 48/80.21 Moreover, mast cell-
derived Ang I-generating activity appeared to contribute to the norepinephrine release and 
arrhythmias occurring after ischemia and reperfusion in guinea pig and mouse hearts. 
These data contrast with earlier studies failing to detect renin in the heart after a bilateral 
nephrectomy,3, 22 and thus definite proof should now be obtained to ascertain that the mast 
cell-derived Ang I-generating activity in the coronary effluent truly represents renin.   
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REPRODUCTIVE SYSTEM
The reproductive system is a major source of prorenin. In men, prorenin is produced in the 
testis. In women, the ovaries, the uterus and, during pregnancy, the placenta are sources 
of prorenin. During pregnancy, a distinction should be made between prorenin-secreting 
tissues of maternal and of embryonic origin. Of maternal origin are the decidua, which 
corresponds with the endometrium in the non-pregnant state, and the ovaries. Of embryonic 
origin are the placenta, the amnion and the chorion. 
Ovaries
The ovary secretes prorenin into the circulation and produces high plasma prorenin levels 
during early pregnancy and in women with hyperstimulated cycles.23 The rise in prorenin is 
directly related to the number of ovarian follicles, and theca cell-stimulation by luteinizing 
hormone (LH) or human chorionic gonadotropin (hCG) is responsible for this prorenin 
release.24 The release depends on de novo prorenin synthesis via the adenylyl cyclase-cAMP 
pathway, and both protein kinase C (PKC) activation and tumor necrosis factor α (TNFα) 
inhibit it.25 Studies during pregnancy in a woman with primary ovarian failure26 provided 
definite proof for the ovarian origin of prorenin. Follicular fluid prorenin levels are >10 
times higher than those in plasma, and correlate inversely with follicular atresia.27 This 
suggests that prorenin affects follicular development and oocyte maturation.   
Uterus/Decidua
Decidual cells contain and release prorenin, but not renin.28, 29 The total renin content of 
decidual homogenates is 3-fold larger than that in endometrial homogenates, suggesting 
that pregnancy enhances renin production by the cells lining the uterus. Decidual 
prorenin release occurs constitutively, as decidual cells do not contain dense core 
vesicles. The adenylyl cyclase-cAMP pathway, relaxin and endothelin stimulate prorenin 
production.28, 30, 31 PKC potentiated the effect of cAMP,28 while interleukin-1β and TNF-
α inhibited the release of prorenin.32 Decidual (pro)renin production has been linked to 
preeclampsia, e.g. because decidual tissue-derived angiotensin acts in placental tissue.33  
Placenta 
Prorenin secreted from the placenta is released into the maternal but not the fetal circulation.34 
It may thus contribute to the elevated plasma prorenin levels observed later in pregnancy, 
after the initial theca cell-dependent prorenin rise. Total renin in the maternal effluent from 
the perfused placenta consisted for <10% of renin, whereas in placental tissue the renin 
percentage was ≈50%. This finding is consistent with the idea of prorenin activation at 
tissue sites, either in vitro or in vivo. β
1
- and, to a lesser extent, β
2
-adrenergic stimulation, 
hCG as well as cAMP stimulated placental prorenin synthesis and release, while Ang II 
blocked it.35, 36 Placental prorenin release might be regulated in a paracrine fashion as hCG 
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is also secreted from the placenta. 
Amnion and chorion 
The amnion lines the amniotic cavity containing the amniotic fluid, while the chorion is 
adherent to the maternal side of the amnion. The total renin concentration in amniotic fluid 
is on average ≈16 times the plasma concentration found in the second and third trimester 
of human pregnancy, and the major (>95%) form of renin in amniotic fluid is prorenin.37 
Interestingly, the prorenin levels measured in gestational sacs during the first trimester, 
when the chorionic cavity is much larger than the amniotic cavity, were among the highest 
ever detected: close to 1 μg/mL.37 This suggests a possible role of prorenin in embryonic 
and fetal development. Most likely, the chorion leave is the primary source of this prorenin, 
since cultured chorionic, but not amnionic cells, synthesize and released prorenin.38 This 
release is constitutive, and stimulated by cAMP, PKC and calcium.39 
Testis 
The testis secretes prorenin, but not renin,40 and Leydig cells are the most likely source of 
this prorenin.41 An important stimulant of testicular prorenin release is hCG.42 
SUBMANDIBULAR GLAND
Humans and rats have only one renin gene, whereas mice have two alternative genotypes at 
the renin locus: some strains have one copy (Ren1c, as found in the C57Bl/6 strain), whereas 
others have two renin genes (Ren1d and Ren2, as in DBA/2 and 129J). The mouse renin 
genes are expressed in distinct, although overlapping, tissue-specific and developmental 
patterns. For example, Ren1d and Ren2 are expressed at equivalent levels in the kidney, 
but Ren2 is expressed at high levels in the submandibular gland, and is under the control 
of testosterone. Ren2 knockout mice are healthy and viable, and display a normal blood 
pressure,43 indicating that the remaining Ren1d in these mice is functionally equivalent 
to Ren1c. The Ren1 and Ren2 proteins share 97% amino acid similarity, but differ in 
their potential glycosylation sites. Ren2 has no consensus sites for asparagine-linked 
glycosylation, whereas Ren1c and Ren1d have three sites. Thus, Ren2 is nonglycosylated. 
Although this does not affect its biochemical properties, it reduces the stability of the 
protein. Deleting Ren1d results in sexually dimorphic hypotension,44 accompanied by 
elevated prorenin levels and reduced renin levels in female mice. Thus, Ren2 only partially 
compensates the loss of Ren1d in females, whereas in males, via the androgen-responsive 
Ren2 gene, full compensation occurs. Ren1d knockout mice display a complete absence of 
juxtaglomerular cell granulation, in agreement with the fact that glycosylation determines 
prorenin trafficking to dense core secretory vesicles.7 Most likely, Ren2 is constitutively 
secreted in the inactive form, although the low levels of renin in Ren1d knockout mice 
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suggest that some prorenin-renin conversion does occur in these animals. Such conversion 
is also believed to take place in the submandibular gland. Yet, submandibular renin does not 
make its way into the circulation in large quantities. Interestingly, Ren2 expression in the rat 
((mRen2)27 rat) results in severe hypertension, most likely due to the fact that mouse Ren2 
renin reacts as well with rat angiotensinogen as rat renin.45 
EXTRARENAL PRORENIN AND TISSUE ANGIOTENSIN GENERATION
Virtually all extrarenal renin-expressing tissues synthesize and release prorenin. Renin 
release rarely ocurs. Combined with the fact that 75% of JG cell preprorenin, after its 
conversion to prorenin in the endoplasmatic reticulum, is released in the inactive form, it is 
clear why we have such high prorenin levels.6 The function of prorenin is however unknown. 
It seems reasonable to assume that, if prorenin has a function, this depends on its ability to 
generate angiotensins. 
 Evidence for prorenin-renin conversion outside the kidney is not available.46 Non-
proteolytic activation of prorenin (i.e., activation without actual removal of the prosegment) 
might provide an alternative. This is a reversible process. It can best be imagined as an 
unfolding of the prosegment from the enzymatic cleft. This unfolding consists of at least 
two steps. In the first step the prosegment moves out of the enzymatic cleft, and in the 
second step the renin part of the molecule assumes its enzymatically active conformation. 
Non-proteolytic activation can be induced by exposure to low pH and cold, called acid 
activation and cryoactivation, respectively.15 Acid activation leads to complete activity of 
prorenin, cryoactivation to partial (~15%) activity. Non-proteolytically activated prorenin is 
enzymatically fully active, and can be recognized by monoclonal antibodies that are specific 
for the active site. Kinetic studies of the non-proteolytic activation process have indicated 
that an equilibrium exists between the closed (inactive) and open (active) forms of prorenin. 
The inactivation step is highly temperature-dependent and occurs very rapidly at neutral 
pH and 37°C. Consequently, under physiological conditions <2% of prorenin is in the open, 
active form. This percentage is sufficient to explain the low plasma ‘renin’ and angiotensin 
levels in anephrics, but will not result in significant angiotensin production at tissue sites. 
 The discovery of the (pro)renin receptor47 has changed this view. This receptor, 
a 350-amino acid protein with a single transmembrane domain, was first identified on 
cultured human mesangial cells. The receptor binds prorenin with higher affinity than 
renin.48 Binding induces a conformational change in the prorenin molecule allowing it to 
display catalytic activity without being cleaved to renin (i.e., prorenin is non-proteolytically 
activated). Interestingly, an 8.9 kDa fragment of the (pro)renin receptor called M8-9 is 
known to co-precipitate with a vacuolar H+-ATPase (V-ATPase).49 V-ATPases play important 
roles in acidification of intracellular compartments and cellular pH homeostasis (e.g., in the 
secretory granules of the JG cells6 and in the tubulus10), thereby providing a potential link 
between the (pro)renin receptor and acid activation. Since there is only one gene for the 
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Production site Release into the 
blood
Stimulators Inhibitors Ref.
Kidney +
JG cells β
1
-AR agonist, 
PGI
2
, PGE
2
, NO, 
adrenomedulin, 
dopamine, CGRP, 
cAMP
 α-AR agonist, 
Ang II, endothelin, 
vasopressin, ANP, 
Na+, cGMP, Ca+
6,8
Collecting duct Ang II 9
Adrenal +
Zona glomeru-
losa
ACTH, K+, cAMP, 
Ang II
Ang II, Na+ 12,13
Eye ?
Muller cells ? ? 16,19
Mast cells ? compound 48/80 
(degranulator) 
cromolyn, lodox-
amine (stabilizer)
20,21
Ovary +
Thecal cells hCG, LH, cAMP TNF-α, PKC 24,25
Uterus -
Myometrium/ 
decidual cells
relaxin, endothelin, 
cAMP, PKC
TNF-α, IL-1β 30-32, 
36
Placenta + hCG, β
1
/β
2
   -AR 
agonist,cAMP
Ang II 35, 36
Chorion cAMP, PKC, Ca2+ 38, 39
Table 1: Renin/prorenin production sites and the known stimulators and inhibitors of this 
production. Abbreviations: ACTH, adrenocorticotrophic hormone; ANP, atrial natriuretic peptide; 
AR, adrenoceptor; cAMP, cyclic 3’,5’-adenosine monophosphate; cGMP, cyclic 3’,5’-guanosine 
monophosphate; CGRP, calcitonin gene-related peptide; hCG, human chorionic gonadotropin; IL-1β, 
interleukin-1β; LH, luteinizing hormone; NO, nitric oxide; PG, prostaglandin; PKC, protein kinase 
C; TNFα, tumor necrosis factor α.
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(pro)renin receptor and the M8-9 protein, it is likely that both proteins derive from the same 
transcript. The M8-9 fragment corresponds to the cytoplasmic domain, the transmembrane 
domain and part of the extracellular domain of the receptor.  
 After the discovery of the receptor, (pro)renin receptor antagonists were designed 
based on the idea that the prosegment contains a handle region which binds to the receptor.50 
These (peptidic) antagonists (also known as ‘handle region peptides’, HRP) mimic 
the handle region, and thus will bind to the receptor instead of prorenin, thus blocking 
receptor-mediated prorenin activation. In support of this concept, HRP infusion normalized 
the elevated renal angiotensin content in diabetic rats50 without affecting blood pressure. 
Concomitantly, the development of diabetic nephropathy was prevented, suggesting that 
these phenomena depend on prorenin-induced tissue angiotensin generation. For reasons that 
are currently unknown, HRP infusion did not affect angiotensin levels in circulating blood, 
nor in tissues of healthy control rats. This was unexpected, since circulating angiotensins are 
largely derived from tissue sites, and prorenin is easily detectable in rats. Furthermore, since 
renin also binds to the receptor, it remains to be determined whether HRP interferes with 
renin binding, and what percentage of the receptors is occupied by renin, particularly in the 
kidney. 
 Surprisingly, renin and prorenin were also found to induce signaling via the 
(pro)renin receptor, resulting in p42/p44 and p38 mitogen-activated protein kinase 
activation.47, 51 These effects occurred in an angiotensin-independent manner and required 
high (pro)renin concentrations. The importance of this phenomenon in humans in vivo is 
unknown. 
CONCLUSION
The kidney is the main, if not the only, source of renin in the body. Yet, several organs 
release prorenin into the circulation, and prorenin remains detectable in humans at relatively 
high levels following a bilateral nephrectomy. For many years, prorenin was considered 
to be just the inactive precursor of renin, having no function of its own. However, the 
high prorenin levels in ocular fluids, follicular fluid and amniotic fluid, as well as the 
elevated plasma prorenin levels in subjects with diabetes complicated by microvascular 
complications suggested otherwise. The discovery of the (pro)renin receptor now offers a 
solution. The ‘inactive’ renin precursor gains Ang I-generating activity by binding to this 
receptor, without undergoing proteolytic cleavage. Thus, it might be prorenin, rather than 
renin, that contributes to tissue angiotensin generation. This concept is attractive, because 
it puts the much higher prorenin than renin levels in plasma into perspective. Nevertheless, 
there still are some uncertainties. For instance, tissue angiotensin levels in animals are 
low to undetectable following a bilateral nephrectomy.3 This may relate to the fact that in 
animals, more than in humans, prorenin is kidney-derived. An alternative explanation is 
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that the different glycosylation patterns of renal and extrarenal prorenin determine their 
tissue uptake and/or receptor binding.46 Furthermore, prorenin exerts direct effects via its 
receptor, in an angiotensin-independent manner. The relevance of this phenomenon remains 
to be verified in humans. Based on these observations, a new class of drugs might eventually 
emerge, i.e., the (pro)renin receptor blockers, which prevent both angiotensin generation at 
tissue sites and (pro)renin-induced, angiotensin-independent effects.
AIM OF THE THESIS
Extrarenal renin synthesis is highly controversial. Most studies claiming extrarenal renin 
expression report the release of prorenin, the inactive precursor of renin, rather than renin 
release. This may explain, at least in part, why humans have much more prorenin than renin. 
Nevertheless, recent studies suggest that mast cells in cardiac and pulmonary tissue are a 
new source of renin. Simultaneously, a (pro)renin receptor has been discovered which, upon 
binding, allows prorenin to display enzymatic activity. This receptor also binds renin. 
 Blockers of the renin-angiotensin system (RAS) predominantly increase renin, 
because they attenuate the negative feedback effect of angiotensin II on renin release. The 
rise in renin during renin inhibition with aliskiren has been suggested to be larger than 
during other types of RAS blockade. In addition, the beneficial effects of aliskiren last 
longer than expected on the basis of its half life. 
 
Given the above controversies, the following aims were defined: 
1) to quantify the  amount of extrarenal renin/prorenin in the human body, and to   
 evaluate the kinetics of renin/prorenin binding to their receptor as well as   
 the possibility that this results in angiotensin generation at tissue sites 
 (Chapters 2 & 3); 
2) to investigate whether mast cells release renin/prorenin, and whether mast cell-  
 derived renin/prorenin contributes to cardiac and pulmonary angiotensin   
 generation, both under normal - and pathophysiological conditions 
 (Chapters 4 & 5); 
3) to study two characteristics of renin inhibition, i.e., an excessive renin rise and a  
 long-lasting effect, and to evaluate a newly designed prorenin kit 
 (Chapters 6 & 7). 
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Chapter 2 
Renin and prorenin disappearance in humans post-
nephrectomy: Evidence for binding?
Based on:
Krop M, de Bruin JHB, Derkx FHM, Danser AHJ. Renin and prorenin 
disappearance in humans post-nephrectomy: Evidence for binding? Frontiers in 
bioscience. 2008 May; 13: 3931-9.
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ABSTRACT
To study the distribution of kidney-derived renin-angiotensin system (RAS) components 
in humans, we monitored the decline in plasma prorenin, renin, angiotensin (Ang) I and 
Ang II post-nephrectomy. Prorenin and renin decreased biphasically, prorenin displaying 
a slower elimination. The distribution half life was similar for both. Angiotensins followed 
the disappearance of renin. Within two days post-nephrectomy, stable plasma concentrations 
at 5-10% (renin and angiotensins) and 25-30% (prorenin) of pre-nephrectomy levels were 
reached. The total amount of kidney-derived renin and prorenin in the body was ≈10 times 
as much as the amount in blood. Prorenin also originated at extrarenal sites. The renin levels 
in anephrics corresponded with the percentage of prorenin that in vitro has a so-called 
‘open conformation’ (i.e., displays enzymatic activity), suggesting that renin in anephrics 
is in fact ‘open’ prorenin. Haemodialysis nor captopril significantly affected the level of 
any RAS component in anephrics. In conclusion, renal renin/prorenin enters tissue sites in 
humans, and renal renin is the main determinant of plasma angiotensins. Whether prorenin 
contributes to tissue angiotensin generation in humans remains to be determined.  
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INTRODUCTION
Angiotensin (Ang) production occurs at tissue sites rather than in circulating blood.1, 52 Such 
tissue production efficiently results in the activation of Ang II type 1 (AT
1
) receptors and/or 
Ang II type 2 (AT
2
) receptors, and requires the local presence of renin, angiotensinogen and 
angiotensin converting enzyme (ACE). Yet, although ACE is indeed expressed locally in 
multiple organs, renin and angiotensinogen are not.3, 22, 53, 54 Thus, to allow Ang I synthesis at 
tissue sites, renin and angiotensinogen need to be taken up from circulating blood. Indeed, 
both proteins diffuse into the interstitial fluid.53, 55, 56 In addition, renin binds to receptors. Up 
to now, two of such receptors have been described: the mannose 6-phosphate (M6P) receptor 
(which is identical to the insulin-like growth factor II receptor) and the ‘renin receptor’. M6P 
receptors bind any phosphomannosylated (M6P-containing) protein, and therefore cannot 
be considered as renin-specific receptors. These receptors most likely contribute to renin 
clearance.46, 57, 58 Renin receptors bind renin on the cell surface.47, 48 
 Importantly, both receptors also bind prorenin, the inactive precursor of 
renin.47, 48, 50 The renin receptor is therefore currently known as the (pro)renin receptor. M6P 
receptor-bound prorenin is internalized, and, as part of a clearance process, is converted to 
renin and subsequently degraded.57, 59 (Pro)renin receptor-bound prorenin remains on the cell 
surface, and, due to a conformational change, becomes catalytically active. Recent studies 
suggest that prorenin, rather than renin, is the endogenous ‘agonist’ of this receptor.48, 60 
Consequently, tissue angiotensin generation may actually depend on prorenin.15 Such a role 
for prorenin would explain not only why we have so much prorenin (its levels in blood are 
usually >10-fold higher than those of renin),5 but also why some extrarenal organs selectively 
release prorenin into the circulation. Examples of prorenin-releasing organs are the ovary, 
the testis, the eye, and the adrenal.14, 16, 23, 40 
 Up to now, all evidence for prorenin contributing to tissue angiotensin production 
comes from animal studies.50, 61-63 Such studies have made use of animals overexpressing 
prorenin or the (pro)renin receptor, and/or the application of a (pro)renin receptor antagonist, 
the so-called handle region peptide (HRP). Studies in humans on this topic are, for obvious 
reasons, much more difficult to perform, if not impossible.
 In the present study, we set out to investigate the kinetics of renin and prorenin 
in humans, making use of subjects undergoing a complete nephrectomy, resulting in the 
removal of their last remaining kidney. A detailed analysis of the disappearance curves of 
both proteins provides insight into their tissue distribution. In addition we quantified the 
levels of renin-angiotensin system (RAS) components in subjects that had been anephric for 
several years, both before and after haemodialysis, and we studied the effect of captopril, 
ACE inhibitor, on these levels.   
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METHODS
The studies were approved by the Ethics Committee of the Erasmus MC, and all subjects 
gave their informed consent.
Subjects undergoing nephrectomy
Four subjects (3F, 1M; age 53-69 years) undergoing nephrectomy because of chronic 
pyelonephritis or renal adenocarcinoma participated in the study. One subject was taking 
25 mg captopril twice daily. Blood samples for RAS component measurements were taken 
from an antecubital vein 30 minutes before, during (t=0) and 10, 20, 30, 60, 120, 240, 480, 
720, 1440 and 2880 minutes after clamping of the renal vein and subsequent removal of the 
kidney. 
Anephric subjects
Thirteen anephric subjects (9F, 4 M; age 24-79 years), who had been anephric for 1-17 
years (mean 8 years), participated in the study. The reasons for nephrectomy were chronic 
pyelonephritis (n=4), chronic interstitial nephritis (n=1), chronic glomerulonephritis 
(n=1), renal adenocarcinoma (n=2), M. Goodpasture (n=1), polycystic kidneys (n=2), 
reflux nephropathy (n=1), and uncontrollable severe hypertension (n=1). All subjects 
were receiving maintenance haemodialysis, 2-3 times a week, with a Fresenius A2008C 
dialyzer and a disposable polyacrylonitryl membrane kidney. The subjects were seated for 
30 minutes before the haemodialysis was started and remained seated during the procedure. 
Blood samples for RAS component measurements were taken from an antecubital vein 
immediately before and after haemodialysis. 
 On a second occasion, 5 anephric subjects (4 F, 1M; age 38-67 years) were given 
50 mg captopril orally after they had been seated for 30 minutes. Haemodialysis was 
started 2 hours after captopril and lasted 4 hours. Blood samples for RAS component 
measurements were taken from an antecubital vein immediately before, and 2 hours and 
6 hours after captopril was given. The patients remained seated throughout the entire period. 
Blood pressure was measured by standard sphygmomanometry at 0, 30, 45, 60, 90, 120 and 
180 minutes after captopril had been taken. Heart rate was computed from a continuous 
electrocardiographic tracing. 
 For comparison, blood samples for renin, prorenin, Ang I and Ang II measurements 
were taken from 17 healthy controls (9F, 8M; age 21-60 years), after they had been seated for 
30 minutes. 
 Blood for renin, prorenin, angiotensinogen, ACE and total protein measurements 
was centrifuged at 3000 g for 10 minutes at room temperature, and plasma was stored at 
-20°C.64 Blood for angiotensin measurements was centrifuged at 3000 g for 10 minutes at 
4°C, and plasma was stored at -70°C.64
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Biochemical measurements
Renin and prorenin were measured by enzyme-kinetic assay (EKA).65 To measure prorenin 
by EKA, it was first converted to renin by incubation with Sepharose-bound trypsin. Results 
of the enzyme-kinetic assay are expressed as mU/L using the WHO human kidney renin 
standard 68/356 as reference standard. The lower limit of detection was 0.5 mU/L. Renin + 
prorenin (‘total renin’) were also measured by immunoradiometric assay (IRMA), using the 
monoclonal antibodies R3-27-6 and R3-36-16.66 These two antibodies recognize different 
epitopes of the renin molecule and react equally well with renin and prorenin. The results of 
this assay are also expressed as mU/L, and the lower limit of detection was 5 mU/L.
 Angiotensinogen was determined as the maximum quantity of Ang I generated 
in the presence of excess human kidney renin.67 The lower limit of detection was 
1 nmol/L. Ang I and II were measured by radioimmunoassay after SepPak extraction and 
high-performance liquid chromatography separation. The lower limit of detection was 
0.5 pmol/L for Ang I, and 0.25 pmol/L for Ang II, respectively.1 ACE activity was measured 
with a commercial kit (ACEColor, Fujirebio, Tokyo, Japan). Total protein was measured 
with a routine laboratory method. 
Statistical analysis
Data are presented as mean±SD or geometric mean and range. The plasma disappearance 
of RAS components after nephrectomy was studied by plotting the plasma levels 
semilogarithmically against time. The plasma levels reached 24-48 hours after nephrectomy 
were similar to those found in subjects who had been nephrectomized for several years, 
and these levels were therefore considered to be of non-renal origin. In order to correct for 
RAS components of non-renal origin, the plasma levels found 48 hours after nephrectomy 
were subtracted from the actual levels as measured during the first 12 hours. The plasma 
disappearance curves were then analyzed using a two-compartment exponential model. 
Differences between half lives were evaluated using Scheffé’s test for multiple comparison. 
Associations were assessed by calculating Pearson’s coefficient of correlation. Differences 
between plasma levels before and after haemodialysis or captopril were evaluated using 
Student’s t-test for paired observations. Values were considered significant at P<0.05.
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RESULTS
Subjects undergoing nephrectomy
RAS component levels at 0.5 hour prior to the clamping of the renal vein and the moment of 
clamping (t=0) were identical (Table 1). The plasma levels of prorenin, renin, Ang I and Ang 
II dropped rapidly after clamping of the renal vein and subsequent removal of the kidney 
(Figure 1 and Table 1). Prorenin levels reached a plateau at ≈25-30% of the levels at t=0, 
whereas renin, Ang I and Ang II decreased to levels <5% of the levels at t=0. Ang I and II 
were still above the detection limit after 48 hours (Figure 2 and Table 1). The disappearance 
curves were biphasic, and the half life of the fast component of the curve (1.0±0.2, 0.7±0.2, 
0.6±0.2 and 0.7±0.3 hour for prorenin, renin, Ang I and Ang II, respectively) was identical 
for all 4 RAS components. The half life of the slow component (which corresponds with 
the effective plasma half life) was significantly (P<0.05) longer for prorenin (7.6±2.0 hours) 
than for the other 3 RAS components (2.8±0.6, 3.3±0.4 and 3.5±0.7 hours for renin, Ang I 
and Ang II, respectively). The area under the curve (AUC) for prorenin was 234 (geometric 
mean; range 61.6-1299) U/L.min, as opposed to 17.7 (10.4-45.0) U/L.min for kidney-derived 
renin. 
Figure 1. Plasma disappearance curves of prorenin, renin, angiotensin I and angiotensin II in patients 
after nephrectomy. Data (mean+SD of 4 subjects) have been expressed as a percentage of the values at 
t=0 (the time of renal vein clamping).
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Figure 2. Angiotensin I and II levels found in HPLC fractions after SepPak extraction and HPLC 
separation of plasma obtained 30 minutes before (open bars) and 48 hours (closed bars) after 
nephrectomy.
RAS components  Nx before Nx after Controls
Prorenin (mU/L) 86.3 (25.5-537) 87.1 (20.7-676) 161 (75-548)
Renin (mU/L) 0.9 (0.3-4.4) 0.9 (0.3-4.0 13.2 (2.7-39.1)
Angiotensinogen (nmol/L) 2736 (1700-5277) 2879 (1737-6071) not done
ACE (U/L) 11.8 (4.0-20.3) 13.5 (4.5-21.6) not done
Angiotensin I (pmol/L) 4.5 (1.6-6.5) 5.2 (1.8-8.6) 21.8 (8.0-53)
Angiotensin II (pmol/L) 1.1 (0.4-2.8) 1.0 (0.3-4.3) 4.0 (1.2-8.5)
Table 2: RAS component plasma levels (geometric mean and range) in 13 anephric subjects (Nx) 
before and after heamodialysis and in 17 healthy controls.
Time
(hours)
Prorenin 
(mU/L)
Renin (mU/L) Angiotensin I
(pmol/L)
Angiotensin II
(pmol/L)
-0.5 260 (92-1471) 55.7 (26.2-160) 69.1 (16.5-215) 12.8 (2.3-93.3)
0 278 (116-1656) 57.3 (26.4-145) 70.5 (17.6-187) 14.3 (3.8-77.2)
48 59.3 (15.5-107) 1.5 (0.6-3.1) 1.9 (0.5-4.1) 1.0 (0.6-1.4)
Table 1: Plasma prorenin, renin, angiotensin I and angiotensin II (geometric mean and range) before 
and after nephrectomy in 4 subjects. At t=0 the renal vein was clamped.
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Figure 3. Comparison of the total renin concentration measured by enzyme-kinetic assay and by 
immunoradiometric assay in plasma samples obtained from 13 anephric subjects before (closed 
symbols) and after (open symbols) haemodialysis. The regression line is not significantly different 
from the line of identity (r=0.98; P<0.001).
Anephric subjects
Haemodialysis did not alter the levels of renin, prorenin, angiotensinogen, ACE, Ang I and 
Ang II (Table 2). EKA measurements were identical to IRMA measurements (Figure 3), 
confirming that the Ang I-generating activity measured in the EKA was entirely renin-
dependent. The renin, Ang I and Ang II levels in anephric subjects were ≈5-10 times lower 
than those in healthy controls, whereas the prorenin levels in anephric subjects were ≈2 
times lower than in healthy controls (Table 2). In anephric subjects, renin amounted to 
2.0±0.8% of total renin, and correlated strongly with prorenin (Figure 4; r=0.97, P<0.001). 
In healthy controls, renin amounted to 8.4±4.0% of total renin (P<0.01 vs. anephric subjects), 
and correlated less well with prorenin (Figure 4; r=0.64, P<0.01). In 6 subjects (5F, 1M), 
total renin had also been measured 4 years prior to this study. Results were identical to 
those measured here (47±13 vs. 41±6 mU/L). The relationship between renin and Ang I and 
the relationship between Ang I and Ang II were identical in healthy and anephric subjects 
(Figure 5). 
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Figure 5. Relationship between renin and Ang I (left panel; log[Ang I]=0.62xlog[renin]+0.61, r=0.85, 
P<0.001) and between Ang I and Ang II (right panel; log[Ang II]=0.69xlog[Ang I]-0.35, r=0.75, 
P<0.001) in healthy subjects (open symbols) and anephric subjects (closed symbols). 
Figure 4. Relationship between renin and prorenin in healthy subjects (open symbols; 
log[renin]=0.96xlog[prorenin]-1.00, r=0.64, P<0.01) and anephric subjects (closed symbols; 
log[renin]=0.59xlog[prorenin]-0.94, r=0.97, P<0.001). 
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 Captopril reduced plasma Ang II in anephric subjects by 50-60% (P=NS) 2 hours 
after the dose. It did not alter the plasma levels of prorenin, renin, angiotensinogen, Ang I or 
total protein (Figure 6), nor did it affect blood pressure and heart rate (Figure 7).   
DISCUSSION
This study demonstrates that in humans, kidney-derived renin and prorenin are not limited 
to the circulation. The distribution of both proteins over the body occurs relatively fast, with 
a half life of 0.5-1 hour, whereas their metabolism takes much longer, with a half life of 
several hours. The latter resembles data in cynomolgus monkeys and marmosets following 
infusion of prorenin.68, 69 The elimination half life of prorenin in humans was twice as long 
as that of renin. This probably relates to the larger hepatic extraction of renin versus prorenin 
(hepatic vein/arterial concentration ratio 0.8±0.1 vs. 0.9±0.1, n=115, P<0.01; F.H.M. Derkx 
et al., unpublished observations). Differences in glycosylation most likely underlie these 
differences in hepatic extraction.70 Since the liver blood flow corresponds with ≈25% of 
cardiac output (≈3 L plasma/min), it can be calculated that the hepatic clearances of renin 
and prorenin are 0.15 and 0.075 L/min, respectively. The AUC’s of kidney-derived renin 
and prorenin in this study were 17.7 and 234 U/L.min. With this information it is possible 
to estimate the total amount of kidney-derived renin and prorenin in the body (=AUC x 
clearance): 3 and 18 U, respectively. This is roughly ten times the total amount of renin 
and prorenin in blood. Apparently, therefore, 90% of both proteins is localized outside 
the circulation, i.e., is present at tissue sites. This could be an underestimation, in case a 
significant amount of renin and prorenin is also cleared outside the liver. However, when 
infusing 125I-labeled prorenin in rats, the radiolabeled protein reached hepatic levels that 
were 10 times higher than those in the kidney, while <1% of the dose accumulated in other 
organs, and thus, the liver is by far the most important prorenin/renin-clearing organ in the 
body.68  
 What might be the location of renin and prorenin outside the circulation? Both renin 
and angiotensinogen are known to enter the interstitium, reaching interstitial fluid levels in 
the rat heart that are comparable to those in blood.53, 55, 71 Interstitial fluid amounts to ≈15% of 
tissue wet weight, and thus an equal distribution of renin and prorenin over the extracellular 
fluid space cannot fully explain total body renin and prorenin. Indeed, the tissue levels of 
renin (expressed per g wet weight) are often as high as its levels per mL blood,1, 3, 65 which is 
impossible if tissue renin is limited to extracellular fluid and reaches concentrations in the 
interstitium that are identical to those in plasma. Therefore, an additional site must exist, 
which allows selective tissue accumulation of renin and prorenin. Nephrectomy studies in 
rats almost thirty years ago already suggested that arterial wall renin washout occurred 
more slowly than plasma renin washout, in full agreement with a ‘renin binding site’ in the 
vascular wall.72 Two likely candidates for such binding sites are the M6P receptor,46, 57, 58 and 
the recently discovered (pro)renin receptor.47 Studies with antagonists of these receptors 
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Figure 6. Plasma levels (mean+SD) of total protein, renin, prorenin, angiotensinogen, Ang I and Ang 
II in plasma of 5 anephric subjects given 50 mg captopril orally at t=0. 
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Figure 7. Systolic blood pressure (open circles), diastolic blood pressure (closed circles) and heart rate 
(squares) in 5 anephric subjects given 50 mg captopril orally at t=0. Data are mean+SD.
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would be required to definitely settle this issue. An argument in favor of the (pro)renin 
receptor is that prorenin binding to this receptor allows prorenin to display enzymatic 
activity,47, 48 thus explaining why the majority of ‘tissue renin’ is usually active. However, 
an alternative explanation for the latter is prorenin to renin conversion during the tissue 
homogenization and extraction procedure. 
 Importantly, Ang I and Ang II disappearance from plasma following nephrectomy 
closely resembled renin disappearance, suggesting that kidney-derived renin (and not 
prorenin) is the major determinant of circulating angiotensins. Approximately 24-48 hours 
after nephrectomy, the renin, Ang I and Ang II levels in plasma were identical to those 
in subjects who had been anephric for years, that is they were ≤10% of the levels before 
nephrectomy or in healthy controls. This is in full agreement with previous studies in anephric 
humans.73 Prorenin did not decrease to such low levels. Its levels in anephric subjects were 
sometimes even in the normal range and remained stable over the years. Immunoreactive 
measurements confirmed that the prorenin levels measured by EKA truly resembled 
prorenin. Thus in humans, as has been suggested before,74, 75 a major percentage of prorenin 
is of extrarenal origin. Although prorenin is enzymatically inactive, it is well-known that, 
depending on pH and temperature, prorenin is capable of undergoing a conformational change, 
involving the unfolding of the prosegment from the enzymatic cleft. Such unfolding is also 
known as ‘non-proteolytic activation’, and allows prorenin to become fully enzymatically 
active. Under in vitro conditions that mimick normal physiology as closely as possible (pH 
7.4, 37°C), approximately 2% of prorenin is in this open conformation.46, 48, 76 The present 
study shows that 2% of total renin in anephric subjects is active (as opposed to >8% in 
healthy controls). Moreover, ‘renin’ in anephric subjects correlated highly significantly with 
prorenin, whereas normally the renin-prorenin relationship is much less strong (Figure 4).5 
Taken together, these data suggest that ‘renin’ in anephric subjects is most likely open, non-
proteolytically activated prorenin. Thus, the true renin levels in these subjects may actually 
be zero. This is in full agreement with human studies showing exclusive prorenin (and not 
renin) release from tissue sites,35, 40 and animal studies showing no prorenin-renin conversion 
in the circulation following prorenin infusion or when overexpressing prorenin in the 
liver.63, 69 A further possibility to attribute the Ang I-generating activity to prorenin is 
that (part of) plasma prorenin occurs in a truncated form, lacking a portion of the NH2 
terminus of the prosegment.77 Under such conditions, the prosegment will not fully cover the 
enzymatic cleft, and thus this truncated prorenin is enzymatically active. 
 The renin (=activated prorenin)-Ang I relationship in anephrics was identical to 
that in healthy controls, confirming that once prorenin has obtained its open conformation, 
its reaction with angiotensinogen is identical to that of renin. The Ang I-Ang II relationship 
was also normal, suggesting that the ACE levels in anephrics are not altered. Captopril 
tended to reduce Ang II in anephrics, but the differences were, due to the closeness of the 
Ang II values to the detection limit, not significant. No changes occurred in either renin or 
Ang I, thereby confirming the idea that the renin rise following captopril is entirely kidney-
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dependent, and that the simultaneous Ang I rise is due to the rise in renin rather than its 
diminished conversion by ACE.78 The same applies to the RAS component changes that 
normally occur after haemodialysis.79 In contrast with a previous study,80 we did not observe 
a change in blood pressure following captopril exposure in anephrics. This may relate to the 
difference in experimental setup: in that study captopril was applied in the fluid-depleted 
state, one hour after haemodialysis, whereas in the present study captopril was applied 
immediately prior to haemodialysis, i.e., in the fluid-repleted state. A captopril-induced 
blood pressure drop in anephrics might be due to a suppression of prorenin-dependent Ang 
II generation and/or bradykinin potentiation. To exclude the latter, similar studies should be 
performed in anephrics using a renin inhibitor or an AT
1
 receptor antagonist.  
 Studies with the (pro)renin receptor blocker HRP in animals have suggested that, 
under pathological conditions, prorenin contributes to tissue angiotensin generation, but 
(virtually) not to angiotensin generation in the circulation.50, 62 Our data support the latter, 
since the majority of plasma angiotensins (>90%) disappeared in parallel with plasma renin 
following a nephrectomy, and plasma angiotensin levels remained low in anephrics, despite 
the continued presence of prorenin. No conclusions can be drawn on the contribution of 
prorenin to tissue angiotensin generation from our current results. In rats and pigs, tissue 
angiotensin levels dropped to or below the detection limit following a nephrectomy.3, 81, 82 As 
opposed to the situation in humans however, prorenin in these animals does not constitute 
90% or more of total renin in plasma.3, 62 Moreover, its levels dropped, at least in the pig, to 
almost the same degree as the renin levels after nephrectomy.3 Thus, one explanation for 
the lack of tissue angiotensin following a nephrectomy in animals might be a lack of both 
renin and prorenin. This would imply that in animals, more than in humans, prorenin is 
kidney-derived. An alternative, although less likely explanation, is that only kidney-derived 
prorenin contributes to tissue angiotensin generation, for instance because the glycosylation 
pattern of non-renal prorenin does not allow its penetration (via receptor-binding?) at tissue 
sites. Indeed, as has been discussed, glycosylation determines (pro)renin clearance,70 and 
M6P receptors do not bind non-glycosylated (pro)renin.46, 57 
 In summary, our study has revealed that kidney-derived renin and prorenin enter 
tissue sites in humans, and may thus contribute to local angiotensin production. A major 
percentage of prorenin is of extrarenal origin, and the strong correlation between ‘renin’ 
and prorenin in anephric subjects suggest that ‘renin’ in these subjects actually is non-
proteolytically activated prorenin. Such activated, intact prorenin reacts normally with 
angiotensinogen, and thus, in combination with the doubled angiotensinogen levels and the 
unaltered ACE levels in anephric subjects, allows the generation of low levels of both Ang I 
and II in blood plasma following nephrectomy. To what degree prorenin also contributes to 
tissue angiotensin generation in humans remains to be determined.  
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Chapter 3
Prorenin is the endogenous agonist of the (pro)renin 
receptor. Binding kinetics of renin and prorenin in rat 
VSMC’s overexpressing the human (pro)renin receptor
Based on:
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ABSTRACT
Mannose 6-phosphate receptors (M6PR) bind both renin and prorenin, and such binding 
contributes to renin/prorenin clearance but not angiotensin generation. Here, we evaluated 
the kinetics of renin/prorenin binding to the recently discovered human (pro)renin receptor 
(h(P)RR), and the idea that such binding underlies tissue angiotensin generation. Vascular 
smooth muscle cells from control rats and transgenic rats with smooth muscle h(P)RR 
overexpression were incubated at 4ºC or 37ºC with human renin or prorenin. Incubation at 
37ºC greatly increased binding, suggesting that (pro)renin-binding receptors cycle between 
the intracellular compartment and the cell surface. Blockade of the M6PR reduced binding by 
≈50%. During M6PR blockade, h(P)RR cells bound twice as much prorenin as control cells, 
while renin binding was unaltered. Incubation of h(P)RR (but not control) cells with prorenin 
+ angiotensinogen yielded more angiotensin than expected on the basis of the activity of 
soluble prorenin, whereas angiotensin generation during incubation of both cell types with 
renin + angiotensinogen was entirely due to soluble renin. The renin + angiotensinogen-
induced vasoconstriction of isolated iliac arteries from control and transgenic rats was also 
due to soluble renin only. The recently proposed (P)RR antagonist HRP, which resembles 
part of the prosegment, blocked neither prorenin binding nor angiotensin generation. H(P)RR 
preferentially bind prorenin, and such binding results in angiotensin generation, most likely 
because binding results in prorenin activation. 
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INTRODUCTION
Prorenin is generally assumed to be nothing more than the inactive precursor of renin. Yet, 
its elevated levels in diabetes mellitus complicated by retinopathy and nephropathy suggest 
otherwise.16, 83 Recently, the renal vasodilator response to captopril in diabetic subjects 
was reported to correlate better with plasma prorenin than with plasma renin.84 Possibly 
therefore, prorenin contributes to tissue (e.g., renal) angiotensin generation. Studies in 
transgenic animals support this concept,63, 85 but the underlying mechanism is still unknown. 
Evidence for prorenin to renin converting enzyme(s) outside the kidney is lacking. Thus, 
other mechanisms than proteolytic cleavage are required to understand why prorenin might 
contribute to tissue angiotensin production. Indeed, prorenin activation may also occur in a 
(reversible) non-proteolytic manner, i.e., not requiring the irreversible proteolytic cleavage 
step.15 At low pH and temperature, prorenin is capable of undergoing a conformational 
change, involving the unfolding of the prosegment from the enzymatic cleft. Such non-
proteolytically activated, ‘open’ prorenin is fully enzymatically active.76, 86 
 A few years ago Nguyen et al. identified a (pro)renin receptor ((P)RR) that binds 
both renin and prorenin.47 Renin binding to the receptor enhanced the catalytic activity 
of renin 4-fold. Unexpectedly, prorenin, when bound to the receptor, displayed enzymatic 
activity without proteolytic removal of the prosegment. Apparently therefore, binding to 
the receptor induces comparable changes in the prorenin molecule as a decrease in pH or 
temperature. After the discovery of the receptor, a (P)RR antagonist was designed based on 
the idea that the prosegment contains a ‘handle’ region which binds to the receptor.50 This 
(peptidic) antagonist (also known as ‘handle region peptide’, HRP) resembles the handle 
region, and thus will bind to the receptor instead of prorenin, thereby preventing receptor-
mediated prorenin activation. In support of this concept, HRP infusion normalized the 
elevated renal angiotensin content in diabetic rats,50 without affecting blood pressure.
 A second receptor capable of binding renin and prorenin is the mannose-6 phosphate 
receptor (M6PR). M6PRs however, unlike (P)RRs, internalize renin and prorenin, and 
M6PR-binding of renin and prorenin has now been recognized as a clearance mechanism, 
not resulting in angiotensin generation.59
 To further establish the role of the (P)RR, transgenic rats overexpressing the human 
(P)RR (h(P)RR) in vascular smooth muscle cells (VSMCs) have been created.61 These 
rats display increased prorenin binding to vascular tissue and develop a cardiovascular 
phenotype with elevated systolic blood pressure and an augmentation in heart rate at an age 
of 7 months. 
 In the present study, aortic VSMCs were collected from these transgenic rats and 
their control littermates, to quantify the kinetics of renin and prorenin binding to the h(P)RR, 
and to investigate the idea that such binding underlies tissue angiotensin generation.  
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METHODS
Cell culture
All experiments were performed according to the regulations of the Animal Care Committee 
of the Erasmus MC, in accordance with the Guiding Principles of the American Physiological 
Society. Primary cultures of VSMCs were prepared from aortas of 6-week old transgenic 
rats with smooth muscle cell expression of the h(P)RR61 and their control littermates.87 In 
short, VSMCs were isolated from the aorta, plated and maintained at 37°C in a humidified 
5% CO
2
 incubator in supplemented SmBM-2 medium (Cambrex) containing 10% FBS. 
Cells were cultured to confluence in a 75 cm2 flask (in supplemented SmBm-2 medium; 
passage 3-8), trypsinized and seeded into 12- or 24-well plates using the above medium. 
This yielded a confluent monolayer of ≈4 x 105 cells/cm2 after 3 days. Before the start of the 
experiment the cells were cultured for 24 hours under serum-free conditions. 
Human (pro)renin receptor expression
To verify whether h(P)RR overexpression had increased the (P)RR level in h(P)RR 
VSMCs, control and h(P)RR cells were lysed using Nonidet P-40 lysisbuffer and kept on 
ice for 15 minutes. Next, the cell lysates were centrifuged at 14000 g for 15 minutes at 4°C. 
Supernatants were collected and stored at -20°C until further analysis. Western blotting was 
performed with 20 µg of protein using antibody 1623 (diluted 1:1000), which recognizes the 
N-terminal domain of both the rat and human (P)RR. A peroxidase-conjugated antibody 
(goat anti-rabbit, 1:5000) was used to visualize the receptor protein.
Prorenin and renin binding kinetics 
To study the time- and concentration-dependency of renin and prorenin binding, as well 
as the contribution of M6PRs and (P)RRs to this process, cells were incubated at 4°C or 
37°C with 0-1200 U/L recombinant human prorenin or renin (a kind gift of Dr. S. Mathews, 
Hoffmann-LaRoche, Basel, Switzerland) for maximally 6 hours in the absence or presence 
of 10 mmol/L M6P (to block M6PR) and/or rat HRP (RILLKKMPSV-OH, to block rat 
(P)RR) or human HRP (IFLKRMPSI-OH, to block h(P)RR) (Biosyntan, Berlin, Germany; 
1 nmol/L-1µmol/L). At the end of the incubation period the culture medium was removed. 
Each well was washed three times with 1 mL ice-cold PBS before the cells were lysed with 
ice-cold 0.2 % triton X-100 in PBS. Cell lysates were quickly frozen in liquid N2 and stored 
at -70°C. To investigate the intracellular presence of the (P)RR, incubations with prorenin 
were also performed after cell permeabilization with PBS containing 0.2 % saponin. 
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Angiotensin generation
To study whether (P)RR-binding of renin and prorenin results in facilitated angiotensin (Ang) 
I generation, cells were incubated at 37°C for maximally 4 hours with 150 nmol/L human 
angiotensinogen and 100 U/L human prorenin or 3-30 U/L human renin, in the absence 
or presence of 1 µmol/L HRP. Cells incubated without angiotensinogen, renin or prorenin 
served as control. Ang I generation under the above conditions was also monitored in the 
absence of cells, in order to correct for the enzymatic activity of soluble renin and prorenin. 
The first order rate constant for Ang I elimination was determined by incubating the cells 
with 100 nmol/L Ang I for maximally 4 hours. Medium samples (50 μL) were collected at 0, 
1 and 4 hours, mixed with 2.5 μL inhibitor stock solution (containing 0.1 mmol/L aliskiren 
(a kind gift of Novartis Pharmaceuticals, Basel, Switzerland), 200 mmol/L EDTA and 
0.2 mmol/L lisinopril), frozen in liquid N2, and stored at -70°C. Cells were collected and 
stored as described before.57 
Functional studies
To study whether renin-induced, Ang II-mediated vasoconstriction involves Ang I generation 
by membrane-bound renin, iliac arteries were removed from 7-9-month old h(P)RR 
transgenic rats and their controls, and stored overnight in a cold (4°C), oxygenated Krebs 
bicarbonate solution of the following composition (mmol/L): NaCl 118, KCl 4.7, CaCl
2
 2.5, 
MgSO
4
 1.2, KH
2
PO
4
 1.2, NaHCO
3
 25 and glucose 8.3; pH 7.4. Artery segments (diameter 
≈500 µm) were then mounted in Mulvany myographs (J.P. Trading) with separated 6-mL 
organ baths containing Krebs bicarbonate solution, aerated with 95% O
2
 and 5% CO
2
, and 
maintained at 37°C. Tissue responses were measured as changes in isometric force, using a 
Harvard isometric transducer. Following a 30-min stabilization period, the optimal internal 
diameter was set to a tension equivalent to 0.9 times the estimated diameter at 100 mm Hg 
effective transmural pressure as described by Mulvany and Halpern.88 To determine the 
maximum contractile response, the tissue was exposed to 100 mmol/L KCl. The segments 
were then allowed to equilibrate in fresh organ bath fluid containing 10 µmol/L L-NAME 
for 30 min and exposed to Ang I (1 nmol/L-1 µmol/L), Ang II (1 nmol/L-1 µmol/L) or 
100 U/L renin + 1 µmol/L angiotensinogen, with or without  0.1 µmol/L aliskiren. To 
monitor Ang I and/or II formation, 50 μL organ bath fluid was collected 10 minutes (i.e., at 
the time of maximum constriction) after the addition of Ang I or renin + angiotensinogen. 
The samples were rapidly mixed with 2.5 μL inhibitor solution and frozen in liquid N
2
. 
 Due to the the low intrinsic activity of prorenin, combined with the fact that 
the vascular segments bind only a small fraction (<5%) of prorenin in organ bath fluid,61 
the Ang II generation in the organ bath setup at 100 U/L prorenin would be too low to 
induce vasoconstriction, even under conditions where all bound prorenin is active. Using 
substantially higher prorenin concentrations might solve this problem, but, given the 
relatively large volume of the organ bath, such concentrations are beyond our current stock. 
Therefore, we were unable to perform organ bath studies with prorenin.
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Biochemical measurements
Renin and cell-activated prorenin were measured by enzyme kinetic assay (EKA).46 Total 
(i.e., cell-activated plus nonactivated) prorenin was also measured by EKA, after prorenin 
had been converted to renin by incubation of the sample for 48 hours at 4°C with plasmin 
(0.5 caseinolytic U/mL). Protein content was determined according to Bradford. Ang I and II 
levels in medium were measured by radioimmunoassay (detection limit 40 and 20 fmol/mL, 
respectively). Ang I and II levels in cell homogenates were measured by radioimmunoassay 
after SepPak extraction and reversed-phase high-performance liquid chromatography 
separation (detection limit 4 and 2 fmol/106 cells, respectively).
Data analysis
Results are expressed as mean±SEM. Contractile responses are expressed as a percentage 
of the constriction to 100 mmol/L KCl. Angiotensin concentration-response curves (CRCs) 
were analyzed as described to obtain pEC
50
 (10logEC
50
) values.89 Statistical analysis was 
performed using one-way or two-way ANOVA where appropriate. P<0.05 was considered 
significant.
RESULTS
Human (pro)renin receptor expression 
Western blot analysis confirmed (P)RR protein expression in VSMCs at the expected size of 
39 kD (Figure 1).47 Expression was ≈3-fold higher in h(P)RR-overexpressing VSMCs than 
in control cells. 
Figure 1. Quantification of (P)RR protein 
in control- and h(P)RR VSMCs. Western 
blotting with antibody 1623 revealed the 
expected (P)RR band at 39 kDa, with 
a higher expression in h(P)RR cells. 
Detected (P)RR protein (mean±SEM of 
6 measurements) is expressed relative to 
total protein. *P<0.05 vs. control
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Figure 2. A, time-dependent increase in the levels of cell-associated total and activated prorenin 
during incubation of the cells at 37°C with 100 U/L prorenin. B and C, levels of cell-associated total 
and activated prorenin after incubation of the cells at 4°C (B) or 37°C (C) with 0-1000 U/L prorenin 
for 4 hours. Data (mean±SEM of 3-5 experiments) are expressed per mg protein. Left panels, control 
VSMCs, right panels, h(P)RR VSMCs. 
control h(P)RR
1 10 100 1000
0
5
10
15
20
25
m
U
/m
g 
p
ro
te
in
0 1 2 3 4 5 6
0.0
0.5
1.0
1.5 total
activated
time (hours)
m
U
/m
g 
p
ro
te
in
0 1 2 3 4 5 6
0.0
0.5
1.0
1.5
time (hours)
1 10 100 1000
0
5
10
15
20
25
[prorenin] (U/L)
m
U
/m
g 
p
ro
te
in
1 10 100 1000
0
5
10
15
20
25
[prorenin] (U/L)
A
B
1 10 100 1000
0
5
10
15
20
25
C
Project1:fig 2 - Fri Oct 09 13:59:38 2009
Book 1.indb   39 14-Oct-2009   15:27:46
Prorenin is the endogenous agonist of the (pro)renin receptor
40
C
ha
pt
er
 3
Prorenin and renin binding kinetics
When VSMCs were incubated with 100 U/L prorenin at 37°C, the level of cell-associated 
total prorenin increased in both control and h(P)RR VSMCs in a time-dependent manner 
(Figure 2A; n=3 for both), plateau levels being reached after 2 hours. Cell-association of 
prorenin resulted in its activation. For both cell types, the levels of cell-associated activated 
prorenin at 6 hours did not differ from those at 4 hours. This suggests that the levels of cell-
associated activated prorenin had reached a plateau after 4 hours. On the basis of these data, 
an incubation period of 4 hours was chosen for all further binding studies. 
 VSMCs bound prorenin in a concentration-dependent manner, both at 4°C (Figure 
2B; n=5) and 37°C (Figure 2C; n=5). Activation of prorenin did not occur at 4°C. The levels 
of cell-associated total prorenin were  ≈3-4-fold higher at 37°C than at 4°C. This suggests that 
prorenin binding at 37°C depends on recycling of membrane receptors and/or intracellular 
receptors.46 In agreement with the latter concept, cell permeabilization increased prorenin 
binding at 4°C 3-4-fold (P<0.05), whereas no change occurred at 37°C (Figure 3; n=5). 
Figure 3. Levels of cell-associated total prorenin in cells permeabilized with 0.2% saponin after their 
incubation at 4°C (left panel) or 37°C (right panel) with 1000 U/L prorenin for 4 hours in the absence 
or presence of 10 mmol/L M6P. Data (mean±SEM of 5 experiments) are expressed as a percentage 
of the total prorenin level without prior permeabilization (dotted line). Open bars, control VSMCs, 
closed bars, h(P)RR VSMCs. *P<0.05 vs. 100%, #P<0.05 vs. control. Please note that, although M6P 
reduced prorenin binding at 37°C but not at 4°C (see also Figure 4), it did not block the effect of 
saponin. This indicates that the majority of the prorenin-binding receptors (M6PR and non-M6PR) 
in this study is located intracellularly. At 4°C, these intracellular receptors can only be reached by 
prorenin after cell permeabilization, whereas at 37°C they are reached equally well with and without 
permeabilization, most likely because at this temperature the receptors cycle between the intracellular 
compartment and the cell surface. 
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Figure 4. A, levels of cell-associated total prorenin or renin after incubation of VSMCs at 4°C or 
37°C with 0-1200 U/L prorenin or renin for 4 hours. B, levels of cell-associated total prorenin or 
renin after incubation of VSMCs at 4°C or 37°C with 0-1200 U/L prorenin or renin for 4 hours in 
the presence of 10 mmol/L M6P. C, M6P receptor (M6PR)-specific binding (calculated from the 
difference between A and B) of total prorenin and renin after incubation of VSMCs at 4°C or 37°C 
with 0-1200 U/L prorenin or renin for 4 hours. Data (mean±SEM of 5 experiments) are expressed 
per mg protein. Open symbols, control VSMCs, closed symbols, h(P)RR VSMCs. *P<0.01, control 
vs. h(P)RR.
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 At 37°C, after incubation with the highest prorenin concentration in the medium 
(1000 U/L), the levels of cell-associated total prorenin were ≈25% higher in h(P)RR VSMCs 
than in control VSMCs (Figure 4A, middle panel; P=0.07). Parallel experiments performed 
in the presence of M6P (Figure 4B) revealed that this difference was not related to the 
M6PR, since a) M6PR-specific prorenin binding (calculated from the difference between 
the levels of cell-associated total prorenin with and without M6P; Figure 4C) was identical 
in both cell types, and b) the difference between the two cell types increased to ≈2-fold 
(P<0.01) in the presence of M6P (Figure 4B, middle panel). Thus, the consequences of 
h(P)RR overexpression could only be observed during M6PR blockade.   
 Importantly, no differences in prorenin binding were observed between the two 
cell types at 4°C (Figure 4A), and binding at this temperature was not significantly affected 
by M6P. Cell permeabilization at 4°C increased prorenin binding to h(P)RR VSMCs in the 
presence of M6P ≈6 times (as compared to ≈2 times in control VSMCs, P<0.05), thereby 
indicating that the majority of the h(P)RRs was located intracellularly (Figure 3). 
 Finally, renin binding at 37°C was identical in both cell types, and equaled 
prorenin binding in control VSMCs. Renin binding involved both M6PR- and M6PR-
independent mechanisms (Figure 4C). Based on these data we conclude that, at least under 
our experimental conditions, renin did not bind to the h(P)RR, and that in the absence of the 
h(P)RR overexpression, renin and prorenin display a similar binding pattern. Apparently, 
only prorenin binds to the h(P)RR in cells expressing this receptor. Using the double 
reciprocal plot approach, assuming that the difference in prorenin binding between control- 
and h(P)RR VSMCs represents prorenin binding to the h(P)RR, the Kd for the binding 
of prorenin to its human receptor was estimated to be 469±131 U/L (or 5.9±1.6 nmol/L). 
The number of h(P)RRs/cell (Bmax) was ≈5000. When calculating the Kd (range 0.5-1.4 
nmol/L, mean 1.1 nmol/L) and Bmax (range 4000-8000 sites/cell, mean ≈7500 sites/cell) 
for the M6P receptor-specific binding, the double reciprocal plot approach yielded identical 
values for renin and prorenin in control and h(P)RR cells. 
 Unexpectedly, on top of 10 mmol/L M6P, neither rat HRP (n=8) nor human HRP 
(n=7) affected prorenin binding, prorenin activation or renin binding in our experimental 
setup (Figure 5A, B). HRP (1 μmol/L) did not affect renin-induced Ang I generation in the 
EKA (data not shown). 
 Despite the increased total prorenin binding to h(P)RR VSMCs at 37°C, the 
level of cell-associated activated prorenin was identical in both cell types (Figure 2). 
Immunoradiometric measurements of renin confirmed this result (data not shown). 
Consequently, the percentage of cell-associated total prorenin that was activated tended to 
be lower in h(P)RR cells (36±11%) than in control cells (50±4%) (P=NS). 
Book 1.indb   42 14-Oct-2009   15:27:47
Binding kinetics of renin and prorenin in rat VSMC’s overexpressing the human (P)RR
43
C
hapter 3
Figure 5. A and B, levels of cell-associated total prorenin, activated prorenin and renin after 
incubation of VSMCs at 37°C with 1000 U/L prorenin or renin for 4 hours in the presence of 
increasing concentrations of rat HRP (rHRP, A) or human HRP (hHRP, B). M6P (10 mmol/L) was 
present in all experiments. Prorenin and renin data (mean±SEM of 7-8 experiments) are expressed 
as a percentage of the levels of total prorenin and renin, respectively, in the absence of HRP. Left 
panels, control VSMCs, right panels, h(P)RR VSMCs. C, medium Ang I levels following a 4-hour 
incubation of VSMCs with 150 nmol/L angiotensinogen and 100 U/L prorenin at 37°C in the absence 
(no treatment) or presence of 1 µmol human HRP. Data are mean±SEM of 3 experiments. Left panels, 
control VSMCs, right panels, h(P)RR VSMCs. *P<0.05 vs. control cells.  
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Angiotensin generation
Figure 6 shows the Ang I and II levels in the medium following incubation of control 
and h(P)RR VSMCs at 37°C with angiotensinogen and prorenin (100 U/L) or renin 
(3, 10 or 30 U/L) for 0, 1 and 4 hours. Levels measured in the absence of angiotensinogen, 
renin or prorenin were at or below the detection limit. With prorenin, the medium Ang I 
levels of h(P)RR VSMCs after 1 hour and 4 hours of incubation were ≈3-fold higher than 
those of control VSMCs (P<0.001, n=4). For Ang II, a similar pattern was observed after 
4 hours, although no significance was reached (P=0.2). Cellular Ang II levels after 4 hours 
of incubation with prorenin + angiotensinogen amounted to 3±1 and 10±2 fmol/well in 
control and h(P)RR VSMCs, respectively (P=NS). This amount corresponds with ≈5% of 
the total amount of Ang II in the medium. Cellular Ang I levels after 4 hours of incubation 
were 7±2 and 19±4 fmol/well (P<0.01). This amount corresponds with <1% of the total 
amount of Ang I in the medium. 
 With renin, the medium Ang I and II levels increased in both cell types in a similar 
manner (n=6). The levels reached after 1 hour of incubation clearly correlated with the renin 
concentration, but this relationship was no longer visible after 4 hours of incubation, due to 
the fact that after that time the angiotensinogen concentration in the medium had become 
too low to sustain the same degree of Ang I generation as after 1 hour of incubation. 
 To evaluate whether expression of the h(P)RR enhanced Ang I generation by 
prorenin and/or renin, experiments were also performed in the absence of cells. Without 
cells, 100 U/L prorenin, 3 U/L renin, 10 U/L renin and 30 U/L renin generated 2.2, 5.4, 17.3 
and 34.5 pmol Ang I/mL per hour (‘Ang I-generating capacity’; mean of 2 measurements 
each). From these data it can be calculated that 1.5±0.2% of prorenin displayed enzymatic 
activity. The first order rate constants for Ang I elimination (kel) were 0.8±0.2 and 0.9±0.2 
min-1, respectively (n=6), in control and h(P)RR cells (data not shown). Using the Ang 
I-generating capacity and the kel, the medium Ang I level during incubation with renin/
prorenin and angiotensinogen was predicted as follows: 
 [Ang I]predicted = [Ang I-generating capacity]/k
el
 x [1-exp(-k
el
 x t]).
 Figure 7 compares the predicted and measured medium Ang I levels after 1 hour of 
incubation. With renin, the predicted Ang I levels were identical to the measured levels. This 
was also the case for prorenin when incubated with control cells. For prorenin incubated 
with h(P)RR cells however, the measured Ang I levels were ≈2 times higher than the 
predicted Ang I levels. Apparently therefore, the presence of the h(P)RR doubled prorenin 
activity.  Human HRP (1 μmol/L) did not affect the amount of Ang I generated by prorenin 
+ angiotensinogen in control or h(P)RR VSMCs (Figure 5C; n=3).  
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Figure 6. Medium Ang I and II levels following incubation of VSMCs with 150 nmol/L angiotensinogen 
and 100 U/L prorenin (A), 3 U/L renin (B), 10 U/L renin (C) or 30 U/L renin (D) at 37°C after 0, 1 and 
4 hours. Data are mean±SEM of 4-6 experiments. Open bars, control VSMCs, closed bars, h(P)RR 
VSMCs. *P<0.001 vs. control cells.  
Ang I Ang II
0 1 4
0
10
20
*pm
ol
/m
L
0 1 4
0.00
0.25
0.50
0.75
0 1 4
0
10
20
p
m
ol
/m
L
0 1 4
0.0
2.5
5.0
7.5
0 1 4
0
10
20
p
m
ol
/m
L
0 1 4
0.0
2.5
5.0
7.5
0 1 4
0
10
20
time (hours)
p
m
ol
/m
L
0 1 4
0.0
2.5
5.0
7.5
time (hours)
renin
10 U/L
renin
30 U/L
A
B
D
C
renin
3 U/L
prorenin
100 U/L
Project1:fig 6 - Fri Oct 09 14:06:38 2009
Book 1.indb   45 14-Oct-2009   15:27:48
Prorenin is the endogenous agonist of the (pro)renin receptor
46
C
ha
pt
er
 3
Figure 7.  A, measured versus predicted medium Ang I levels following a 1-hour incubation of VSMCs 
with 150 nmol/L angiotensinogen and 100 U/L prorenin. B, measured versus predicted medium Ang I 
levels following a 1-hour incubation of VSMCs with 150 nmol/L angiotensinogen and 3, 10 or 30 U/L 
renin. Data are mean±SEM of 4-6 experiments. Left panels, control VSMCs, right panels, h(P)RR 
VSMCs. Please note that only in h(P)RR VSMCs incubated with prorenin, the measured levels were 
in all cases higher than the predicted levels. In all other situations, the measured levels were identical 
or lower than the predicted levels. *, measured level was higher than predicted level in all cases. 
Functional studies
Ang I and II constricted iliac artery segments obtained from 4 control rats in a concentration-
dependent manner (pEC
50 
7.6±0.8 and 7.8±0.5, respectively; E
max
 104±40% and 108±29%, 
respectively; Figure 8A). Ang I and II CRCs in iliac artery segments of 5 h(P)RR transgenic 
rats were indistinguishable (pEC
50
 7.5±0.6 and 7.7±0.4, respectively; E
max
 61±29% and 
96±25%, respectively; Figure 8B) from those in control rats. The contraction induced by 
control h(P)RR
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renin (100 U/L) + angiotensinogen (1 µmol/L) amounted to 41±20% and 28±25% in control 
and h(P)RR transgenic rats, respectively (Figure 8C; P=NS). Aliskiren fully prevented this 
contraction (P<0.01). Renin alone did not exert an effect. The Ang II levels in the organ 
bath fluid at the time of constriction following Ang I application amounted to <5% of the 
Ang I levels. Thus, for a given contraction, the organ bath fluid Ang II levels during Ang I 
exposure were 50-100 times lower than those during Ang II (<0.01). This relates to the fact 
that vasoconstriction is determined by tissue Ang II and not Ang II in the organ bath. 
Figure 8. A and B, contractions of iliac 
arteries obtained from control (A) and 
h(P)RR transgenic (B) rats to Ang I and 
II. Also shown are the contractions versus 
the Ang II levels in the organ bath during 
exposure to Ang I, and contractions 
versus the Ang I and II levels in the organ 
bath during exposure to 100 U/L renin 
(R) + 1 µmol/L angiotensinogen (Aog). 
C, contractions of iliac arteries obtained 
from control and h(P)RR transgenic rats 
following exposure to 100 U/L renin + 1 
µmol/L angiotensinogen in the absence 
(open bars) or presence (closed bars) of 0.1 
µmol/L aliskiren. Data (mean±SEM of 4-5 
experiments) are expressed as a percentage 
of the constriction to 100 mmol/L KCl.
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 A similar pattern might be expected for Ang I in organ bath fluid following the 
application of renin and angiotensinogen, provided that renin generates Ang I at tissue 
sites, e.g., after binding to the (P)RR. However, the organ bath fluid Ang I (and II) levels 
present during the contraction observed following renin and angiotensinogen application 
were identical to the organ bath fluid Ang I (and II) levels present in the organ bath at the 
same level of contraction following Ang I application. This finding argues against the idea 
of receptor-bound renin as a contributor to tissue Ang I generation, both in control- and 
transgenic rats. The organ bath fluid Ang I and II levels in the presence of aliskiren were 
below the detection limit (data not shown).    
DISCUSSION
This study, making use of rat VSMCs overexpressing the h(P)RR, shows that the h(P)RR 
preferentially binds prorenin, and that prorenin binding to this receptor is associated with 
enhanced Ang I generation. Unexpectedly, the previously reported (P)RR antagonist, HRP,50 
did not block prorenin binding or prorenin-induced Ang I generation in h(P)RR VSMCs. 
 Rat VSMCs express M6PRs in comparable quantities (≈7500 sites/cell) as rat 
cardiomyocytes, rat fibroblasts, and human endothelial cells.46, 57 These receptors bind and 
internalize both human renin and prorenin, as confirmed in the present study by the decrease 
in renin and prorenin binding in the presence of M6P. M6PRs largely occur intracellularly 
(in Golgi and endosomes),46 and at 37°C, but not at 4°C, they cycle between the cell surface 
and the intracellular compartment. This explains why M6PR-mediated renin and prorenin 
uptake is particularly apparent at 37°C. Both renin and prorenin bind with high affinity 
(Kd≈1 nmol/L)46, 57 to the M6PR, due to the fact they possess multiple M6P moieties, 
allowing them to interact with both M6P binding sites of the receptor.90
 Excess M6P did not fully suppress renin and prorenin binding. This indicates 
that renin and prorenin also accumulate in VSMCs in a non-specific manner and/or via 
binding to a second, low-affinity receptor, like the rat (P)RR. The lack of effect of the rat 
(P)RR antagonist, rat HRP, argues against the latter. Overexpression of the h(P)RR did 
not affect M6PR-mediated binding of renin or prorenin, but greatly enhanced the M6PR-
independent binding of prorenin at 37°C. The difference vs. non-h(P)RR- expressing cells 
was particularly apparent at high prorenin levels, and the Kd for this non-M6PR binding site 
was estimated to be ≈6 nmol/L. This value is in close agreement with the value calculated by 
Nabi et al. (8.0 nmol/L)60 for the interaction between human prorenin and the recombinant 
h(P)RR, and with the Kd proposed by Nguyen47 for the interaction between the h(P)RR and 
human renin (5.0-7.8 nmol/L). This observation, together with the increased (P)RR protein 
levels in h(P)RR VSMCs (Figure 1), strongly supports the idea that the enhanced prorenin 
accumulation is due to binding to the h(P)RR. Since such binding did not occur at 4°C, it 
appears that the majority of the (P)RRs is not located on the cell surface, but rather present 
intracellularly. Indeed, previous western hybridization studies in cardiomyocytes indicated 
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predominant (P)RR expression in the cytosol/microsome fraction.51 The intracellular 
location of the receptor was not further evaluated in the present study.
 Overexpression of the h(P)RR in VSMCs did not result in a significant increase 
in renin binding. Since several previous studies have already shown that human renin, 
at concentrations of 10-100 nmol/L,47, 91 exerts effects via this receptor, the most likely 
explanation of our observation is that renin binds with lower affinity to the receptor than 
prorenin. Indeed, according to Nabi et al.,60 the Kd of the h(P)RR for renin is 20 nmol/L, 
i.e., 3 times higher than our Kd for prorenin (and also 3-4 times higher than the Kd reported 
by Nguyen et al.).47 Such a high Kd would be in agreement with the fact that even the 
highest renin concentration tested in our experimental setup (1200 U/L or ≈25 nmol/L) 
did not result in clearly distinguishable binding to the h(P)RR. We did not test higher renin 
concentrations, since a renin concentration of 25 nmol/L is already more than 4 orders of 
magnitude above the normal levels of renin in blood plasma (0.5 pmol/L).5 For prorenin, 
the h(P)RR-induced increase in binding became apparent at concentrations of 300 U/L and 
higher. Although the prorenin levels in blood are approximately 10 times higher than those 
of renin, even a prorenin concentration of 300 U/L is still 3 orders of magnitude above the 
normal plasma prorenin levels. Thus, significant prorenin binding to the h(P)RR in vivo 
will most likely only occur at tissue sites where prorenin is produced locally, i.e., in the 
kidney, ovaries, testis, adrenal and eye.19, 23, 92, 93 Studies in the kidney already support the 
idea of such prorenin-induced tissue angiotensin generation.50 The high renin concentrations 
that would be required to induce (P)RR-dependent effects probably also only exist in the 
kidney. 
 Renin binding to the h(P)RR has been reported to induce a 4-fold increase of 
the catalytic efficiency of angiotensinogen-Ang I conversion, whereas prorenin became 
fully activated in a non-proteolytic manner.47 We tested the increased catalytic activity 
of renin by quantifying Ang I and II generation during the incubation of VSMCs with 
angiotensinogen and renin, and during the constriction of rat iliac arteries when exposed to 
renin + angiotensinogen. Both with and without h(P)RR overexpression, Ang I generation 
by soluble renin was sufficient to fully explain the measured Ang I levels. Aliskiren blocked 
this generation, indicating that renin was the only Ang I-generating enzyme. Importantly, 
no evidence was obtained supporting the idea that the renin-induced, Ang II-dependent 
vasoconstriction involved Ang I generation by membrane-bound renin. At the same time, 
the well-established Ang I-II conversion at tissue sites did underlie the vasoconstriction 
induced by Ang I and renin + angiotensinogen.2, 94 
 Ang I and II generation also occurred during incubation of VSMCs with prorenin 
and angiotensinogen. In control VSMCs, this angiotensin generation could be fully 
explained on the basis of the activity of soluble prorenin. This activity is due to the fact 
that the prosegment is capable of unfolding from the enzymatic cleft, in a temperature- and 
pH-dependent manner.15 Under physiological conditions (37°C, pH=7.4), <2% of prorenin 
displays catalytic activity. The 1.5% noted in this study is exactly within this range. 
Book 1.indb   49 14-Oct-2009   15:27:48
Prorenin is the endogenous agonist of the (pro)renin receptor
50
C
ha
pt
er
 3
However, this activity was insufficient to explain the Ang I (and II) levels generated by 
VSMCs expressing the h(P)RR. Since these levels were <2 times higher than the levels 
in the medium of control cells or the levels expected on the basis of the 1.5% activity of 
soluble prorenin, it appears that the presence of the h(P)RR has resulted in a doubling of the 
enzyme’s activity. 
 Previous studies have shown that prorenin binding to the M6PR results in 
internalization of the M6PR-prorenin complex, after which prorenin is rapidly activated 
in a proteolytic manner.46, 56, 57 This conversion to renin did not result in either intra- or 
extracellular angiotensin generation, and therefore it was concluded that the activation step 
was part of a clearance process.57 Indeed, cell-associated renin has been reported to be 
degraded intracellularly without being released back to the medium.46, 56, 57 A significant 
percentage of cell-associated prorenin in the present study was activated (i.e., converted 
to renin), as expected on the basis of the M6PR-mediated internalization and activation 
of prorenin. The level of cell-associated activated prorenin was identical in control and 
h(P)RR VSMCs. This is not surprising in view of the identical number of M6PRs in both 
cell types. Thus, to explain the increased catalytic activity of prorenin in h(P)RR VSMCs, 
a mechanism other than M6PR-mediated proteolytic prorenin-renin conversion is required. 
Since prorenin binding to the (P)RR has been suggested to result in a conformational change, 
allowing prorenin to become enzymatically active in a non-proteolytic manner,47 the most 
likely explanation of our data is that (P)RR binding of prorenin has indeed resulted in non-
proteolytic activation. Unfortunately, cell lysis with triton X-100 (as applied in this study to 
collect cell lysates) destroys the delicate balance between inactive and non-proteolytically 
activated prorenin, thereby not allowing us to demonstrate this concept by EKA. The low 
cellular Ang I levels however, corresponding with <1% of the total amount of Ang I in the 
medium, fully support cell surface Ang I generation. 
 Given the higher affinity of prorenin (vs. renin) for the h(P)RR, it seems reasonable 
to assume that the prosegment facilitates binding, although this is clearly not the only 
binding determinant. Thus, we were surprised to see that even a 1 μmol/L concentration of 
the (P)RR antagonist HRP, which was designed on the basis of the prosegment of human 
prorenin,50 affected neither prorenin binding nor Ang I generation. Apparently, HRP is either 
a relatively weak antagonist, requiring concentrations >1 μmol/L to exert blocking effects 
under our experimental conditions, or the in-vivo angiotensin-reducing effects that have 
been reported previously with this drug50, 62 are exerted in an alternative, as yet unknown 
manner, not (only) involving the (P)RR. 
 In summary, the h(P)RR preferentially binds prorenin, suggesting that this 
inactive precursor of renin is its endogenous agonist. Prorenin binding resulted in Ang I 
generation, most likely because bound prorenin becomes activated non-proteolytically. 
Since binding occurred with low affinity, prorenin levels that are sufficiently high to allow 
(P)RR-dependent angiotensin generation are likely to occur only in tissues that synthesize 
prorenin locally, like the kidney and the adrenal. This could explain why HRP reduced 
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renal but not circulating Ang II in rats in vivo,50 and why h(P)RR overexpression resulted 
in glomerulosclerosis and elevated aldosterone levels.61, 95, 96 The lack of effect of HRP as 
a (P)RR antagonist in the present study warrants further investigations into the binding 
epitopes of prorenin. Finally, renin inhibitors, which are now being introduced in the 
clinical arena, will block the enzymatic activity of non-proteolytically activated prorenin to 
the same degree as that of renin. Therefore, these drugs are expected to suppress prorenin-
induced tissue angiotensin production, particularly under conditions where prorenin levels 
are increased, e.g., in diabetic subjects with microvascular complications83 and during RAS 
blockade.5             
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Chapter 4
Cardiac renin levels are not influenced by the amount of 
resident mast cells
Based on:
Krop M, van Veghel R, Garrelds IM, de Bruin RJ, van Gool JM, van den Meiracker 
AH, Thio M, van Daele PL, Danser, AH. Cardiac renin levels are not influenced by 
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ABSTRACT
To investigate whether mast cells release renin in the heart, we studied renin and prorenin 
synthesis by such cells, using the human mast cell lines HMC-1 and LAD2, and fresh 
mast cells from mastocytosis patients. We also quantified the contribution of mast cells to 
cardiac renin levels in control and infarcted rat hearts. HMC-1 cells contained and released 
angiotensin I-generating activity, and the inhibition of this activity by the renin inhibitor 
aliskiren was comparable to that of recombinant human renin. Prorenin activation with 
trypsin increased angiotensin I-generating activity in the medium only, suggesting release 
but not storage of prorenin. The adenylyl cyclase activator forskolin, the cAMP analogue 
8-db-cAMP and the degranulator compound 48/80 increased renin release, without 
affecting prorenin. Angiotensin II blocked the forskolin-induced renin release. Angiotensin 
I-generating activity was undetectable in LAD2 cells and fresh mast cells. Non-perfused 
rat hearts contained angiotensin I-generating activity, and aliskiren blocked ≈70% of 
this activity. A 30-min buffer perfusion washed away >70% of the aliskiren-inhibitable 
angiotensin I-generating activity. Prolonged buffer perfusion or compound 48/80 did not 
decrease cardiac angiotensin I-generating activity further, nor induced angiotensin I-
generating activity-release in the perfusion buffer. Results in infarcted hearts were identical, 
despite the increased mast cell number in such hearts. In conclusion, HMC-1 cells release 
renin and prorenin, and the regulation of this release resembles that of renal renin. However, 
this is not a uniform property of all mast cells. Mast cells appear an unlikely source of renin 
in the heart, both under normal and pathophysiological conditions. 
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INTRODUCTION
The majority of cardiac angiotensin (Ang) II is produced at tissue sites by conversion of in-
situ synthesized Ang I.1 Yet, the renin required for this angiotensin generation is largely, if 
not completely, derived from the kidney, since after a bilateral nephrectomy, both cardiac 
renin and Ang II decrease to undetectable levels.3, 22, 81 Circulating, kidney-derived renin 
diffuses into cardiac interstitial fluid,56 and/or binds to ‘renin receptors’. In support of this 
concept, the washout of renin from isolated perfused rat Langendorff hearts loaded with 
porcine renin followed a biphasic pattern: an initial, rapid (t
½
<0.5 min) phase representing 
disappearance from the extracellular fluid compartment, and a secondary, slower 
(t
½
≈3-4 minutes) phase, representing disappearance from tissue sites, possibly cell surface 
renin receptors.53 Two of such receptors have recently been identified: the mannose 6-
phosphate receptor (M6PR) and the (pro)renin receptor.46-48, 58 M6PR’s bind  phospho-
mannosylated proteins, including renin and its inactive precursor, prorenin. Binding to such 
receptors is followed by internalization, intracellular proteolytic cleavage of prorenin to 
renin, and subsequent proteolytic/hydrolytic removal or clearance.46 M6PR’s are therefore 
considered to act as clearance receptors for both renin and prorenin. (Pro)renin receptors 
bind renin and prorenin on the cell surface, without resulting in internalization.47, 48
 Recently, the idea of cardiac renin being kidney-derived was challenged. Silver et 
al. provided evidence for the presence of renin in cardiac mast cells, using both the human 
mastocytoma (HMC-1) cell line and frozen tissue sections of buffer-perfused Sprague-
Dawley rat hearts.20 HMC-1 cells contained renin, as demonstrated by immunoblot and 
immunocytochemical analyses, and released Ang I-generating activity following their 
exposure to the mast cell degranulator compound 48/80 (48/80). The human renin inhibitor 
BILA2157 (IC
50
 2.5 nmol/L),97 at a concentration of 100 nmol/L, blocked part of this Ang I-
generating activity. A monoclonal mouse anti-renin antibody recognized renin in mast cells 
in the rat heart. Moreover, in a follow-up study,21 a bolus injection of 48/80 was reported 
to release Ang I-generating activity from Langendorff-perfused guinea pig hearts, and 
a comparable release occurred following exposure of the heart to 20 minutes of global 
ischemia and 30 minutes of reperfusion. BILA2157 not only blocked the Ang I-generating 
activity in the perfusate, but also prevented the norepinephrine overflow and arrhythmias 
occurring after ischemia. Thus, it was concluded that ischemia promotes cardiac angiotensin 
generation by mast cell-derived renin. 
 In the present study, we set out to confirm the renin synthesis and release 
by HMC-1 cells, applying both the selective human renin inhibitor aliskiren (IC
50
 0.6 
nmol/L)98 and immunoradiometric assays making use of monoclonal antibodies that 
recognize renin’s active site.46 We also studied the regulation of mast cell renin release, using 
known stimulators and inhibitors of renal renin release, and we investigated to what degree 
these cells release prorenin. Results obtained in HMC-1 cells were compared with results in 
the mast cell line LAD2 and in primary mast cells isolated from mastocytosis patients.   
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 Finally, we evaluated the washout of endogenous rat renin from the rat heart when 
perfused according to Langendorff, both with and without 48/80, in order to quantify the 
contribution of mast cells to cardiac renin levels. This was done both in control animals 
and animals subjected to myocardial infarction (MI), a procedure known to significantly 
increase the cardiac mast cell number.21, 99
METHODS
Cell culture studies
HMC-1 cells were a kind gift of dr. J.H. Butterfield (Mayo Clinic, Rochester, MN).100 Cells 
were grown in 75 cm2 culture flasks (37ºC, 5%CO
2
) for 7 days using supplemented Iscove’s 
modified Dulbecco’s medium containing 10% heat-inactivated calf serum. Next, the cells 
were separated from the culture medium by centrifugation at 1500 g at room temperature. The 
culture medium was collected and stored at -20ºC, and the cells were resuspended in fresh 
medium at a concentration of ≈5 million cells per mL. Cells (0.5 mL) were then stimulated 
for up to 4 hours with compound 48/80 (20-100 μg/mL; final concentration in medium), the 
β-adrenoceptor agonist isoproterenol (1 nmol/L-1 μmol/L), the adenylyl cyclase activator 
forskolin (50 μmol/L), the membrane-permeable cAMP analogue 8-db-cAMP (1 mmol/L), 
Ang II (1 nmol/L-1 μmol/L), and/or the protein kinase C (PKC) inhibitor chelerythrine 
chloride (0.1-1 μmol/L) at 37ºC.101 All drugs were obtained from Sigma and dissolved in 
water, except forskolin, which was dissolved in DMSO. Cells incubated with vehicle served 
as control. After the stimulation period, cells were separated from the stimulation medium 
by centrifugation at 1500 g, and the medium was collected and stored at -20ºC. The pellet 
was resuspended in lysis buffer (0.2% Triton-X in PBS), and also stored at -20ºC. 
 The human mast cell sarcoma cell line LAD2102 was obtained from NIH (Bethesda, 
USA). Cells were cultured in StemPro 34 with nutrient supplement and 100 ng/mL stem cell 
factor for 7 days. Cells were then centrifuged and medium was collected and stored at -20°C. 
The pellet was resuspended in lysis buffer (≈1 million cells/mL), and also stored at -20°C. 
 Bone marrow aspirates were obtained from 2 women with systemic mastocytosis 
(age 67 and 41). Mast cells were isolated by FACS (FACS Aria, BD Biosciences) on the basis 
of CD117-PE-Cy7 and CD33-PE expression. Cells were resuspended in lysis buffer (≈0.8 
and 0.2 million cells/mL, respectively) and stored at -20°C.  
Animal studies
Ninety-one male Sprague-Dawley rats (Harlan), weighing 300-400 g, were housed in groups 
of 2 or 3 on a 12-hour light-dark cycle. Standard rat chow and water were available ad 
libitum. All experiments were performed according to the regulations of the Animal Care 
Committee of the Erasmus MC, in accordance with the Guiding Principles of the American 
Physiological Society. Sixty rats underwent coronary artery ligation as described before.103 
They were then allowed to recover for 2 weeks. Of the MI animals, 36 rats died within 24 
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hours after coronary ligation, and 1 animal died in the subsequent 2 weeks. Three MI rats 
were excluded from further analysis due to insufficient infarct size. 
Isolated heart studies
Rats were anaesthetised with sodium pentobarbital (60 mg/kg, i.p.). Blood (0.5 mL) was 
collected to measure plasma renin activity. Hearts were rapidly excised, cooled in ice-cold 
Krebs-Henseleit buffer (composition in mmol/L: NaCl 125, KCl 4.7, NaHCO
3
 20, NaH
2
PO
4 
0.43, MgCl
2
 1.0, CaCl
2
 1.3 and D-glucose 9.1; pH 7.4) until contractions stopped, and then 
either frozen in liquid N
2
, or prepared for Langendorff perfusion. Continuously carbogen-
gassed (95% O
2
 / 5% CO
2
) Krebs-Henseleit buffer at 37°C was perfused immediately after 
cannulation of the aorta, at a constant perfusion pressure of 80 mm Hg. A water-filled latex 
balloon was placed in the left ventricle via the left atrium to measure LVP. The volume of 
the balloon was adjusted to achieve a stable left ventricular end-diastolic pressure (LVEDP) 
of 5 mm Hg during initial equilibration, and this volume was maintained throughout the 
experiment. Hearts were paced at 450 beats/min. Coronary flow was measured with an in-
line flow probe (Transonic Systems, Ithaca, NY, USA). After 30 or 120 minutes of buffer 
perfusion, hearts were removed and frozen in liquid N
2
. In a separate series of experiments, 
hearts were perfused with buffer for 30 minutes, and then exposed to a bolus injection of 
compound 48/80 (300 µg in 100 µL Krebs-Henseleit buffer). Coronary effluent was collected 
from 5 minutes before until 5 minutes after the exposure to compound 48/80, and stored at 
-20ºC. Five minutes after the exposure to compound 48/80, hearts were removed and also 
frozen in liquid N
2
. 
Biochemical measurements
Renin and prorenin were measured in medium and cell lysates by enzyme-kinetic assay 
(EKA) and/or immunoradiometric assay (IRMA; Cisbio), using recombinant human renin 
as a control. In order to allow its measurement by EKA or IRMA, prorenin was converted 
to renin by incubating the sample for 72 hours with trypsin-sepharose at 4°C, followed by 
5 min centrifugation at 1300 rpm to remove trypsin-sepharose. This approach yielded the 
same result as prorenin activation via a 48-hour exposure at 4°C to plasmin (0.5 caseinolytic 
U/mL; data not shown). Renin in cardiac tissue and coronary effluent was measured as 
described before, using rat kidney renin and rat plasma renin as a control.53 In short, hearts 
were homogenized in phosphate buffer (1:15, wt:vol), pH 7.4, and dialyzed for 48 hours 
at 4°C against 0.05 mol/L glycine buffer (pH 3.3), followed by a 24-hour dialysis against 
phosphate buffer. This procedure effectively removes all angiotensinase activity. Since the 
levels in coronary effluent were expected to be low, the effluent was concentrated 10-fold 
by centrifugal filtration (Millipore). Finally, to verify the contribution of renin to the Ang 
I-generating activity detected in the EKA, all EKA measurements were repeated in the 
presence of increasing concentrations of the renin inhibitor aliskiren (1 pmol-0.1 mmol/L; 
provided by Novartis Pharmaceuticals, Basel, Switzerland). Detection limits of the EKA 
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and IRMA were 0.05 ng Ang I/mL per hour, and 1 pg renin/mL, respectively, and 1 ng 
Ang I/mL per hour corresponds with 2.6 pg human renin/mL. 
Data analysis
Results are expressed as mean±SEM. IC50 values were calculated as described before.89 
Statistical analysis was performed using one-way ANOVA. P<0.05 was considered 
significant. 
RESULTS
Is HMC-1 cell-derived angiotensin I-generating activity due to renin? 
The Ang I-generating activity of medium incubated without cells was below the detection 
limit of the assay. Cell lysates and medium of 48/80-stimulated cells did contain Ang I-
generating activity. Comparison of these measurements with those by IRMA yielded the 
line of identity (Figure 1, left panel), suggesting that all Ang I-generating activity was due to 
renin. The inhibition curve obtained in the presence of increasing concentrations of aliskiren 
confirmed this view, since the IC
50
 values for Ang I-generating activity in medium and cell 
lysate (0.13±0.04 and 0.18±0.07 nmol/L; Figure 1, right panel) were comparable to that for 
recombinant human renin (IC
50
 0.30 nmol/L). Full blockade of the Ang I-generating activity 
was observed at aliskiren concentrations of 0.1 μmol/L and higher, indicating that renin is 
the only Ang-I generating enzyme present.
Figure 1. Left, comparison of the renin concentration in medium and lysates of HMC-1 cells 
measured by enzyme-kinetic assay (EKA) and immunoradiometric assay (IRMA). For the sake of 
clarity, EKA data in μg Ang I/mL per hour have been converted to ng renin/mL. The regression 
line (log[renin]
EKA
 = 0.96xlog[renin]
IRMA
–0.53, r=0.95) was not significantly different from the line 
of identity. Right, concentration-dependent inhibition of the Ang I-generating activity by aliskiren 
in medium and lysates of 48/80-stimulated HMC-1 cells. Data (mean±SEM of 5 experiments) have 
been expressed as a percentage of the Ang I-generating activity in the absence of aliskiren (‘control’). 
For comparison, results obtained with recombinant human renin are also shown.  
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Prorenin release by HMC-1 cells 
Trypsin treatment increased the renin level in the culture medium, but not in the cell lysates 
or the stimulation medium of 48/80-stimulated cells (Figure 2). This indicates that only 
the culture medium contained prorenin. The stimulation medium of forskolin- (n=9) and 
8-db-cAMP-stimulated (n=4) cells also did not contain prorenin (data not shown). 
Regulation of renin release by HMC-1 cells
48/80 induced renin release into the medium in a concentration-dependent manner (Figure 
2), without significantly lowering the renin levels in the cell lysates. The latter relates to the 
fact that the amount of renin released into the stimulation medium amounted to less than 
10% of the levels in the cell lysates. Ang II and chelerythrine chloride, at concentrations 
up to 1 µmol/L, did not affect the 48/80-induced renin release into the medium, nor did 
these drugs affect renin release by themselves (Figure 3; n=4-5). Forskolin increased renin 
release into the medium to the same degree as 48/80 (Figure 3), and identical results were 
obtained with 8-db-cAMP (renin level in stimulation medium 209±36% of control; n=4). 
Ang II and chelerythrine chloride, both at a concentration of 1 µmol/L, fully prevented the 
forskolin-induced renin release (Figure 3). Isoproterenol, at concentrations up to 1 µmol/L, 
did not affect renin release (n=5, data not shown).
LAD2 and primary mast cells
Renin and prorenin levels were below detection limit in the culture medium and cell 
lysates of LAD2 cells, as well as in the cell lysates of primary mast cells obtained from 2 
mastocytosis patients.
Figure 2. Renin in culture medium (A), stimulation medium (B) and lysates (C) of HMC-1 cells 
before (open bars) and after (black bars) trypsin activation of prorenin. Culture medium represents 
medium obtained from cells cultured for 7 days without stimulators. Stimulation medium represents 
medium of cells stimulated with 48/80 (0, 20 or 100 µg/mL) for 30 minutes. The lysates are derived 
from the 48/80-stimulated HMC-1 cells. Data are mean±SEM of 5 experiments. *P<0.05 vs. before 
trypsin activation, #P<0.05 vs. control. 
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Does renin in the rat heart originate in mast cells?
Non-perfused acidified rat heart homogenates contained Ang I-generating activity, and 
aliskiren blocked ≈70% of this activity at concentrations that fully blocked rat kidney and 
rat plasma renin (Figure 4). The IC
50
 values towards the cardiac, renal and plasma Ang I-
generating activity were, respectively, 0.6±0.2, 0.2±0.1 and 0.2±0.1 µmol/L (P=NS), i.e., 
within the range of the previously published IC
50
 of aliskiren for rat renin (0.1 µmol/L).98 
Buffer perfusion greatly decreased the cardiac Ang I-generating activity, and under those 
conditions the effect of aliskiren, even at high concentrations, was marginal or absent 
(Figure 5, top left panel). 
 Renin-attributable Ang I-generating activity was calculated by subtracting the 
mean Ang I-generating activity in the presence of the 3 highest aliskiren concentrations from 
the Ang I-generating activity without aliskiren. Figure 5 (top right panel) shows that a 30-
min buffer perfusion of the heart reduced the aliskiren-inhibitable (i.e., renin-attributable) 
Ang I-generating activity by >70%. Perfusion for longer periods (120 minutes) did not 
decrease this activity further, nor did exposure to 48/80 affect this activity. In the perfusion 
buffer, Ang I-generating activity was below the limit of detection both during 5 minutes 
before and during 5 minutes after exposure to 48/80. Stimulation with 48/80 reduced 
coronary flow from 8.7±0.6 to 4.4±0.4 mL/min (P<0.01). When performing these studies 
following MI (Figure 5, bottom panels), the results were identical, despite the increased 
mast cell content of the infarcted heart (Figure 6). Stimulation with 48/80 in MI hearts 
reduced coronary flow from 8.2±0.3 to 1.5±0.4 mL/min (P=0.02 vs. control hearts). The 
much larger effect of 48/80 in MI hearts also supports the concept of an increased mast cell 
content in these hearts.99 However, Ang I-generating activity remained below the detection 
limit in the perfusion buffer of the MI hearts, both before and after 48/80 exposure.         
DISCUSSION
This study confirms the observation by Silver et al.20 that HMC-1 cells store and release 
Ang I-generating activity. Although mast cells have been reported earlier to synthesize the 
angiotensinogen-cleaving enzyme cathepsin D,104 our study, making use of the selective 
human renin inhibitor aliskiren (IC
50
 for human cathepsin D: 5 µmol/L)98 and monoclonal 
antibodies that recognize renin’s active site, now demonstrates that renin is the sole contributor 
to the Ang I-generating activity in the lysates and medium of HMC-1 cells. The current 
findings also indicate that activation of the adenylyl cyclase-cAMP pathway stimulates 
renin release from HMC-1 cells, whereas interference with the Ca2+-PKC pathway blocks 
this release. In addition, HCM-1 cells release prorenin in a constitutive manner, without 
storing the inactive precursor of renin intracellularly. Thus, the regulation of (pro)renin 
release in HMC-1 cells is identical to that in other renin-producing cells, including renal 
juxtaglomerular cells and adrenal glomerulosa cells.8, 13, 105 
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Figure 3. Renin release from HMC-1 cells induced by 100 µg/mL 48/80 or 50 µmol/L forskolin, in the 
absence (open bars) or presence of 1 µmol/L angiotensin II (hatched bars) or 1 µmol/L chelerythrine 
chloride (black bars). Data (mean±SEM of 4-10 experiments) are expressed as a percentage of the 
value obtained without the above agonists and antagonists. *P<0.05 vs. control.
Figure 4. Concentration-dependent inhibition of the Ang I-generating activity by aliskiren in rat heart 
homogenates, plasma and kidney extracts (left panel) and the percentage of the Ang I-generating 
activity in these samples that is due to renin (right panel). Data (mean±SEM of 3-8 experiments) 
have been expressed as a percentage of the Ang I-generating activity in the absence of aliskiren 
(‘control’: 9±3, 26±15 and 47617±8918 ng Ang I/ml per hour, respectively). *P<0.05 vs. 100%.
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 Yet, activation of the adenylyl cyclase-cAMP pathway with the non-selective 
β-adrenoceptor agonist isoproterenol did not affect renin release from HMC-1 cells. This 
most likely relates to the mast cell-stabilizing action of β
2
-adrenoceptors,106 which are 
the predominant β-adrenoceptors on mast cells.107 Such an effect would oppose the well-
known β
1
-adrenoceptor-mediated stimulation of renin release. Indeed, mast cell stabilizers 
(e.g., cromolyn and lodoxamide) suppress the release of Ang I-generating activity from mast 
cells.21 
 Furthermore, the mast cell degranulator compound 48/80 enhanced renin release 
from HMC-1 cells, and this effect could not be blocked by activation of the Ca2+-PKC pathway. 
This is probably due to the non-specific action of basic secretagogues like 48/80, involving 
multiple receptors and/or direct intracellular actions.108 Whether mast cell degranulators 
and stabilizers also interfere with renin release by non-HMC-1 cell renin-producing cells is 
currently unknown. 
 Unexpectedly, fresh mast cells obtained from mastocytosis patients and the mast 
cell line LAD2 did not contain or release Ang I-generating activity. Apparently therefore, 
HMC-1 cells are not representative for all mast cells, and thus the proposal that mast cells are 
a source of renin in the heart20 needs to be viewed with care. This proposal also challenges 
the current concept that cardiac renin is strictly kidney-derived. This concept is based on 
the inability to detect renin mRNA at cardiac tissue sites,109, 110 the disappearance of renin 
from the heart after bilateral nephrectomy,3, 22 and the lack of renin synthesis by cardiac 
fibroblasts and myocytes.54, 111 In fact, the majority of cardiac renin disappears within minutes 
when perfusing the heart with a renin-free buffer,53 in full agreement with studies showing 
that cardiac renin is largely confined to the interstitial fluid compartment.55, 71 Obviously, 
some retention may occur at sites that do not readily exchange with the extracellular fluid 
compartment. For instance, M6PR-internalized (pro)renin is cleared intracellularly (with 
a half life of several hours)46, 57 without being released to the extracellular fluid.56, 59 In 
addition, renin stored in mast cell granules would only be released after exposure to a mast 
cell degranulator. 
 To investigate these possibilities, in view of the discrepant findings in 
HMC-1 cells, LAD2 cells and fresh mast cells, we quantified cardiac renin after perfusing 
the rat heart with a renin-free buffer for several hours or following exposure of the heart to 
the mast cell degranulator 48/80. When expressed per g wet weight, non-buffer perfused 
rat hearts contained renin in quantities that were of the same order of magnitude as the 
levels per mL blood plasma. This is identical to the situation in the porcine and human 
heart.3, 65 In our experiments, Ang I-generating activity was measured after acidification 
of the cardiac homogenates. This procedure effectively removes angiotensinases, but also 
activates prorenin.3 We did not attempt to measure Ang I-generating activity without the 
acidification step, and thus the cardiac renin in the present study represents the sum of 
renin and prorenin. However, previous studies have already indicated that the increase 
in Ang I-generating activity of cardiac homogenates after acidification is marginal or 
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Figure 5. Concentration-dependent inhibition of the Ang I-generating activity by aliskiren in heart 
homogenates (left panels) and the cardiac renin levels calculated from these curves (right panels). 
Top, control rats; bottom, MI rats. Data represent non-buffer-perfused rat hearts (0’), and hearts 
that had been buffer-perfused for 30 min (30’), 120 min (120’), or 30 minutes followed by exposure 
to compound 48/80 (30’+ 48/80). Data are mean±SEM of 4-8 experiments. *P<0.05 vs. 0’, #P<0.10 
vs. 0’.
absent, thereby implying that the heart contains predominantly renin and virtually no 
prorenin.3, 65 About 25-30% of the Ang I-generating activity in the cardiac homogenates could 
not be inhibited by aliskiren. Thus, non-renin enzymes like cathepsin D also contributed to 
the Ang I-generating activity in the homogenized rat heart. This has been noted before,111 
but does not necessarily imply that such non-renin enzymes generate Ang I under in-vivo 
circumstances.  
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 As expected, within 30 minutes after the start of buffer perfusion, more than 70% 
of cardiac renin (i.e., aliskiren-inhibitable Ang I-generating activity) disappeared. Longer 
perfusion did not decrease renin further, and exposure to 48/80, at quantities that were 
previously shown to release Ang I-generating activity in the coronary effluent of the isolated 
perfused guinea pig heart,21 neither decreased the cardiac renin content, nor resulted in the 
appearance of detectable renin quantities in the coronary effluent. The cardiac renin content 
after 30 minutes of buffer perfusion amounted to ≈2.0 ng Ang I/g wet weight per hour. 
At an estimated rat heart weight of 1.5 gram, a coronary flow of 5 mL/min, and provided 
that the effluent in our assay was concentrated 10 times, this should have resulted in a 
coronary effluent renin level of 10 x (2.0 x 1.5)/(5 x 5) = 1.2 ng Ang I/mL per hour, had all 
cardiac renin been released within 5 minutes after the exposure of the heart to 48/80. Even 
if only 10% of this cardiac renin had been released, the renin level in the coronary perfusate 
would still have been above the detection limit of our assay. Since this was not the case, we 
conclude that the remaining cardiac renin was neither located in a compartment accessible 
to 48/80 (i.e., storage granules), nor in a compartment that allowed further washout. 
It might have been present in cardiac cells, e.g. after binding to and internalization by 
M6PR’s.46, 57 This finding, in combination with the rapid washout of angiotensinogen from 
cardiac tissue sites (t
½
 <1 minute),53, 112 strongly argues against the possibility of mast cell 
renin contributing to Ang I generation in the isolated rat heart. Such local angiotensin 
generation has been proposed in the isolated perfused guinea pig and mouse heart following 
ischemia and reperfusion (another condition resulting in mast cell degranulation),21 although 
actual measurements of Ang I and II under these conditions were not performed. 
Figure 6. Mast cells (*), stained with toluidine blue,20 in transversal slices of the cardiac left ventricle 
obtained from a control rat (left panel) and a rat that underwent a myocardial infarction 14 days prior 
to the removal of the heart (right panel). Hearts were perfused with Krebs-Henseleit buffer for 30 
minutes, and fixed in 3.5-4% formaldehyde solution. Scale bar = 25 µm. 
* *
*
*
**
**
Book 1.indb   64 14-Oct-2009   15:27:51
Cardiac renin levels are not influenced by the amount of resident mast cells
65
C
hapter 4
 Importantly, 2 weeks following a MI, when mast cells have accumulated at cardiac 
tissue sites (Figure 6),99 the findings on cardiac renin were identical to those in control hearts. 
If anything, renin tended to be lower in MI hearts, and again 48/80 did not induce renin 
release or lower cardiac renin. Nevertheless, the 48/80-induced coronary flow reduction was 
much stronger in infarcted hearts, suggesting that a factor other than renin was massively 
released from mast cells in infarcted hearts, e.g. serotonin.113 However, the identity of this 
factor was not investigated in the present study.       
Perspective
HMC-1 cells synthesize renin and prorenin, but this is not a uniform property of all human 
mast cells. Evidence to support the idea that mast cell-derived renin contributes to cardiac 
angiotensin production in humans is currently lacking, but seems unlikely in view of the 
current study and previous measurements in human heart tissue.65 The present study also 
does not support such contribution in the infarcted rat heart, even though such hearts 
display an enhanced mast cell content.99 This finding opposes observations on mast cell-
derived renin synthesizing Ang I in buffer-perfused guinea pig and mouse hearts following 
ischemia and reperfusion.21 A further complicating factor in the isolated perfused rat heart 
to allow such production would have been the low or undetectable levels of angiotensinogen 
at cardiac tissue sites following buffer perfusion (≈0.4 pmol/mL in interstitial fluid after 30 
minutes of buffer perfusion, i.e. ≈3 orders of magnitude below the levels in blood plasma.53 
Using the equation V = Vmax x [S] / (Km + [S]), where Vmax = 2.0 ng Ang I/g per hour, 
Km = 2400 pmol/mL53 and [S] = 0.4 pmol/mL, it can be calculated that the maximum 
degree of Ang I generation (under the unlikely condition that all cardiac renin had access 
to angiotensinogen) after 30 minutes is 0.3 pg Ang I/g per hour. This is far below the range 
required to result in physiologically relevant angiotensin concentrations. Clearly therefore, 
the role of mast cell-derived renin is unique for the guinea pig and mouse heart, and cannot 
be translated to the rat heart. In addition, the importance of mast cell-derived renin, if any, 
in humans needs to be reconsidered. 
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Chapter 5
Mast cell degranulation mediates bronchial contraction via 
serotonin and not via renin release
Based on:
Krop M, Özünal ZG, Chai W, de Vries R, Bouhuizen AM, Garrelds IM, Danser 
AHJ. Mast cell degranulation mediates bronchoconstriction via serotonin and not 
via renin release. Submitted 2009
Book 1.indb   67 14-Oct-2009   15:27:51
Mast cell degranulation mediates bronchial contraction 
68
C
ha
pt
er
 5
ABSTRACT
To verify the recently proposed concept that mast cell-derived renin facilitates angiotensin 
(Ang) II-induced bronchoconstriction, bronchial rings from male Sprague-Dawley rats were 
mounted in Mulvany myographs, and exposed to the mast cell degranulator compound 48/80 
(300 µg/mL), Ang I, Ang II, bradykinin or serotonin. Both in the absence or presence of the 
renin inhibitor aliskiren (10 µmol/ L), the ACE inhibitor captopril (10 µmol/L), the Ang II 
type 1 (AT
1
) receptor blocker irbesartan (1 µmol/L), the mast cell stabilizer cromolyn (0.3 
mmol/L), the 5-HT
2A/2C
 receptor antagonist ketanserin (0.1 µmol/L) or the α
1
-adrenoceptor 
antagonist phentolamine (1 µmol/L). Bath fluid was collected to verify angiotensin 
generation. Bronchial tissue was homogenized to determine renin and angiotensinogen 
content. Compound 48/80 contracted bronchi to 24±4% of the KCl-induced contraction. 
Ketanserin fully abolished this effect, while cromolyn reduced the contraction to 16±5%. 
Aliskiren, captopril, irbesartan and phentolamine did not affect this response, and the Ang I 
and II levels in the bath fluid after 48/80 exposure were below the detection limit. Ang I and 
II equipotently contracted bronchi. Captopril shifted the Ang I curve ≈10-fold to the right, 
whereas irbesartan fully blocked the effect of Ang II. Bradykinin-induced constriction was 
shifted ≈100-fold to the left with captopril. Serotonin contracted bronchi, and ketanserin 
fully blocked this effect. Finally, bronchial tissue contained low Ang I-forming activity, but 
this could not be blocked by aliskiren, and the bronchial angiotensinogen content was below 
the detection limit. In conclusion, mast cell degranulation results in serotonin-induced 
bronchoconstriction, and is unlikely to involve renin-induced angiotensin generation. 
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INTRODUCTION
Mast cells have been proposed to synthesize and release renin.20 This observation was made 
in the human mastocytoma cell line HMC-1. However, subsequent studies in the mast cell 
line LAD2 and in primary mast cells isolated from mastocytosis patients did not confirm 
such synthesis,114 suggesting that renin synthesis is not a uniform property of mast cells.  
  Recently, the mast cell degranulator compound 48/80, when applied to 
isolated rat bronchial rings, was shown to elicit bronchoconstriction.115 Since both a renin 
inhibitor, BILA2157, and the active metabolite of the angiotensin (Ang) II type 1 receptor 
antagonist losartan, EXP3174, prevented this constriction, it was concluded that angiotensin 
generated by mast cell-derived renin mediated this phenomenon. Indeed, exogenous Ang 
II was capable of constricting isolated rat bronchi. Remarkably however, the level of 
exogenous Ang II that was required to mimic the compound 48/80-induced constrictor 
response amounted to ≈0.1 μmol/L. This is roughly 5 orders of magnitude above the plasma 
levels of angiotensins. Given the well-established kinetics of the renin x angiotensinogen 
reaction,116, 117 where micromolar angiotensinogen levels in blood plasma result in picomolar 
circulating Ang I and II levels,64, 118 the generation of submicromolar concentrations of Ang 
II would require substantial concentrations of angiotensinogen and/or renin. Moreover, mast 
cells contain a wide range of other mediators, e.g., histamine and serotonin, which might 
also induce bronchoconstriction.119 Finally, although BILA2157 is a human renin inhibitor,97 
it also blocks cathepsin D, and thus its antagonizing properties do not necessarily reflect rat 
renin inhibition. In addition, both losartan and its active metabolite EXP3174 have a wide 
range of non-AT
1
 receptor-mediated effects120-124 so that here too, blocking effects cannot 
with 100% certainty be attributed to AT
1
 receptor antagonism. 
 Given these uncertainties, we set out to further investigate the compound 48/80-
induced constriction of rat bronchi. Not only did we study the blocking effects of a renin 
inhibitor (aliskiren), an ACE inhibitor (captopril) and an AT
1
 receptor blocker (irbesartan) 
on the constriction induced by compound 48/80 in rat bronchial rings, but we also verified 
angiotensin generation under these conditions, and determined the renin and angiotensinogen 
content of rat bronchi. 
METHODS 
Animals
Fortyfive male Sprague-Dawley rats (Harlan, The Netherlands), weighing 300-350 g, were 
housed in groups of 2 or 3 on a 12-hour light-dark cycle. Standard rat chow and water were 
available ad libitum. All experiments were performed according to the regulations of the 
Animal Care Committee of the Erasmus MC, in accordance with the Guiding Principles of 
the American Physiological Society. 
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 Lungs were rapidly excised under pentobarbital anesthesia (60 mg/kg i.p.), and 
cooled in ice-cold Krebs solution (composition in mmol/L: NaCl 125, KCl 4.7, NaHCO
3
 20, 
NaH
2
PO
4
 0.43, MgCl
2
 1.0, CaCl
2
 1.3 and D-glucose 9.1; pH 7.4). Bronchi were dissected 
free of parenchymal lung tissue, connective tissue, and fat, and either frozen immediately in 
liquid N
2
, or stored overnight in Krebs solution at 4°C. 
Myograph studies
Following overnight storage, the main bronchi were cut into segments of approximately 
2 mm in length and mounted in Mulvany myographs (J.P. Trading, Aarhus, Denmark) with 
separated 6-mL organ baths containing oxygenated Krebs solution at 37°C. The Krebs 
solution was continuously aerated with 95% O
2
 and 5% CO
2
, and tissue responses were 
measured as changes in isometric force using a Harvard isometric transducer. Resting 
tension was set at 2 mN. Subsequently, tissue was exposed to 100 mmol/L KCl, to determine 
maximum contraction. The segments were then allowed to equilibrate in fresh buffer for 30 
min.
 Segments were incubated for 30 minutes with the renin inhibitor aliskiren 
(10 µmol/L), the AT
1
 receptor blocker irbesartan (1 µmol/L), the ACE inhibitor 
captopril (10 µmol/L), the 5-HT
2A/2C
 receptor antagonist ketanserin (0.1 µmol/L), the α
1
-
adrenoceptor antagonist phentolamine (1 µmol/L) or the mast cell stabilizer cromolyn 
(0.3 mmol/L). Thereafter, concentration-response curves (CRCs) were constructed to 
Ang I, Ang II, bradykinin or methacholine, or the segments were exposed to a single dose 
(300 µg/mL) of the mast cell degranulator compound 48/80. Aliskiren was a kind gift of 
Novartis Pharmaceuticals, Basel, Switzerland. All other chemicals were from Sigma. 
 To measure Ang I and II in organ bath fluid, 50 μL-samples were obtained from 
the organ bath at the time the vasoconstrictor response had reached a plateau. Samples were 
rapidly mixed with 10 µL angiotensinase inhibitor solution89 and stored at  -80°C. 
Tissue preparation
Frozen bronchi from 5 rats were pooled and crushed using a mortar and 1:1 homogenized 
in phosphate buffer (pH 7.4). To convert prorenin to renin, and to remove angiotensinase 
activity,53, 125 homogenates were dialyzed for 48 hours at 4°C against 0.05 mol/L glycine 
buffer (pH 3.3), followed by a 24-hour dialysis against phosphate buffer. 
Biochemical measurements
Ang I-generating activity in bronchial homogenates was measured by incubating the 
acidified samples with excess sheep angiotensinogen in the absence or presence of 10 µmol/
L aliskiren, a concentration that fully blocks rat renin.114 Renin-dependent Ang I generation 
 was defined as the amount of Ang I generation that could be blocked by this concentration of 
aliskiren. The detection limit was 0.20 ng Ang I/g per hour. Angiotensinogen was measured 
in non-acidified homogenates by determining the amount of Ang I generated following 
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exposure of the samples to excess recombinant human renin.53, 125 The detection limit was 
0.1 pmol/g. Ang I and II in organ bath fluid were measured with sensitive radioimmunoassay.2 
The detection limits were 40 and 20 fmol/mL, respectively. 
Data analysis
Data are given as mean±SEM. Contractile responses are expressed as a percentage of the 
maximal contraction to 100 mmol/L KCl. CRCs were analyzed as described earlier126 to 
obtain pEC
50
 (-10log[EC
50
]) values. In the case of Ang I, Ang II and bradykinin, CRCs did 
not always reach a maximum (E
max
) at the highest angiotensin concentration of 1.0 µmol/L. 
In such cases we determined the concentration required to obtain 2.5% of the K+-induced 
contraction (EC
2.5%K+
), in order to calculate the pEC
2.5%K+
 value. Statistical analysis was 
performed by one-way ANOVA, followed by post hoc evaluation (according to Bonferroni). 
P<0.05 was considered significant.
RESULTS
Methacholine constricted bronchial rings in a concentration-dependent manner (pEC
50
 
6.5±0.2) to maximally 215±19% of the constriction to 100 mmol/L KCl (Figure 1; n=5). As 
compared to methacholine, Ang II only modestly constricted bronchial rings (n=9), and no 
clear E
max
 was reached (Figure 1A). This was not due to overnight storage of the bronchial 
rings, since the results in freshly obtained rings were identical (data not shown). The 
constrictor effects of Ang I (n=11) were comparable to those of Ang II, although its potency 
(pEC
2.5%K+
 6.8±0.1 vs. 7.3±0.3) tended to be somewhat lower (Figure 1A). In agreement with 
this lower potency, the Ang II levels in the organ bath following the addition of 1 μmol/L 
Ang I were 0.2±0.1 µmol/L (n=5). Irbesartan fully blocked the effect of Ang II (n=3). 
Figure 1. Effects of methacholine in rat 
bronchial rings. Values are mean±SEM 
of 5 experiments and have been expressed 
as a percentage of the response to 100 
mmol/L KCl. 
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Captopril shifted the Ang I CRC ≈10 fold to the right (pEC
2.5%K+
 5.9±0.4, n=5; P<0.05 vs. 
control). Bradykinin also constricted bronchial rings (pEC
2.5%K+
 6.4±0.3, n=8; Figure 1B), 
and captopril potentiated bradykinin almost 100-fold (pEC
2.5%K+
 8.1±0.3, n=5; P<0.01 vs. 
control). The maximum bradykinin-induced effects were comparable to those of Ang I and 
II.  
 Compound 48/80 constricted bronchial rings to 23.9±4.2% of the constriction to 
100 mmol/L KCl (Figure 3; n=14). None of the applied renin-angiotensin system (RAS) 
blockers affected this constriction (Figure 3; n=6-7), nor did these blockers affect baseline 
tension (data not shown). In agreement with this obseration, the Ang I and II levels in the 
organ bath fluid following exposure to compound 48/80 were below the limit of detection, 
both with and without RAS blockers (n=4-8 for each condition). 
 Cromolyn (n=7) reduced the compound 48/80-induced bronchial constriction, 
whereas ketanserin (n=7) virtually abolished it (Figure 4, left panel). Phentolamine (n=5) 
was without effect. These data indicate that the compound 48/80-induced constriction 
depends on the release of serotonin. We therefore also verified the effect of serotonin. 
Indeed, serotonin constricted bronchial rings to maximally 54.8±17.5% of the constriction 
to 100 mmol/L KCl (Figure 4, right panel; n=6), and ketanserin (n=5) fully prevented this 
effect. By comparing the compound 48/80-induced bronchial constriction with the serotonin 
CRC, it could be estimated that mast cell degranulation had resulted in serotonin levels in 
the order of 0.5 µmol/L. 
Figure 2. Effects of angiotensine (Ang) I and II (A) and bradykinin in rat bronchial rings, in the 
absence and presence of captopril and irbesartan. Values are mean±SEM of 3-11 experiments and 
have been expressed as a percentage of the response to 100 mmol/L KCl.
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Figure 3. Effect of compound 48/80 (300 µg/mL) in rat bronchial rings in the absence or presence 
of aliskiren, captopril or irbesartan. Values are mean±SEM of 6-14 experiments and have been 
expressed as a percentage of the response to 100 mmol/L KCl. 
Figure 4. Effect of compound 48/80 (300 µg/mL, left panel) or serotonin (right panel) in rat bronchial 
rings in the absence or presence of cromolyn, ketanserin or phentolamine. Values are mean±SEM 
of 5-8 experiments and have been expressed as a percentage of the response to 100 mmol/L KCl. 
*P<0.05, #P<0.01 vs. control. 
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 Finally, the Ang I-generating activity in acidified bronchial homogenates was 
1.2±0.4 ng Ang I/g tissue per hour (n=3, representing pooled tissue of 5 rats each). This 
level was unaltered in the presence of 10 µmol/L aliskiren (1.2±0.3 ng Ang I/g tissue per 
hour), indicating that it was not due to renin. The angiotensinogen content of bronchi was 
below detection limit (n=3). 
DISCUSSION
The current study shows that mast cell-derived renin is not involved in the compound 48/80-
induced constriction of rat bronchial rings mounted in organ baths, in contrast to the proposal 
by Veerappan et al..115 First, RAS blockade at 3 levels did not prevent this constriction. This 
was not due to inefficacy of the applied blockers, since, in the same preparation, the ACE 
inhibitor captopril significantly blocked the effects of Ang I and potentiated bradykinin, 
while the AT
1
 receptor blocker irbesartan fully prevented the constrictor effects of Ang II. 
Second, Ang I and II were undetectable in the organ bath fluid after the addition of compound 
48/80, although Ang II did appear in this fluid when Ang I was added. Third, neither renin 
nor angiotensinogen could be detected in bronchial homogenates in physiologically relevant 
amounts, in full agreement with the lack of renin mRNA in lung tissue.127 The low level of 
Ang I-generating activity in these homogenates most likely represented non-renin enzymes 
(e.g., cathepsins) from intracellular sites that are capable of reacting with angiotensinogen, 
but that normally do not see angiotensinogen because they are located intracellularly.3, 111  
 Importantly, the 5-HT
2A/2C
 receptor antagonist ketanserin fully prevented the 
compound 48/80-induced bronchoconstriction. Therefore, it seems more likely that mast 
cell-derived serotonin is responsible for the observed constriction, as has already been 
suggested by Ikawati et al..113 To exclude the possibility that the α
1
-adrenoceptor blocking 
properties of ketanserin were responsible for its effect, we also tested the α
1
-adrenoceptor 
antagonist phentolamine. However, phentolamine did not affect the compound 48/80-
induced constriction. Moreover, exogenous serotonin, like compound 48/80, effectively 
caused bronchoconstriction in a 5-HT
2A/2C
 receptor-dependent manner. Thus indeed, stored 
serotonin, and not renin, induced bronchoconstriction in our experimental setup. The 
serotonin levels reached in our preparation following degranulation appeared to be in the 
order of 0.5 µmol/L.
 What could explain the contradictory results in our study versus that of Veerappan 
et al.?115 It is unlikely to be a methodological issue, since both the contractile response to 
methacholine and the compound 48/80-induced response were identical in the two studies. 
It might therefore relate to the use of BILA2157 and EXP3174 by Veerappan et al.,115 as 
opposed to aliskiren, captopril and irbesartan in the present study. BILA2157 is a human renin 
inhibitor with an IC
50
 for human renin of 2.5 nmol/L.97 At ≈100-fold higher concentrations, 
it also blocks cathepsin D. The IC
50
 of aliskiren for human renin is 0.6 nmol/L,98 and 10.000-
fold higher concentrations are required to also block cathepsin D. For aliskiren, detailed 
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information is available regarding its blocking effects towards rat, mouse and guinea pig 
renin.98, 128 For BILA2157 no such information is available, and one possibility is that this 
drug, particularly in animals, blocks renin less effectively, and/or rather blocks the non-
renin enzyme(s) (e.g., cathepsins) that are known to be released from mast cells.129, 130 
EXP3174, the active metabolite of losartan, is also well-known for mediating AT
1
 receptor-
independent effects.120, 123 In particular, it increases the hKv1.5 current,120 thereby potentially 
counteracting the serotonin-induced inhibition of these channels.131 Such a mechanism could 
underlie the blockade of the compound 48/80-induced bronchoconstriction by EXP3174.
 In conclusion, mast cell degranulation does not result in bronchoconstriction 
via renin release. Isolated bronchial tissue does not contain detectable levels of renin and 
angiotensinogen, and thus the local generation of angiotensin concentrations in the high 
nanomolar (or even low micromolar) range, i.e. the range at which angiotensins exert 
bronchoconstriction (Figure 1), is highly unlikely. This does not mean that locally produced 
angiotensin cannot be a novel therapeutic target in the management of airway disease, as 
suggested by Veerappan et al..115 In fact, ACE inhibitors have recently been reported to 
decrease mortality in subjects hospitalized with a COPD exacerbation.132 Given their strong 
potentiation of bradykinin-induced bronchoconstriction, as also evidenced in the present 
study, further work is needed to sort out the mechanism of this beneficial effect. 
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Chapter 6
Aliskiren accumulates in renin secretory granules and binds 
plasma prorenin
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ABSTRACT
The vascular effects of aliskiren last longer than expected based on its half life, and this renin 
inhibitor has been reported to cause a greater renin rise than other types of renin-angiotensin 
system (RAS) blockade. To investigate whether aliskiren accumulation in secretory 
granules contributes to these phenomena, renin-synthesizing mast cells were incubated 
with aliskiren, washed and exposed to forskolin in medium without aliskiren. (Pro)renin 
concentrations were measured by renin- and prorenin-specific immunoradiometric assays, 
and renin activity was measured by enzyme-kinetic assay. Without aliskiren, the culture 
medium contained predominantly prorenin, the cells exclusively stored renin, and forskolin 
doubled renin release. Aliskiren dose-dependently bound to (pro)renin in the medium and 
cell lysates, and did not alter the effect of forskolin. The aliskiren concentrations required 
to bind prorenin were 1-2 orders of magnitude higher than those needed to bind renin. 
Blockade of cell lysate renin activity ranged from 27±15 to 79±5%, and these percentages 
were identical for the renin that was released by forskolin, indicating that they represented 
the same renin pool, i.e., the renin storage granules. Comparison of renin and prorenin 
measurements in blood samples obtained from human volunteers treated with aliskiren, 
both before and after prorenin activation, revealed that up to 30% of prorenin was detected 
in renin-specific assays. In conclusion, aliskiren accumulates in renin granules, thus 
allowing long-lasting RAS blockade beyond the half life of this drug. Aliskiren also binds 
to prorenin. This allows its detection as ‘renin’, and might explain, in part, the renin rise 
during renin inhibition.  
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INTRODUCTION
Renin inhibitors, like all renin-angiotensin system (RAS) blockers, increase the plasma 
concentration of renin because they attenuate the negative feedback effect of angiotensin 
(Ang) II on renin release.133, 134 Whether they also increase kidney renin is still being 
debated.133-135 The rise in blood plasma has been suggested to be larger than during other 
types of RAS blockade,136 either because the degree of RAS blockade is superior during 
renin inhibition,137 and/or because renin inhibitors increase the half life of renin.138 It 
may also be an artifact, because renin inhibitors ‘activate’ renin’s precursor, prorenin 
(Figure 1).76 This ‘activation’ is due to the fact that the prorenin prosegment is capable of 
unfolding from the enzymatic cleft, in a pH- and temperature-dependent manner, thereby 
resulting in two prorenin conformations: a ‘closed’, inactive form, and an ‘open’ form that 
displays full enzymatic activity.15 Under physiological conditions, <2% of prorenin is in 
the open conformation.48 Renin inhibitors will bind to prorenin in the open conformation. 
Consequently, due to the presence of the renin inhibitor, the inactivation step (i.e., the return 
to the closed conformation) is now no longer possible, and thus, the equilibrium between 
the closed and open conformation will shift into the direction of the open conformation. 
Eventually, depending on the concentration of the inhibitor, a significant proportion of 
prorenin may be open (‘non-proteolytic activation’), allowing its recognition by the active 
site-directed antibodies used in renin assays, despite the fact that the prosegment is still 
present.76, 138, 139
 Unexpectedly, the vascular effects of aliskiren lasted much longer than expected on 
the basis of its circulating half life.140, 141 This could be due to accumulation of aliskiren-bound 
(pro)renin at tissue sites. In fact, long-lasting aliskiren accumulation has been demonstrated 
in the kidney,128 although the exact site of accumulation could not be established. An 
attractive hypothesis is that aliskiren reaches the renin storage sites in juxtaglomerular 
(JG) cells, thus allowing the release of blocked renin even when aliskiren is no longer 
present in blood. Unfortunately, JG cells loose their capacity to store renin when cultured.6 
However, this does not apply to the recently described renin-synthesizing human mast cells 
(HMC-1).20 These cells abundantly store renin, and release prorenin constitutively and renin 
in a regulated manner, thereby closely mimicking the in-vivo characteristics of JG cells.114 
 In the present study, we set out first to investigate aliskiren accumulation in renin 
secretory granules in HMC-1 cells, and second to determine to what degree the renin rise 
in humans post-aliskiren actually represents prorenin. The latter was possible by applying 
to plasma samples of aliskiren-treated volunteers not only the widely applied renin 
immunoreactive assays, but also a specific prorenin immunoreactive assay that is based on 
the recognition of the prosegment.46, 138
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METHODS
Cell culture studies
HMC-1 cells, developed from a patient suffering from mast cell leukemia, were a kind gift of 
dr. J.H. Butterfield (Mayo Clinic, Rochester, MN).20, 100 Cells were seeded in 25-cm2 culture 
flasks at a concentration of 105 cells/mL and cultured for 7 days in 5 mL supplemented 
Iscove’s modified Dulbecco’s medium (IMDM) containing 10% calf serum, in the absence or 
presence of aliskiren (0.1 nmol/L-1 µmol/L, a kind gift of Novartis Pharmaceuticals, Basel, 
Switzerland) and/or 10 mmol/L mannose 6-phosphate (M6P). Next, cells were separated 
from the culture medium by centrifugation at 1500 g for 5 minutes at room temperature. The 
culture medium was collected and stored at -20ºC. The cells were washed in 10 mL ice-cold 
HBSS, centrifuged as described above, and, after removal of the supernatant, resuspended 
in fresh IMDM containing no aliskiren. Cells were then stimulated with the adenylyl 
cyclase activator forskolin (50 μmol/L; Sigma, dissolved in DMSO) or vehicle for 4 hours 
at 37ºC. After the stimulation period, cells were separated from the stimulation medium by 
centrifugation at 1500 g, and the medium was collected and stored at -20ºC. The pellet was 
resuspended in lysis buffer (0.2% Triton-X in PBS), and also stored at -20ºC. 
Human studies
Plasma samples were obtained from 20 healthy subjects on a low-sodium diet (10 mmol 
daily sodium intake) each receiving 3 out of 4 escalating doses of aliskiren (75, 150, 300 or 
600 mg).142 Each subsequent aliskiren dose was given 2 days after the previous dose. 
Biochemical measurements
Renin and prorenin were measured in plasma, medium and cell lysates by enzyme-kinetic 
assay (EKA) and/or immunoradiometric assay (IRMA; Cisbio), using recombinant human 
(pro)renin as a control. In order to allow its measurement by renin IRMA, prorenin 
was activated in a non-proteolytic manner by incubating the sample for 48 hours with 
10 µmol/L aliskiren at 4°C. The renin inhibitor enters the enzymatic cleft in which the 
active site is located, thereby inducing a slow conformational change of the inactive (closed) 
form of the prorenin molecule into the active (open) form (Figure 1). This approach yields 
the same immunoreactive renin levels (‘total renin’) as proteolytic prorenin activation with 
trypsin138 yet without removing the prosegment. In a select set of samples, prorenin was 
also measured on the basis of its prosegment, replacing the 125I-labeled active site-directed 
monoclonal antibody of the Cisbio kit by a prosegment-directed 125I-labeled monoclonal 
antibody (F258-37-B1) in the IRMA (‘prorenin IRMA’). F258-37-B1 is directed against the 
C-terminal part (p20-p43) of the propeptide and does not react (<0.1%) with renin. F258-37-
B1 also does not react (<0.1%) with intact, inactive prorenin.46 However, it does react with 
prorenin after the above treatment of prorenin with aliskiren. Thus, the aliskiren-induced 
non-proteolytic conformational change, causing the propeptide to move to the surface of the 
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molecule, allows the recognition of prorenin by both the active site-directed antibody of the 
Cisbio kit, and the prosegment-directed antibody of the prorenin IRMA. Detection limits 
of the EKA, the renin IRMA and the prorenin IRMA were 0.1 ng Ang I/mL per hour, 1 pg 
renin/mL, and 5 pg prorenin/mL, respectively. Angiotensinogen in cell lysates and medium 
was measured as described before (detection limit 0.1 pmol/mL).54 Protein was measured 
according to Bradford.
Data analysis
Results are expressed as mean±SEM. IC
50
 values were calculated as described before.89 Ang 
I-generating activities obtained in the EKA were converted to renin concentrations based on 
the fact that 1 ng Ang I/mL per hour corresponds with 2.6 pg human renin/mL. Statistical 
analysis was performed using one-way ANOVA. P<0.05 was considered significant. 
Figure 1. Scheme depicting proteolytic and non-proteolytic prorenin activation, the various prorenin 
configurations and the 3 types of assays that were applied in the present study. Classically, prorenin is 
determined by subtracting the renin measurement before prorenin activation from that after prorenin 
activation. The newly developed prosegment assay now allows the detection of prorenin also directly, 
on the basis of its prosegment. The prosegment can only be recognized when prorenin is in the ‘open’ 
conformation. Low temperatures and low pH shift the equilibrium between closed and open prorenin 
into the direction of the latter. A renin inhibitor (RI) is capable of binding to open prorenin, thereby 
preventing its return to the closed conformation. See text for further explanation.
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RESULTS
Cell culture studies
Immunoreactive (pro)renin levels. In the absence of aliskiren, HMC-1 cells contained 
immunoreactive renin (Figure 2A), as measured with the Cisbio renin IRMA. The cellular 
total renin levels (i.e., the immunoreactive renin levels measured by Cisbio renin IRMA 
following prorenin activation) were identical to the immunoreactive renin levels without 
prorenin activation, suggesting that the cells did not store prorenin. Indeed, when using 
a prosegment-directed antibody, no signal was detected in the cell lysates (Figure 2B). 
The medium of non-aliskiren-exposed cells also contained immunoreactive renin. These 
levels increased ≈5-fold after prorenin activation (Figure 2C). This suggests that the cells 
predominantly released prorenin. The prosegment assay data confirmed this view (Figure 
2D).
 Neither the medium, nor the cells contained detectable amounts of angiotensinogen 
(n=4), thus demonstrating that HMC-1 cells cannot generate Ang II independently. 
A 7-day incubation with aliskiren increased the cellular renin levels in a concentration-
dependent manner (Figure 2A). The maximum increase in renin, reached at 1 
µmol/L aliskiren, was ≈4-fold. Prorenin could not be detected in the cells at any of the 
tested aliskiren concentrations (Figure 2B). To investigate the possibility that the aliskiren-
induced rise in cellular renin was due to the re-uptake of medium renin via M6P receptors 
(as part of a clearance process)59 the experiments were repeated in the presence of excess 
M6P. The aliskiren-induced increase in cellular renin (2.8±0.2 fold, n=3) was unaltered 
in the presence of M6P (2.1±0.4 fold, n=3), and M6P did not alter the cellular renin levels 
in the absence or presence of aliskiren (122±22% and 88±14% of the levels without M6P, 
respectively, P=NS vs. 100%). Therefore, the aliskiren-induced increase in cellular renin is 
not due to reuptake of medium renin via M6P receptors.    
 In the medium, aliskiren also increased renin in a concentration-dependent manner 
(Figure 2C). This increase was much larger (maximally ≈20-fold) than that in the cells 
(P<0.01) and unaffected by M6P (data not shown). In parallel with this rise in secreted renin, 
the effect of prorenin activation on medium renin immunoreactivity diminished, until, at 
aliskiren concentrations of 0.1 µmol/L and higher, prorenin activation no longer yielded an 
increase in medium renin immunoreactivity. Yet, the prosegment assay still allowed the 
detection of intact, prosegment-containing prorenin (Figure 2D). This indicates that the 
7-day incubation of the cells with aliskiren had resulted in non-proteolytic activation of 
prorenin, allowing its detection in both the Cisbio renin IRMA and the prosegment assay. 
Apparently, aliskiren concentrations of 0.1 µmol/L and higher were sufficient to fully ‘open’ 
all prorenin molecules in the medium during a 7-day incubation. Since prorenin activation 
in non-aliskiren-exposed cells resulted in a ≈5-fold rise of renin immunoreactivity, the 20-
fold rise in ‘renin’ should be corrected for this detection of prorenin as renin. This implies 
that the true aliskiren-induced rise in medium renin is around 4-fold, i.e., identical to the 
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Figure 2. Levels of immunoreactive renin, total renin (=immunoreactive renin after prorenin activation) 
and prosegment-containing prorenin in the cell lysates (panels A and B) and culture medium (panels 
C and D) of HMC-1 cells following a 7-day incubation in the absence (C) or presence of aliskiren 
(0.1 nmol/L-1 µmol/L). Immunoreactive renin was measured with an antibody directed against 
the active site, while prosegment-containing prorenin was measured with an antibody against the 
prosegment. Data are mean±SEM of n=8. #P<0.05 vs. total renin control; *P<0.05 vs.corresponding 
immunoreactive renin. 
aliskiren-induced rise in cellular renin. Forskolin doubled renin release both in the absence 
and presence of aliskiren (P<0.01; Figure 3). 
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Renin activity. Both cell lysate and culture medium contained Ang I-generating activity in 
the absence of aliskiren, and the activity in the culture medium was ≈10-fold lower than 
that in the cells (Figure 4, top panels). Aliskiren, when incubated for 7 days with the cells, 
did not alter the Ang I-generating activity in the cell lysates. It did however concentration-
dependently reduce the Ang I-generating activity in the culture medium (P<0.01). To 
verify whether aliskiren had been degraded by the cells, Ang I-generating activity was also 
measured in culture medium of control cells (i.e., cells that that had not been incubated with 
aliskiren) after adding aliskiren to the incubation sample. As shown in Figure 4, the aliskiren-
induced inhibition of Ang I-generating activity was identical under both conditions (IC
50
 
3.5±1.2 vs. 1.2±0.4 nmol/L; P=NS). Thus, a 7-day incubation had not degraded aliskiren. 
 Stimulating the cells with forskolin resulted in the appearance of Ang I-generating 
activity in the stimulation medium (Figure 4, lower panel). Applying forskolin after the 7-
day incubation of the cells with aliskiren, revealed a concentration-dependent decrease in 
the released amount of Ang I-generating activity (P<0.05), despite the fact that the forskolin 
studies were performed without adding aliskiren again to the medium. Moreover, when 
incubating the stimulation medium with excess human renin, the Ang I-generating activity 
of this renin was 110±10% of that without stimulation medium (n=5). This indicates that 
the stimulation medium no longer contained aliskiren concentrations capable of blocking 
HMC-1 cell-released renin, i.e., that the wash procedure had effectively removed aliskiren. 
Figure 3. Immunoreactive renin levels in the stimulation medium of HMC-1 cells exposed to 50 
µmol/L forskolin for 4 hours following a 7-day incubation of the cells in the absence (C) or presence 
of aliskiren (0.1 nmol/L-1 µmol/L). Data are mean±SEM of n=5. Forskolin doubled the renin release 
at all aliskiren concentrations (P<0.01).
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Figure 4. Levels of renin activity 
in the cell lysates, culture 
medium and stimulation medium 
of HMC-1 cells following a 
7-day incubation of the cells in 
the absence (C) or presence of 
aliskiren (0.1 nmol/L-1 µmol/L) 
and a subsequent stimulation with 
50 µmol/L forskolin for 4 hours. 
The right panel also shows the 
renin activity of control medium to 
which aliskiren was added during 
the assay (‘aliskiren added’, vs. 
‘aliskiren present’, which represents 
the medium obtained after the 7-day 
incubation with aliskiren). Data are 
mean±SEM of n=5-8.
 The renin activity data should be viewed in the light of the increased immunoreactive 
renin levels during aliskiren exposure. Figure 5 therefore displays the amount of aliskiren-
bound renin (i.e., inhibited renin) as a percentage of the total amount of renin in the cell 
lysate, culture medium and stimulation medium (i.e., 100% x (1 - [Ang I-generating activity 
x 2.6] / [immunoreactive renin])). It then becomes clear that aliskiren has also blocked 
intracellular renin. In fact, the curves for cell lysate renin and renin in the stimulation 
medium (Figure 5, left panels) were identical (P=NS). This demonstrates that they represent 
the same renin pool, i.e., the renin storage granules. 
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 In the culture medium (Figure 5, right panel), a distinction was made between 
renin and prorenin. The prosegment assay data had indicated that the majority of culture 
medium total renin represented prorenin, both without and with aliskiren (Figure 2D). It 
was therefore assumed that, at all aliskiren concentrations, the percentage of total renin that 
represented renin was identical to that in the absence of aliskiren. The Ang I-generating 
activity data were compared with the renin levels that were thus calculated, in order to 
determine the amount of aliskiren-bound renin in the culture medium. The remainder 
of the total renin levels represented prorenin. To also calculate the amount of aliskiren-
bound prorenin, these levels were compared with the amount of prorenin that was directly 
recognized in the renin IRMA because this recognition is based on the aliskiren-induced 
non-proteolytic activation of prorenin, i.e., on the binding of aliskiren to prorenin. As can 
be seen in Figure 5 (right panel), the aliskiren concentrations required to bind prorenin were 
1-2 orders of magnitude higher than the concentrations needed to bind renin.
Human plasma samples
Figure 6 shows the immunoreactive (pro)renin levels in plasma of human subjects treated 
with aliskiren. These values are based on the Cisbio renin IRMA measurements before 
and after prorenin activation. According to these measurements, aliskiren treatment 
increased plasma renin in a dose-dependent manner, and no increases in prorenin occurred. 
If anything, with this assay prorenin even decreased at t=5 hours after the intake of the 
2 highest aliskiren doses. In contrast, when measuring prorenin based on the presence 
of its prosegment (‘true’ prorenin), prorenin increases were observed, which were most 
prominent at 24 hours after the intake of aliskiren. The difference between the 2 prorenin 
measurements became significant at aliskiren doses of 150 mg and higher, and increased with 
each subsequent aliskiren dose. Importantly, the differences were larger at 24 hours than at 
5 hours post-aliskiren, despite the fact that at 24 hours, the aliskiren concentration in blood 
was much lower than at 5 hours (Figure 6). When using the ‘true’ prorenin concentrations 
to recalculate the ‘true’ renin concentrations, by subtracting ‘true’ prorenin from the total 
renin level measured by Cisbio renin IRMA, it became apparent that the Cisbio renin IRMA 
overestimated renin by up to 30%.          
DISCUSSION
This study reveals first that aliskiren accumulates in renin storage sites in renin-synthesizing 
cells, and second that a significant percentage of the in-vivo ‘renin’ rise after aliskiren is in 
fact non-proteolytically activated, intact prorenin. The latter has been suggested before,139 
and our data are the first to demonstrate the dose-dependency of this phenomenon, and to 
suggest that it also occurs in vivo. At low aliskiren doses, direct prorenin measurements 
(based on the detection of the prosegment) yielded results that were identical to the indirect 
prorenin measurements (calculated from the difference between the results of the renin 
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Figure 5. Percentage of (pro)renin 
that is aliskiren-bound in the 
cell lysates, culture medium and 
stimulation medium of HMC-1 cells 
following a 7-day incubation of the 
cells in the absence (C) or presence 
of aliskiren (0.1 nmol/L - 1 µmol/L) 
and a subsequent stimulation with 50 
µmol/L forskolin for 4 hours. Data 
are mean±SEM of n=5-8, and were 
calculated from the measurements 
in Figures 1-3. 
IRMA before and after prorenin activation). However, at aliskiren doses of 150 mg and 
higher, the indirect measurements yielded lower prorenin levels, and prorenin even appeared 
to decrease at 5 hours after the intake of aliskiren. The direct prorenin measurements 
now show that this is incorrect, and that, in fact, prorenin increases after the intake of 
aliskiren. This increase was of modest proportion in comparison with the increase in renin. 
Furthermore, it was most apparent at 24 hours after intake, as opposed to the rise in renin 
that was already maximal at 5 hours. These data are in full agreement with the fact that 
prorenin and renin release occur in a constitutive and regulated manner, respectively, and 
that RAS stimulation predominantly causes a rise in renin.5 
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 The mechanism underlying the underestimation of prorenin when using renin 
IRMAs involves aliskiren-binding to prorenin in the open conformation, thereby preventing 
its return to the closed conformation.138 Only the former conformation will be recognized 
in renin IRMAs, and thus renin will be overestimated and prorenin underestimated when 
using these assays. Under normal physiological conditions, <2% of prorenin is in the 
open conformation, because at 37°C the inactivation step occurs rapidly.76 Since at low 
temperature the equilibrium shifts considerably towards open prorenin, one may argue that 
the observations in this study are, at most, an ex-vivo phenomenon related to frozen storage 
of the samples. However, the aliskiren effect was most apparent at 24 and 48 hours after 
drug intake, and not at 5 hours after intake, when the plasma aliskiren levels are highest 
(and when the largest consequences of this phenomenon, if solely occurring during storage, 
should have occurred). This therefore suggests that the aliskiren binding to prorenin had 
already occurred in vivo. 
 In further support of this concept, aliskiren, when incubated with HMC-1 cells at 
37°C for 7 days, concentration-dependently blocked both renin and prorenin in the medium, 
until at concentrations of 0.1 µmol/L and higher virtually all renin and prorenin had become 
aliskiren-bound. Such aliskiren concentrations do occur in vivo (Figure 6), and thus these 
results are clinically relevant. The concentrations required to fully block prorenin were 
1-2 orders of magnitude higher than the concentrations needed to block renin. This relates 
to the small percentage of prorenin that is in the open conformation at 37°C. Since this 
percentage is higher at lower temperatures, it is much easier to ‘activate’ prorenin with 
aliskiren at 4°C than at 37°C (i.e., to fully shift the equilibrium between the closed and open 
conformation into the direction of the open, renin IRMA-recognisable conformation).138 
Aliskiren-binding to both renin and prorenin stabilizes the molecule, thereby increasing 
their half life by a factor of 2-3.138 This explains why the medium and cellular levels of 
(pro)renin in the present study increased progressively when incubating the cells with 
increasing concentrations of aliskiren. In vivo, interference with the negative feedback loop 
would have been proposed to explain a rise in (pro)renin.134 However, since we were unable 
to demonstrate angiotensinogen synthesis by these cells, this explanation cannot be applied 
here. In fact, incubation with either captopril (10 µmol/L) or the AT
1
 receptor antagonist 
eprosartan (1 µmol/L) for 7 days did not increase renin (n=3, data not shown). 
 Finally, when exposing HMC-1 cells to forskolin after their 7-day incubation with 
aliskiren, the cells released aliskiren-bound renin. Thus, apparently, aliskiren is taken up 
by HMC-1 cells and reaches renin granules. Indeed, it has been suggested in both mast 
cells143 and JG cells144 that early secretory granules have the ability to take up extracellular 
substances, delivered through retrograde transport via early/recycling endosomes and 
surcompassing the Golgi network.6 This is perhaps not surprising considering that the renin 
granules originate as lysosomes.93 Experiments with excess M6P excluded the possibility 
that the cellular uptake of aliskiren represented internalization of aliskiren-bound renin 
from the medium via M6P receptors, which are known clearance receptors for both renin 
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Figure 6. Renin (top panel), prorenin (middle panel) and aliskiren (bottom panel) levels in plasma 
in 20 subjects on a low sodium diet after aliskiren exposure (75-600 mg), measured with the Cisbio 
renin IRMA (‘Cisbio’ (pro)renin)) and/or a prosegment-directed assay (‘true’ (pro)renin)). For doses 
greater than 75 mg, time 0 usually occurred 48 hours post previous dose. Data are mean±SEM. 
#P<0.05 vs. Cisbio (pro)renin; *P<0.01 vs. Cisbio (pro)renin.
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and prorenin.57, 59 In-vivo studies in rats have already indicated that 3 weeks after stopping 
aliskiren treatment, when plasma levels are below the detection limit, the renal tissue levels 
of aliskiren are still well above its IC
50
.128 When combining these data with the present 
results, it seems reasonable to suggest that the renal ‘reservoir’ of aliskiren is in fact the JG 
cell. Thus, these observations might explain why the effects of aliskiren on blood pressure 
and renin activity last for several weeks after stopping treatment.140, 141
PERSPECTIVE 
The cell culture and clinical data in the present study, when combined, convey two important 
messages. First, aliskiren binds intracellularly to stored renin, thus inhibiting the enzymatic 
activity of this enzyme prior to its secretion. The actual presence of aliskiren-bound renin 
in storage granules implies that the effect of the drug will continue even when drug levels 
in blood are low or undetectable (e.g., when a patient does not take his daily dose or when 
treatment has been stopped altogether). This phenomenon might therefore contribute to 
the long-lasting effects of aliskiren after stopping treatment.140, 141  Obviously, since our 
results were obtained in mast cells, future in-vivo studies should now confirm aliskiren 
accumulation in JG cells, e.g., using fluorescently-tagged aliskiren. 
 Second, aliskiren also binds to prorenin. The cell culture data show that the 
concentrations required to accomplish this, at least at 37°C, are higher than those required for 
its binding to renin. Nevertheless, such concentrations do occur in blood during treatment, 
and thus this phenomenon is of clinical relevance. On the one hand, aliskiren-binding 
allows prorenin to be detected as renin in the commercially available renin IRMAs, and 
it thus explains, at least in part, the large rise in renin that has been noted during aliskiren 
treatment.136 Simultaneously, given the tight binding of the molecule, it would allow aliskiren-
bound prorenin to accumulate at tissue sites. Since prorenin, via binding to the (pro)renin 
receptor,47, 48 has been suggested to be a major contributor to tissue angiotensin production, 
this would imply that aliskiren highly efficiently blocks tissue angiotensin generation. Such 
efficient interference with tissue angiotensin generation might for instance explain why the 
effects of aliskiren on renal plasma flow are much bigger than those of other RAS blockers.142 
In view of the long half life of aliskiren-bound prorenin,138 it might also underlie the long-
lasting effects of aliskiren after stopping treatment. 
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Chapter 7
Evaluation of a direct human prorenin assay
Based on:
Krop M, Derkx FHM, de Bruin RJA, van Gool JMG, Day D, Danser AHJ. Evalua-
tion of a direct human prorenin assay. In preparation 2009.
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ABSTRACT
Prorenin measurement requires prorenin-renin conversion by trypsin, thus allowing its 
detection in an active-site-specific immunoradiometric assay (IRMA). Pretreatment of 
prorenin with the renin inhibitor aliskiren induces a conformational change in the prorenin 
molecule, so that it can also be recognized by an antibody directed against the active site, 
although the prosegment is still present. Recently, a direct prorenin assay has been developed 
by Molecular Innovations. It applies an antibody (4B5-E3) against residues 30-43 of the 
prosegment. This assay measures prorenin directly, without requiring trypsin or aliskiren 
pretreatment. Here we applied this kit to 28 human plasma samples, and a comparison 
was made with the indirect prorenin measurements. We also verified whether the antibody 
interferes with prorenin-renin conversion by trypsin. Prorenin generated in CHO cells was 
used as a standard. Trypsin and aliskiren increased the renin levels detected with the renin 
IRMA from 24±7 to 144±31 and 185±37 pg/mL, resp. The prorenin levels calculated from 
these data correlated significantly (P<0.001) with the prorenin levels measured with the new 
prorenin kit. Trypsin reduced the amount of prorenin detected with the new kit by ≈70%. 
Thus, trypsin cleavage, at least in part, occurs at a site that still allows detection by 4B5-
E3. Aliskiren reduced the prorenin levels measured with the new kit by ≈50%, indicating 
that the aliskiren-induced conformational change hampers prosegment recognition by 4B5-
E3. Finally, 4B5-E3, at concentrations >10 nmol/L, reduced the increase in renin observed 
with the renin IRMA after trypsin conversion by ≈50%. However, since it also reduced 
renin detection at baseline by ≈50%, it appears that 4B5-E3 interferes with the binding 
of the active site-directed antibody used in the renin IRMA. In conclusion, the new kit 
allows rapid detection of prorenin, but should be used with care when measuring samples of 
aliskiren-treated patients.  
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 INTRODUCTION
Direct prorenin assays currently do not exist. Yet, there is a need for such assays now that it 
has become clear that prorenin is more than just the inactive precursor of renin.48, 50 Prorenin 
also originates at sites outside the kidney,145, 146 and its levels are particularly elevated in 
diabetes83 and pregnancy.26, 147 Possibly, the elevated levels of prorenin in diabetes function 
as a marker of the microvascular complications of diabetes,148 and thus the determination 
of plasma prorenin levels at an early stage may help to identify subjects who will develop 
nephropathy and/or retinopathy and require preventive treatment. 
 Currently, prorenin can only be measured indirectly, after its conversion to renin, 
by either an enzyme-kinetic assay, detecting angiotensin (Ang) I-generating activity, or 
an immunoradiometric assay, utilizing monoclonal antibodies that recognize renin’s active 
site. Recently, a monoclonal antibody has been developed that recognizes an epitope near the 
putative cleavage site (R
43
L
44
) of prorenin,149 i.e., the site where normally the 43-aminoacid 
prosegment is cut off. According to the manufacturer, this antibody does not detect renin. 
A kit has been developed that makes use of a capture antibody coated on a microtiter plate, 
the above mentioned cleavage site-directed primary antibody and a secondary antibody 
conjugated to horse radish peroxidase. The substrate tetramethylbenzidine (TMB) is used 
for color development at 450 nm, which is directly proportional to the concentration of 
prorenin in the sample. 
 The prorenin prosegment unfolds from the enzymatic cleft in a pH- and 
temperature-dependent manner, thereby resulting in two potential prorenin conformations: 
a ‘closed’, inactive form, and an ‘open’ form that displays full enzymatic activity.15 Under 
physiological conditions, <2% of prorenin is in the open conformation.46, 48, 76 The recently 
introduced renin inhibitors aliskiren binds to prorenin in the open conformation. As a 
consequence, due to the tight binding of the renin inhibitor, the inactivation step (i.e., the 
return to the closed conformation) is now no longer possible, and thus, the equilibrium 
between the closed and open conformation will shift in favor of the open conformation. 
Eventually, depending on the concentration of the inhibitor, a significant proportion of 
prorenin may be open (‘non-proteolytic activation’), allowing its recognition by the active 
site-directed antibodies used in the above-mentioned direct renin assays, despite the fact 
that the prosegment is still present.76, 138, 150 Therefore, the excessive immunoreactive renin 
rise that has been reported to occur following treatment with the renin inhibitor aliskiren136 
may be an assay artifact.151  
 Prorenin levels normally are ≈10-fold higher than those of renin.5 Thus, even if 
only a small percentage of prorenin is in the open conformation, this might result in a 
significant contribution to Ang I generation in enzyme-kinetic assays and/or the recognition 
of prorenin as renin in renin immunoradiometric assays, particularly when samples have 
been frozen and thawed (‘cryoactivation’), i.e., exposed to conditions allowing prorenin to 
obtain its ‘open’ conformation.15, 86
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  In the current investigation, we tested the new prorenin kit, using blood 
samples containing native prorenin, before and after exposure to the renin inhibitor aliskiren, 
and also after treatment with the prosegment-cleaving enzyme trypsin. Furthermore, 
we compared the Ang I-generating activity of blood plasma samples immediately after 
withdrawal with the activity in the same samples after they had been frozen and thawed, to 
evaluate the possibility that cryoactivation of prorenin is responsible for (part) of the Ang 
I-generating in blood samples that have been frozen.  
 
MATERIAL AND METHODS
Plasma samples 
Plasma samples were obtained from 28 hypertensive patients (12 women, 16 men, age 
23-83 years, mean 57 years) and 6 healthy controls (2 women, 4 men; age 23-45 years, 
mean 31 years). Blood was collected in polystyrene tubes containing 6.25 mmol/L EDTA 
(final concentration). The samples were centrifuged at room temperature at 3000 g for 10 
minutes, and plasma was either used immediately or stored at -20°C. None of the patients 
used aliskiren. 
Biochemical measurements
Immunoreactive assays. Prorenin was measured indirectly with the Cisbio kit, and directly 
with the newly developed Molecular Innovations kit. In order to allow its recognition in the 
Cisbio kit, which makes use of an antibody recognizing renin’s active site, prorenin was 
either converted to renin with immobilized trypsin (72 hours at 4°C), or the samples were 
exposed to 10 µmol/L aliskiren for 48 hours at 4°C. The latter procedure effectively converts 
all prorenin into the ‘open’ conformation, and yields identical renin results as trypsin 
treatment. Details of this approach have been described before.138 In accordance with the 
instructions of the Molecular Innovations kit, 100 µL sample was incubated for 30 minutes 
with the capture antibody coated on a microtiter plate while shaking at 300 rpm. Next, the 
wells were washed with 300 µL wash buffer, and 100 µL primary antibody (4B5-E3) was 
added. Following another 30-min incubation at 300 rpm, the wells were washed again with 
3 times 300 µL wash buffer, and incubated for 30 minutes with 100 µL secondary antibody 
at 300 rpm. Then another wash step followed and the amount of secondary antibody was 
determined by incubating the samples for 8 minutes with 100 µL TMB, and determining the 
absorbance at 450 nm after stopping the reaction with 50 µL 1 mol/L H
2
SO
4
. Recombinant 
human prorenin was used a standard, and the detection limit was 10 pg/mL (Figure 1).
Enzyme-kinetic assay. Ang I-generating activity was determined by incubating plasma with 
excess sheep angiotensinogen, either directly or after 18 hours at 37°C, in the presence of 
angiotensinase inhibitors. Imidazole buffer (final concentration 0.1 mol/L) was added to the 
incubation mixture to keep pH at 7.4. 
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Data analysis
Data are expressed as mean±SEM. Statistical significance was tested by one-way ANOVA, 
followed by Bonferroni’s multiple comparison testing. P<0.05 was considered significant.
Figure 1. Typical standard curve obtained with recombinant human prorenin in the Molecular 
Innovations kit. Each data point represents the mean of a duplicate measurement, and has been 
corrected for the absorbance at 450 nm of a blanc not containing prorenin.  
RESULTS
Plasma samples
Incubating human plasma samples containing excess recombinant human prorenin 
(≈10 ng/mL) with trypsin, yielded identical results in the Cisbio assay as incubating these 
samples with aliskiren (Figure 2, left panel; n=3). This confirms that both procedures allow 
full recognition of prorenin in this assay. Results obtained with the Molecular Innovations 
assay in untreated, excess recombinant human prorenin-containing plasma samples were 
identical to those in the Cisbio assay after trypsin or aliskiren treatment (Figure 2, right 
panel; n=3). Furthermore, as expected, trypsin treatment greatly decreased the amount of 
recombinant human prorenin detected with the Molecular Innovations assay in these samples 
(by 95±4%). Importantly, aliskiren exposure also reduced the amount of prorenin detected 
with the Molecular Innovations assay, by 58±4%. Thus, apparently, the conformational 
change induced by the renin inhibitor blocks the recognition of the R
43
L
44
 epitope by the 
monoclonal antibody applied in the new assay. 
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 Results for endogenous prorenin (n=28) in the Molecular Innovations assay were 
comparable to that obtained with recombinant human prorenin (Figure 3): trypsin and 
aliskiren reduced the prorenin levels detected with this assay by 70±4 % and 50±6 %, 
respectively. The renin level detected with the Cisbio assay in the 28 samples was 24±7 pg/
mL. After trypsin and aliskiren treatment this level increased to 144±31 and 185±37 pg/mL, 
respectively. The prorenin levels calculated from the difference amounted to 123±25 and 
161±31 pg/mL, respectively, and correlated significantly with the prorenin levels measured 
in untreated samples with the Molecular Innovations assay (Figure 4).
 Preincubating plasma samples with 10 nmol/L of the prosegment-directed 
monoclonal antibody for 24 hours at 4°C reduced the amount of renin recognized in 
the Cisbio assay following trypsin activation by 55±5 % (Figure 5; P<0.05, n=3). This 
suggests that the antibody blocks prosegment cleavage by trypsin. However, pretreatment 
of recombinant human renin (in buffer) with the monoclonal antibody (100 nmol/L) also 
reduced the amount of renin recognized in the Cisbio assay (by 80%). Thus, the ‘reduction’ 
in prorenin activation reflects interference of the antibody with the Cisbio assay per se 
rather than blockade of prorenin proteolysis by trypsin. Results obtained with the enzyme-
kinetic assay revealed that the presence of the antibody interfered to a lesser extent with the 
enzymatic activity of renin (Figure 5), although renin activity was also reduced by ≈40% at 
100 nmol/L of the monoclonal antibody.     
Figure 2. Detection of excess recombinant human prorenin added to human plasma with either the 
Cisbio renin kit (left panel) or the Molecular Innovations prorenin kit (right panel). Data (mean±SEM 
of n=3) were obtained without pretreatment (control), or after treatment of the sample with aliskiren 
or trypsin. *P<0.01 vs. control
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Figure 3. Prorenin levels in 28 human plasma samples determined with the Molecular Innovations 
kit. Data were obtained without pretreatment (control), or after treatment of the samples with aliskiren 
or trypsin. The bar represents the mean.  
Figure 4. Correlation between the prorenin levels measured indirectly with the Cisbio renin kit using 
either aliskiren- (left panel; n=28, r=0.83, P<0.001) or trypsin-pretreated samples (right panel; 
n=28, r=0.80, P<0.001), with the prorenin levels measured with the Molecular Innovations (MI) kit 
in untreated samples. 
control aliskiren trypsin
1
10
100
1000
[p
ro
re
n
in
] 
(p
g/
m
L
)
Project1:plasma samples graph - Fri Oct 09 14:25:47 2009
10 100 1000
1
10
100
1000
[prorenin]CISBIO pg/mL
[p
ro
re
ni
n]
M
I
pg
/m
L
10 100 1000
1
10
100
1000
[proreninCISBIO pg/mL
figure4.pzf:Layout 1 - Fri Oct 09 14:27:32 2009
Book 1.indb   99 14-Oct-2009   15:27:56
Evaluation of a human prorenin assay
100
C
ha
pt
er
 7
Cryoactivation
When incubating freshly obtained plasma samples, from 6 healthy controls, with excess 
angiotensinogen at 37°C, Ang I generation was linear over time (Figure 6, top left panel). 
Results obtained in the same samples after they had been frozen and thawed were fully 
identical. All samples were also incubated under the same conditions after adding exogenous 
recombinant human renin. Ang I generation by exogenous renin (corrected for the activity 
of endogenous renin) was also linear over time and unaffected by freezing and thawing 
(Figure 6, bottom left panel). However, when performing the assay after the freshly obtained 
or frozen samples had been kept for 18 hours at 37°C (to inactivate open prorenin) the degree 
of Ang I generation was still linear, but lower, both for endogenous and exogenous renin, 
although the difference was significant only for samples that had been frozen and thawed 
(Figure 6, right panels). This appeared to be due to (pro)renin degradation, since the amount 
of total renin (i.e., the sum of renin and prorenin) detected in the plasma samples that had 
been frozen and subsequently exposed to an 18-hour incubation at 37°C amounted to 90±3% 
(no exogenous renin added) and 79±4% (with exogenous renin), respectively, of the level 
measured without incubation at 37°C (data not shown). The total renin half lives calculated 
from these % were 87±15 and 60±11 hours, respectively (P=NS). In contrast, total renin in 
the freshly obtained samples, also following the addition of exogenous renin, did not change 
over the 18 hour-period.    
Figure 5. Immunoreactive renin levels detected with the Cisbio renin kit (left panel) and Ang I-
generating activity determined with the enzyme-kinetic assay (right panel) in human plasma samples 
before and after trypsin treatment in the presence or absence of the antibody 4B5-E3 (10 nmol/L). 
Data (mean±SEM of n=3) are expressed as a percentage of the level in untreated samples. * P<0.05 
vs. no pretreatment (=control); #P<0.05 vs. trypsin alone. 
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DISCUSSION
This study shows that the newly developed prorenin kit allows a rapid and accurate detection 
of prorenin in human plasma samples. Results are comparable to those detected in an indirect 
manner with a renin-specific kit. Unfortunately, aliskiren interferes with the direct prorenin 
assay, lowering the amount of prorenin that can be detected under the conditions of the 
assay. Although this observation may help to obtain a better understanding of the kinetics 
of the non-proteolytic activation of prorenin,152 it is clear that the contribution of aliskiren-
induced prorenin ‘activation’ to the renin surge after aliskiren cannot be determined with 
Figure 6. Ang I-generating activity by endogenous human renin (top panels) in plasma or by exogenous 
recombinant human renin added to these same plasma samples (bottom panels), determined either 
immediately (left panels) or after incubating the samples for 18 hours at 37°C (right panels). Data 
are mean±SEM of n=6, and represent freshly obtained plasma (closed circles) or the same plasma 
after it had been frozen and thawed once (open triangles).  
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this new prorenin kit. 
 Trypsin-treatment reduced the amount of prorenin recognized in the Molecular 
Innovations kit by 70%. The fact that this percentage did not reach 100% suggests that 
trypsin-cleavage of the prosegment may not always occur at the same site, so that a small 
percentage of renin molecules still contain the R
43
L
44
 epitope recognized by the monoclonal 
antibody of the kit. Alternatively, the antibody may also detect correctly-cleaved renin, 
albeit with low affinity. This is evident from the studies showing that high concentrations 
(≥ 10 nmol/L) of the antibody interfere with the direct renin assay and block renin’s enzymatic 
activity. Clearly, since this required high antibody concentrations, and considering that 
renin levels are usually <10% of the levels of prorenin, this phenomenon is unlikely to be a 
problem when measuring prorenin with the new kit in blood plasma. In fact, the prorenin 
levels determined with the new kit tended to be lower than the prorenin levels determined 
indirectly with the Cisbio kit. The opposite should have been true when simultaneously 
detecting renin with the new kit. 
 A true comparison of the two types of prorenin measurement (direct and indirect) 
would ideally rely on the use of the same standard. Only when aliskiren-pretreated, intact 
prorenin could have been detected by the R
43
L
44
 antibody to the same degree as native 
prorenin this would have been possible. Unfortunately, however, this was not the case, 
and thus now in the Molecular Innovations assay we used untreated recombinant human 
prorenin as the standard, and in the Cisbio assay this same prorenin could only be detected 
after its treatment with either aliskiren or trypsin. In an earlier prorenin assay developed by 
us this problem did not exist, since in that assay the antibody that was used recognized the 
aminoacids 20-43 of the prosegment.46, 138, 150 This antibody reacts with aliskiren-pretreated 
prorenin to the same degree as an active site-directed antibody.  
 Finally, we obtained no evidence for prorenin cryoactivation in samples of young 
volunteers that had been frozen and thawed once. Their Ang I-generating activity was identical 
to that in freshly obtained blood samples from the same subjects. Since cryoactivation is a 
reversible process, we had expected Ang I generation to decrease when keeping frozen and 
thawed plasma samples for a long period (18 hours) at 37°C. Although this did occur in such 
samples (and not in freshly obtained samples), it was due to (pro)renin destruction rather 
than prorenin inactivation. Apparently, freezing and thawing results in the activation of 
one or more (pro)renin-cleaving enzymes. The blood samples tested in our cryoactivation 
experiments were obtained from healthy subjects. Their renin and prorenin levels were in 
the normal range. Whether the absence of significant prorenin activation following freezing 
and thawing also holds true for plasma samples of subjects with high prorenin levels (.e.g., 
diabetics with microvascular complications) remains to be determined.  
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SUMMARY
Chapter 1: Introduction and aim
Angiotensin (Ang) II production at tissue sites efficiently allows Ang II to stimulate its 
receptors, with little spillover to blood. In contrast to what was originally thought, not all 
components required to generate Ang II locally are synthesized at tissue sites. In particular, 
renin is not expressed locally at important cardiovascular tissue sites like the  heart and the 
vessel wall. Because renin is indispensible for angiotensin generation, this implies that such 
sites must sequester kidney-derived renin from circulating blood. Alternatively, these tissue 
sites might sequester prorenin, also because the levels of this inactive precursor of renin are 
so much higher than those of renin. 
 The juxtaglomerular (JG) cells of the kidney are the main, if not only source of 
circulating renin. Other anatomical structures like the adrenal gland, the collecting duct, the 
eyes, and the reproductive system synthesize and release prorenin, but do not convert this 
into renin. In contrast, mast cells were recently suggested to release renin. 
 For unknown reasons, diabetes accompanied by microvascular complications 
(nephropathy and retinopathy) is associated with high prorenin levels. It seems reasonable to 
assume that the function of prorenin, if any, depends on its ability to generate angiotensins. 
However, evidence for prorenin-renin conversion outside the kidney is not available. Non-
proteolytic activation of prorenin (i.e., a reversible, conformational change of the prorenin 
molecule allowing prorenin to display activity without undergoing cleavage of the prosegment) 
might provide an alternative. This is favored by low pH (‘acid-activation’, resulting in 
maximally ≈15% of all prorenin molecules being active) and cold (‘cryoactivation’, resulting 
in 100% activation). However, under physiological conditions (pH=7.4 and 37°C), the 
percentage of prorenin molecules displaying activity is <2%, and it is questionable whether 
in-vivo conditions allow a significant increase of this percentage. 
 The discovery of the (pro)renin receptor ((P)RR) has changed this view. This receptor 
binds prorenin with higher affinity than renin, and binding induces a conformational change 
in the prorenin molecule allowing it to display activity (i.e., similar to the changes induced 
by low pH and cold). In addition, at supraphysiological concentrations, prorenin induces 
signaling via this receptor, for instance inducing p42/44 and p38 MAP kinase activation. A 
second receptor capable of binding renin and prorenin is the mannose 6-phosphate receptor 
(M6PR). However, M6PRs, unlike (P)RRs, internalize renin and prorenin, and binding 
to these receptors has now been recognized as a clearance mechanism, not resulting in 
angiotensin generation.
 In the present thesis, the following aims were addressed: 1) to quantify the  amount 
of extrarenal renin/prorenin in the human body and to evaluate the kinetics of renin/prorenin 
binding to their receptor as well as the possibility that this results in angiotensin generation 
at tissue sites; 2) to investigate whether mast cells release renin/prorenin, and whether mast 
cell-derived (pro)renin contributes to cardiac and pulmonary angiotensin generation, both 
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under normal - and pathophysiological conditions; 3) to study two characteristics of renin 
inhibition, i.e., an excessive renin rise and a long-lasting effect, and to evaluate a newly 
designed prorenin kit.
Chapters 2 and 3: Prorenin distribution, binding and activity
In humans, prorenin and renin decrease biphasically after nephrectomy, with a similar half-
life for distribution, but a longer elimination half-life for prorenin. Angiotensins followed the 
disappearance of renin. One-to-two days post-nephrectomy, stable plasma concentrations 
at 5-10% (renin and angiotensins) and 25-30% (prorenin) of the pre-nephrectomy levels 
were reached. These levels were comparable to those in patients who had been anephric for 
years. From the disappearance kinetics it could be calculated that normally ≈90% of kidney-
derived renin and prorenin is present outside the blood compartment. The high prorenin 
levels in anephrics support extrarenal production of prorenin but not renin. The renin levels 
in anephrics correlated strongly with their prorenin levels and, in fact, corresponded with 
the percentage of prorenin that in vitro has a so-called ‘open conformation’ (i.e., displays 
enzymatic activity). This suggests that renin in anephrics is in fact ‘open’ prorenin. 
Haemodialysis nor captopril significantly affected the level of any renin-angiotensin system 
component in anephrics. 
 To study the kinetics of renin and prorenin binding to the (P)RR, vascular smooth 
muscle cells from rats overexpressing the human receptor (h(P)RR) or from their control 
littermates, were incubated with recombinant human renin or prorenin at 4°C and 37°C. 
Incubation at 37°C greatly increased binding, compared to incubation at 4°C, suggesting 
that (pro)renin-binding receptors cycle between intracellular compartments and the cell 
surface in a temperature-dependent manner. Blockade of the M6PR reduced binding by 
approximately 50%. During M6PR blockade, h(P)RR cells bound twice as much prorenin 
as control cells, while renin binding was unaltered. Incubation of h(P)RR (but not control) 
cells with prorenin and angiotensinogen yielded more angiotensin than expected on the 
basis of the activity of soluble prorenin, whereas angiotensin generation during incubation 
of both cell types with renin and angiotensinogen was entirely due to soluble (non-bound) 
renin. The renin-angiotensinogen-induced vasoconstriction of isolated iliac arteries from 
control and transgenic rats was also due to soluble renin only. The recently proposed (P)RR 
antagonist ‘handle region peptide’ (HRP), which resembles part of the prosegment, blocked 
neither prorenin binding nor angiotensin generation. So, the human (P)RR preferentially 
binds prorenin, and such binding results in angiotensin generation, most likely because 
binding allows prorenin activation.
Chapters 3 and 4: Mast cell-derived renin in heart and lungs
Mast cells are cells of the immune system that reside in all tissues. Recently, mast cells were 
suggested to release renin, both in the heart and in the lung. Indeed, when studying cells 
of the human mast cell line HMC-1, we observed that these cells stored renin and released 
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renin and prorenin. Both the degranulator compound 48/80 and activation of the adenylyl 
cyclase - cAMP pathway resulted in renin (but not prorenin) release, whereas Ang II blocked 
this release. These findings fully resemble renin release from renal JG cells. However, in 
LAD2 mast cells, or freshly isolated mast cells from patients with mastocytosis, no evidence 
for storage or release of renin or prorenin was found. Thus renin/prorenin synthesis may not 
be a uniform property of all mast cells.
 Next, we investigated the contribution of mast cells to cardiac renin levels, both 
under control conditions and two weeks after a myocardial infarction (a condition that is 
known to significantly increase the amount of resident mast cells in the heart). Renin was 
measured in the coronary perfusate of isolated perfused rat hearts, as well as in the hearts 
following perfusion. Non-perfused hearts contained Ang I-generating activity, 70% of 
which could be blocked by the renin inhibitor aliskiren. A 30-minutes buffer perfusion 
washed away >70% of the aliskiren-inhibitable Ang I-generating activity. Prolonged buffer 
perfusion or compound 48/80 did not decrease cardiac Ang I-generating activity further, 
nor induced Ang I-generating activity-release in the perfusion buffer. Results in infarcted 
hearts were identical, despite the increased mast cell number in such hearts. 
 In rat main bronchi, mast cell degranulation with compound 48/80 contracted 
bronchi to 24±4% of the KCl-induced contraction. Blockade of the RAS at each level, i.e., 
inhibiting renin with aliskiren, ACE with captopril, or the AT
1
 receptor with  irbesartan, did 
not affect this response. The Ang I and II levels in the bath fluid after 48/80 exposure were 
below the detection limit, and freshly obtained bronchial tissue did not contain detectable 
Ang I-generating activity or angiotensinogen. Yet, Ang I and II equipotently contracted 
bronchi, and captopril shifted the Ang I curve ≈10-fold to the right, whereas irbesartan fully 
blocked the effect of Ang II. Thus, although Ang II is able to constrict bronchi, compound 
48/80 does not result in sufficient Ang II generation to induce bronchoconstriction. 
 Mast cells contain a wide variety of mediators, including serotonin. Serotonin 
was capable of constricting bronchi, and the 5-HT
2A/2C
 receptor antagonist ketanserin fully 
blocked this effect. Importantly, ketanserin also abolished the compound 48/80-induced 
bronchoconstrcition, while mast cell stabilization with cromolyn reduced the constriction to 
16±5% of that of KCl. Therefore, the compound 48/80-induced bronchoconstriction is due 
to the release of serotonin rather than renin, and mast cells are an unlikely source of renin, 
both in the heart and lungs. 
Chapter 5 and 6: Renin inhibition and the measurement of renin and prorenin 
The vascular effects of the human renin inhibitor aliskiren last much longer than expected 
based on its half life, and this renin inhibitor has been reported to cause a greater renin 
rise than other types of renin-angiotensin system blockers. To investigate whether aliskiren 
accumulation in secretory granules contributes to these phenomena, renin-synthesizing 
mast cells were incubated with increasing aliskiren concentrations for 7 days, washed and 
exposed to forskolin in medium without aliskiren. 
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 Without aliskiren, the culture medium contained predominantly prorenin, the cells 
exclusively stored renin, and forskolin doubled renin release. Aliskiren dose-dependently 
bound to (pro)renin in the medium and cell lysates, but did not alter the effect of forskolin. 
The aliskiren concentrations required to bind prorenin were 1-2 orders of magnitude higher 
than those needed to bind renin. Blockade of cell lysate renin activity ranged from 27±15 
to 79±5%, and these percentages were identical for the renin that was released by forskolin, 
indicating that they represented the same renin pool, i.e., the renin storage granules. 
Comparison of renin and prorenin measurements in blood samples obtained from human 
volunteers treated with aliskiren, both before and after prorenin activation, revealed that up to 
30% of prorenin was detected in renin-specific assays. In conclusion, aliskiren accumulates 
in renin granules, thus allowing long-lasting renin-angiotensin system blockade beyond the 
half life of this drug. Aliskiren also binds to prorenin. This allows its detection as ‘renin’, 
and might explain, in part, the renin rise during renin inhibition.  
 Direct prorenin measurements would be very helpful to resolve the latter issue. 
We therefore examined a prorenin kit marketed by Molecular Innovations. This kit uses an 
antibody that recognizes the prosegment near the cleavage site. Results obtained with the 
new kit in human plasma samples were comparable to those obtained indirectly (following 
prorenin-renin conversion by trypsin, or after prorenin ‘activation’ by aliskiren) with a 
renin-specific assay. Furthermore, as expected, trypsin treatment greatly decreased the 
amount of prorenin recognized in the Molecular Innovations assay. Surprisingly, aliskiren 
exposure also reduced the amount of prorenin recognized in this assay. This suggests that 
the conformational change induced by the renin inhibitor blocks the recognition of the 
prosegment epitope, and thus that unfortunately, the new kit cannot be used to measure 
prorenin in aliskiren-treated patients. 
 Cryoactivation, as a consequence of the storage and thawing of plasma samples, 
might allow prorenin to contribute to the Ang I-generating capacity of human plasma 
samples. However, the Ang I-generating activity of plasma samples obtained from 6 healthy 
volunteers was identical, irrespective of whether the samples were measured immediately 
after blood withdrawal or after they had been frozen and thawed. Thus, under normal 
conditions, cryoactivation appears to be of no importance. Whether this also holds true 
for plasma samples containing high prorenin levels (e.g., from diabetics with nephropathy 
and/or retinopathy) remains to be proven.  
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GENERAL DISCUSSION
Prorenin distribution, binding and activity
There has been a lot of debate about the function of prorenin, ever since its discovery in 
amniotic fluid. The high prorenin concentrations in diabetics and pregnant women further 
fuelled the discussion. It is reasonable to speculate that the role of prorenin, if any, evolves 
around Ang I generation. Rodents displaying high (inducible) hepatic prorenin expression 
support this view,153, 154 since they were hypertensive, had low renin levels (in agreement 
with the negative feedback of prorenin-dependent Ang II generation on renal renin release) 
and responded to RAS blockade. Moreover, this phenotype did not occur when expressing 
active site-mutated prorenin.153 These animals exhibited no signs of glomerulosclerosis or 
cardiac fibrosis. In sharp contrast, an early rat model with liver-specific prorenin expression 
displayed severe renal lesions and hypertrophic cardiomyocytes in transgenic males only.155 
Renal renin content in these rats decreased, and plasma Ang I-generating activity increased, 
in line with the studies by Mercure et al. and Peters et al..153, 154 Yet, these animals were 
normotensive. Based on this phenotype, it was proposed that prorenin itself is vasculotoxic. 
Whether RAS blockade could prevent this phenomenon has never been tested. 
 Although all three above studies imply that prorenin expression somehow resulted 
in Ang II generation, thereby subsequently suppressing renal renin release, it remains 
unclear whether this is due to the endogenous activity of prorenin, prorenin binding to the 
(P)RR and/or actual prorenin-renin conversion. When considering the first possibility, it 
should be kept in mind that even when <1% of prorenin displays activity, a several 100-
fold rise in prorenin is already sufficient to increase Ang II without the need for prorenin-
activating mechanisms. For instance, assuming that only 0.1% of prorenin displays activity 
under physiological conditions, a prorenin rise of 400-fold155 will increase Ang I generation 
4 times. Careful measurements of renin, prorenin, angiotensinogen and Ang I and II, 
preferably in blood and at the tissue level, are required to sort this out. 
 Reudelhuber’s group has generated mice expressing human prorenin in the liver 
and human human angiotensinogen in the heart. These mice displayed increased cardiac 
(but not plasma) Ang I levels.63 Since the renin-angiotensinogen reaction is highly species-
specific (i.e., mouse renin does not react with human angiotensinogen, and vice versa), this 
approach elegantly demonstrates that apparently human prorenin is taken up in the heart 
and reacts locally with angiotensinogen. Importantly, the same phenomenon occurred when 
expressing a noncleavable variant of prorenin.156 Thus, prorenin’s activity at the tissue level 
did not depend on proteolytic removal of the prosegment. Tissue angiotensin generation by 
prorenin in humans is supported by the correlation between the plasma levels of prorenin 
and the renovascular response to captopril in diabetic subjects.84 
 The (P)RR provides an attractive explanation for tissue Ang I generation by 
intact prorenin, also because it is expressed ubiquitously in heart (coronary arteries47 and 
cardiomyocytes51), brain, placenta, liver47, kidney (renal artery47, mesangial area of the 
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glomeruli and distal renal tubule157), retina158 and monocytes.159 Moreover, prorenin appears 
to be its preferred agonist.48 However, the nanomolar affinity of the human (P)RR for 
prorenin (Kd ≈ 6 nmol/L) does not converge with the picomolar prorenin concentrations in 
plasma, and thus significant receptor binding may only occur when overexpressing prorenin 
(as in transgenic animals) or in organs expressing prorenin locally, like the kidney, eye, 
ovaries and placenta.145 The prorenin concentrations in non-prorenin-synthesizing organs 
(heart, vessel wall) are unlikely to be much higher than those in blood plasma,3, 22 and 
thus a (P)RR-mediated contribution of prorenin to Ang I generation at these sites seems 
unlikely. Nevertheless, a whole range of positive effects with the (P)RR blocker HRP has 
been described in both prorenin-expressing organs (kidney, eye)50, 160-163 and organs that rely 
on (pro)renin uptake (heart).62 
 One possibility to explain these data is that the HRP effects are not due to 
interference with local Ang I generation, but rather represent blockade of the direct, 
angiotensin-independent effects of prorenin mediated via its receptor.95, 164 Among others, 
prorenin stimulates signal transduction cascades resulting in the activation of ERK1/2165 
and p38 MAP kinase,51 and the subsequent release of TGF-β1 and PAI-1.166 Renin appears to 
do the same.159 In view of the latter, it is difficult to understand why HRP (which selectively 
blocks prorenin, since it interferes with binding of the prosegment) would be effective at all, 
particularly in the kidney where renin levels far exceed those of prorenin. Possibly, HRP 
binding induces a conformational change in the receptor, no longer allowing renin (and 
prorenin) to bind.167 This needs to be investigated in detail. 
 To complicate things further, the C-terminal part of the (P)RR is identical to an 
8.9 kDa fragment being associated with vacuolar H+-ATPase.49 Consequently, the second 
name of the receptor is ATP6ap2 (ATPase, H+ transporting, lysosomal accessory protein 2). 
Advani et al. recently reported that renin and prorenin increase vacuolar H+-ATPase activity, 
most likely via activation of the (P)RR.168 Since vacuolar H+-ATPase is a key mediator of 
urinary acidification, this implies that renin and prorenin influence the acidification process. 
This is of particular interest given the relationship between low pH and prorenin activation: 
possibly, the conformational change in the prorenin molecule induced by binding to the 
(P)RR involves vacuolar H+-ATPase activation? Moreover, in cultured collecting duct/
distal tubule lineage Madin-Darby canine kidney cells, both renin and prorenin induced 
ERK1/2 phosphorylation, and the selective vacuolar H+-ATPase inhibitor bafilomycin 
prevented this activation. Apparently, ERK1/2 phosphorylation in these cells depends on 
vacuolar H+-ATPase activity. Given the abundant (P)RR expression in collecting ducts, 
distal convoluted tubules and distal tubules,168 and in view of the recent observation that 
collecting duct principal cells might be the source of prorenin in diabetes,11 future studies 
should now unravel the link between prorenin, its receptor, acidification and ERK1/2 
activation in diabetes. In particular, a role for Ang II should be excluded. Among others, 
prorenin measurements in urine of diabetic patients may help to unravel the contribution of 
locally synthesized prorenin in the kidney.  
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 A further potentially important area of prorenin investigation is pregnancy. 
Although it has been known for >2 decades that pregnant women have high prorenin levels, 
which originate in the ovaries and placenta, it is still unknown why prorenin is synthesized 
at all in the female reproductive tract, also because the regional angiotensinogen levels are 
low.169 Decidual (pro)renin expression has been linked to preeclampsia.33 Does this prorenin 
act in decidua and/or placenta? Do the prorenin levels in amniotic fluid reflect decidual 
prorenin expression? Is there a role for the (P)RR? Is prorenin detrimental only, or does it 
have a protective role, as suggested by Reudelhuber?153
 The highest prorenin concentrations ever (1 µg/mL) were found in gestational sacs 
during the first trimester,37 and thus prorenin and its receptor may have a role in embryonic 
and fetal development. Studies investigating the expression of prorenin, the (P)RR and 
other RAS components in decidua and placenta of normal pregnant women and women 
with preeclampsia will help to address these questions. Importantly, animals knockout for 
either renin,44 angiotensinogen170 or ACE171 are viable, whereas (P)RR knockout animals 
are not.172 This already suggests that the receptor has vital non-RAS-related properties, e.g. 
linked to vacuolar H+-ATPase. Interestingly in this regard, patients with a mutation in their 
ATP6ap2 gene, resulting in an impairment of receptor-induced ERK1/2 phosphorylation 
(but not (pro)renin binding) suffered from X-linked mental retardation and epilepsy, without 
displaying cardiovascular or renal dysfunction.173 
 Finally, furin cleavage results in the generation of a soluble form of the receptor.174 
Although this soluble receptor is present in blood plasma, its concentrations are unknown. 
Thus, studies are required to sort out whether it is present in meaningful amounts, to what 
degree it binds renin/prorenin and what the consequences of such binding are. Possibly, 
the soluble receptor-(pro)renin complex acts as an agonist for an as yet unidentified, new 
receptor.175 Alternatively, binding may alter the kinetics of the renin-angiotensinogen 
reaction.47  
Mast cell-derived renin in heart and lungs 
Mast cells play an important role in cardiovascular disorders, as evidenced by their 
significant increase at cardiac tissue sites after myocardial infarction,99, 176-178 and their 
contribution to plaque progression and destabilization in apolipoprotein E-deficient mice.179 
Stabilization of mast cells180 and the use of mast cell-deficient animals181 diminished left 
ventricular remodeling under pathological conditions. Yet, whether this relates to mast cell-
derived renin and/or chymase remains to be determined. After many years of research, the 
concept that chymase is an important Ang I-II converting enzyme in the heart holds no 
longer.2, 125, 182, 183 Of course, this does not mean that chymase has no role in the heart. 
 Considering the wide range of mediators (proteases, histamine, serotonin, 
cytokines, chemokines and growth factors) released from mast cells,119 it is challenging to 
firmly establish a cause-and-effect relationship of one specific mediator. Not surprisingly 
therefore, many other mast cell-derived components have been linked to  cardiovascular 
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pathology as well: TNF-α, TGF-β1, interleukins, cytokines, and even preformed 
Ang II.184-187 From this perspective, a mast cell stabilizer would be more beneficial than a 
selective blocker of one of the many pathways affected by mast cells-derived mediators.
 Mast cells are also involved in the pathogenesis of asthma. In humans, unlike 
rats, mast cell-derived histamine is a potent bronchoconstrictor. Histamine is thought to 
be mainly involved in the primary reaction to allergic stimuli. Mast cells however are also 
indicated in the late phase inflammation and tissue remodeling.188 Our observation that 
mast cells do not contribute to renin release in the rat bronchi, does not mean that locally 
produced angiotensin II cannot be a novel therapeutic target in the management of airway 
disease, as suggested by Veerappan et al..115  In fact, ACE inhibitors have recently been 
reported to decrease mortality in subjects hospitalized with a COPD exacerbation.132 Given 
their strong potentiation of bradykinin-induced bronchoconstriction, as also evidenced in 
our study, further work is needed to sort out the mechanism of this beneficial effect. At 
least from this perspective, renin inhibitors and/or AT
1
 receptor blockers appear to be more 
attractive drugs to block the pulmonary RAS.
 Our observation that mast cells abundantly store renin, and release prorenin 
constitutively and renin in a regulated manner, reveals that these cells closely mimick 
the in-vivo characteristics of JG cells.114 This contrasts with most other extrarenal renin-
expressing cells, which usually do not store renin and solely release prorenin.145 Given that 
JG cells loose their capacity to store renin when cultured, HMC-1 cells might provide an 
unique alternative, allowing further studies on the enzymes involved in prorenin-renin 
conversion, and on the accumulation of a renin inhibitor in renin granules (for instance by 
using a fluorescently labeled variant of aliskiren). The latter study might be extended to in-
vivo studies to also investigate aliskiren accumulation in JG cells. 
Renin inhibition and the measurement of renin and prorenin
Our studies with aliskiren151 demonstrate that the objections against the use of this drug, 
i.e., a limited effectiveness due to a reactive renin secretion,136 are unfounded. Obviously, 
renin concentrations do rise during aliskiren treatment, as they do during every type of 
RAS blockade. However, the observation that these rises are ‘excessive’ is due biochemical 
phenomena: the detection of prorenin as renin,151 and a prolonged half life of renin (and 
prorenin) following aliskiren binding.138 When correcting for these phenomena the rise is 
unlikely to be as excessive as originally thought. Moreover, the aliskiren levels are high 
enough to suppress renin activity, even when it has increased excessively,189 and no evidence 
was obtained for aliskiren-induced increases in blood pressure. At most, low-renin patients 
appeared to be somewhat resistant to aliskiren.190
 The detection of prorenin as renin in renin immunoradiometric assays appeared to be 
the consequence of aliskiren-binding to prorenin in vivo, i.e., at 37°C. Prolonged incubation 
of prorenin with aliskiren at 37°C in vitro mimicked this observation. These findings support 
the concept of prorenin occurring in 2 conformations: a closed conformation displaying no 
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activity, and an open conformation that can generate Ang I. The latter will bind aliskiren, 
and due to the high affinity of the inhibitor, the inactivation step (i.e., the return to the 
closed conformation) is now no longer possible, so that the equilibrium between the closed 
and open conformation shifts into the direction of the open conformation. Clearly, our data 
support the occurrence of ‘open’ prorenin in humans in vivo. Sensitive prorenin assays, 
allowing a distinction between the open and closed conformation are required to obtain a 
more complete picture. The recently introduced Molecular Innovations assay, which allows 
the rapid detection of intact , closed prorenin, may be of help in this regard.   
 Since low temperature, like aliskiren, shifts the equilibrium between open and 
closed prorenin into the direction of the former, freezing and thawing of plasma samples 
theoretically will cause an increase in the levels of open prorenin, thus increasing the 
Ang I-generating capacity of plasma. However, the Ang I-generating activities in freshly 
obtained and frozen and thawed blood plasma samples (obtained from healthy volunteers) 
were identical. Thus, the impact of this phenomenon is apparently minimal, and it is safe 
to store plasma samples in the freezer before measuring their Ang I-generating activity, 
at least when it concerns plasma containing ‘normal’ prorenin levels. Whether this also 
holds for plasma samples of diabetic patients (containing high prorenin levels) remains to be 
determined. 
 To what degree renin inhibitors differ from other RAS blockers, and if so, whether 
this results in clinically meaningful, additional effects, is still uncertain. Often blockade 
of the (P)RR by aliskiren is put forward. However, aliskiren does not interfere with renin/
prorenin binding to their receptor, nor does it block post-receptor signaling.128, 159, 191 Yet, 
like many agonists, renin and prorenin downregulate their receptor, through interaction 
with the transcription factor promyelocytic zinc finger protein.91, 191 Simultaneously, 
hypertension, Ang II (via AT
1
 receptors) and/or oxidative stress192 upregulate the receptor, 
and thus a complex picture arises in which the receptor may both increase and decrease 
in the face of changing blood pressure- and (pro)renin (and Ang II) levels during RAS 
blockade.128, 192-194 If aliskiren, for a given decrease in blood pressure, causes a larger rise in 
renin/prorenin than ACE inhibitors and AT
1 
receptor blockers, one might predict that the 
receptor downregulation is most prominent during renin inhibition. However, to sort this 
out, (P)RR expression should be studied following treatment with various RAS blockers at 
equi-hypotensive doses.   
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bbreviations
5-HT  5-hydroxy tryptamine or serotonin
8-db-cAMP 8-dibromo-cyclic 3’-5’ adenosine monophosphate
AC  adenylyl cyclase
ACE  angiotensin converting enzyme
ACTH  adrenocorticotrophic hormone 
Ang  angiotensin
ANP  atrial natriuretic peptide; 
ATP  3’,5’ adenosine triphosphate
AT
1/2
R  angiotensin II type 1/2 receptor
cAMP   cyclic 3’,5’-adenosine monophosphate 
cGMP  cyclic 3’,5’-guanosine monophosphate 
CGRP  calcitonin gene-related peptide 
COPD  chronic obstructive pulmonary disease
CRC  concentration response curve
E
max
  maximum effect
EC
50
  concentration where agonist reaches half of maximum effect
EKA  enzyme kinetic assay
ERK  extracellular signal regulated kinase
hCG  human chorionic gonadotropin 
HMC-1  human mastocytoma cell line
HPLC  high pressure liquid chromatography
HRP  handle region peptide
IC
50
   half-maximal inhibitory concentration
IL-1β  interleukin-1β 
IMDM  Iscove’s modified Dulbecco’s medium 
IRMA  immunoradiometric assay
JG  juxtaglomerular 
K
M
  Michealis-Menten constant
LH  luteinizing hormone; 
M6P  mannose-6-phosphate
Nx  anephric subjects
NO  nitric oxide; 
PAI-1  plasminogen activator inhibitor 1
PG  prostaglandin; 
PKC  protein kinase C 
(P)RR  (pro)renin receptor
RAS   renin-angiotensin system
RI  renin inhibitor
[S]  substrate concentration
SD  standard deviation
SEM  standard error of the mean
t
1/2
  half-life
TNF-α  tumor necrosis factor α
V 
(MAX)
  (maximum) velocity
V-ATPase  vacuolar H+-ATPase
VSMC  vascular smooth muscle cell
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Hoofdstuk 1: Introductie en doel
Angiotensine (Ang) II is een hormoon dat een belangrijke rol speelt in de regulering van de 
bloeddruk- en de zouthuishouding. Productie van Ang II vindt vooral plaats in weefsels waar 
zich ook de receptoren voor Ang II bevinden. Echter, niet alle componenten die nodig zijn 
voor lokale Ang II productie worden ook lokaal geproduceerd. Dit geldt zeker voor renine, 
een enzym dat onmisbaar is voor de productie van angiotensines. Dus Ang II productie is 
afhankelijke van circulerend renine, en misschien ook van prorenine, de inactieve precursor 
van renine, die in hoge concentraties in het bloed voorkomt. 
De juxtaglomerulaire cellen in de nier zijn de belangrijkste, en waarschijnlijk 
de enige bron van circulerend renine. Andere organen, zoals de bijnier, de ogen en het 
reproductieve systeem produceren prorenine net als de nier, maar zijn niet in staat om dit 
om te zetten naar actief renine, d.w.z. het verwijderen van het prosegment dat het actieve 
domein van afschermt. Er zijn echter recente aanwijzingen dat mestcellen, ontstekingscellen 
die vooral bekend zijn door productie van histamine bij acute allergische reactie, wel actief 
renine maken.
  Bij diabetes wordt het ontstaan van microvasculaire complicaties, resulterend in 
nier- en oogschade, voorafgegaan door een stijging van de prorenine concentratie in plasma. 
Het is waarschijnlijk dat het effect van prorenine, als het al een effect heeft, afhankelijk is 
van de productie van angiotensines. Prorenine kan non-proteolytisch geactiveerd worden, 
d.w.z. het actieve domein kan blootgelegd worden door een conformatie verandering zonder 
dat het prosegment hiervoor verwijderd hoeft te worden. Dit gebeurt bij lage temperatuur en 
pH, echter, onder fysiologische omstandigheden is het percentage actief prorenine minder 
dan 2%.
 In 2002 werd een receptor gevonden die zowel renine als prorenine kan binden, 
de zgn. (pro)renine receptor, (P)RR . Binding van prorenine aan de receptor zorgt voor een 
verandering naar een actieve conformatie, vergelijkbaar met die veroorzaakt door lage pH en 
temperatuur, waardoor angiotensine vorming mogelijk wordt. Bij extreem hoge concentraties 
(non-fysiologisch) activeert het ook intracellulaire kinases. Er is nog een tweede receptor, de 
mannose-6-fosfaat receptor (M6PR) die ook zowel renine als prorenine bindt. Echter, de 
M6PR zorgt alleen voor internalisatie van renine en prorenine, waarna intracellulair afbraak 
plaatsvindt. Deze receptoren zorgen dus voor klaring (eliminatie) van (pro)renine uit de 
bloedbaan, zonder dat dit resulteert in angiotensine vorming.
In deze thesis werden de volgende doelen gesteld: 1) het kwantificeren van de hoeveelheid 
renine/prorenine in mensen die niet afkomstig is uit de nier, en het bestuderen van de kinetiek 
van renine/prorenine binding aan zijn receptor en de daarmee potentieel samenhangende 
angiotensine vorming in weefsels; 2) te onderzoeken of mestcellen renine/prorenine bevatten, 
en of dit bijdraagt aan angiotensine vorming in het hart en de luchtpijp onder normale 
omstandigheden en tijdens ziekte; 3) de werkingsmechanismen van twee klinische observaties 
bij renine remming onderzoeken, d.w.z. de extreme stijging van renine concentraties in bloed 
en een langdurend aanhoudend klinisch effect in vergelijking met de halfwaardetijd, en ook 
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het evalueren van een nieuwe manier om direct prorenine te meten. 
Hoofdstukken 2 en 3: Prorenine distributie, binding en activiteit
Na het verwijderen van beide nieren verdwijnen renine en prorenine uit het bloed volgens een 
bi-fasisch patroon, met een vergelijkbare distributie halfwaardetijd voor renine en prorenine, 
en een langere eliminatie halfwaardetijd voor prorenine. Angiotensines verdwijnen gelijk 
met de eliminatie van renine. Eén tot twee dagen na het verwijderen van de nieren worden 
stabiele plasma concentraties van 5-10% (renine and angiotensine) en 25-30% (prorenine) 
van het originele niveau bereikt. Deze niveaus zijn vergelijkbaar met die in patiënten die al 
jaren zonder nieren leven (anefrici). Uit deze data kan berekend worden dat ongeveer 90% 
van renine en prorenine afkomstig uit de nier, zich in weefsels bevindt. De hoge prorenine 
concentratie in plasma van anefrici geeft aan dat naast de nier, ook andere organen een 
belangrijke bijdrage leveren aan de hoeveelheid prorenine in het bloed. Er was een sterke 
correlatie tussen de renine en de prorenine concentraties in anefrici; het percentage renine 
correspondeert met het percentage prorenine dat in vitro een actieve conformatie aanneemt. 
Dit suggereert dat renine in anefrici in feite prorenine in de open conformatie is, en dat de 
nier de enige bron van renine is. Zowel hemodialyse, als captopril behandeling had geen 
effect op de renine-angiotensine componenten in anefrici.
 Vasculaire gladde spiercellen van ratten met en zonder de humane prorenine receptor 
(h(P)RR) werden gebruikt om de receptorbinding van renine en prorenine te bestuderen. De 
cellen bonden veel meer humaan renine en prorenine bij 37°C dan bij 4°C. Dit suggereert 
dat de h(P)RR in een temperatuur-afhankelijke manier beweegt tussen intracellulaire 
compartimenten en plasma membraan, en dat de meerderheid van de receptoren zich in 
de cel bevindt. Blokkade van de M6PR reduceerde de binding tot ongeveer 50%. Tijdens 
M6PR blokkade bonden h(P)RR positieve cellen ongeveer twee keer zoveel prorenine als 
controle cellen, terwijl de renine binding niet verschilde tussen h(P)RR en controle cellen. 
Met cellen positief voor de h(P)RR zorgde incubatie met prorenine en angiotensinogeen 
voor meer angiotensine vorming dan verwacht op basis van de activiteit van vrij prorenine, 
in tegenstelling tot controle cellen. Hetzelfde experiment met renine leverde geen verschil 
op in activiteit tussen cellen met en zonder de receptor. De recent geïntroduceerde (P)RR 
antagonist ‘handle region peptide’ (HRP), een peptide dat gelijk is aan het prosegment van 
prorenine, was niet in staat om prorenine binding of angiotensine productie tegen te gaan. 
Dus, de humane (P)RR bindt het liefst prorenine, wat resulteert in angiotensine productie, 
waarschijnlijk omdat binding prorenine activeert. 
Hoofdstukken 3 en 4: Renine uit mestcellen in het hart en de longen
Mestcellen zijn cellen van het immuunsysteem, die aanwezig zijn in alle weefsels. Een 
kenmerk van mestcellen is dat ze een heel scala aan signaalstoffen opslaan, en recent werd 
voorgesteld dat mestcellen ook renine afgeven in zowel het hart als de luchtpijp. De humane 
mestcellijn HMC-1 slaat inderdaad renine op, en geeft zowel renine als prorenine af. Zowel 
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de degranulatie-bevorderende stof compound 48/80 als directe activatie van adenylyl cyclase 
met forskoline resulteerden in afgifte van renine. Dit kon worden geremd door Ang II, wat 
in volledige overeenstemming is met de renine afgifte uit juxtaglomerulaire cellen. Echter, 
in LAD2 mestcellen, en in mestcellen geïsoleerd uit patiënten met mastocytose, werd geen 
renine of prorenine gevonden. Dus renine/prorenine productie is geen uniform kenmerk van 
alle mestcellen.
Ook waren we geïnteresseerd of mestcellen bijdragen aan de renine concentratie in 
het hart, zowel onder normale condities, als na een infarct (wat zorgt voor een toename van 
mestcellen in het hart). Geïsoleerde ratteharten werden geperfuseerd via de kransslagaders, 
en renine werd gemeten in zowel de perfusievloeistof  als in de harten. Niet-geperfuseerde 
harten bevatten Ang I-genererende activiteit, waarvan 70% geblokkeerd kon worden met de 
renine remmer aliskiren. Deze 70% is dus renine, en de andere 30% word veroorzaakt door 
een enzym anders dan renine. Dertig minuten perfusie zorgde ervoor dat minder dan 30% 
van de originele concentratie renine nog aanwezig was. Dit percentage werd niet verlaagd 
door langer perfuseren, of door een bolus injectie met compound 48/80. Ook werd er geen 
Ang I-genererende activiteit gevonden in de perfusie buffer. Resultaten in de harten twee 
weken na een infarct waren identiek, hoewel het aantal mestcellen verhoogd was.
            In rat bronchiën, zorgde mestcel degranulatie met compound 48/80 voor contractie. 
Blokkade van het renine-angiotensine systeem op verschillende niveaus, d.w.z., remming 
van renine met aliskiren, van ACE met captopril of van AT
1
 receptoren met irbesartan, 
beïnvloedde de contractie niet. De Ang I en II concentraties in de badvloeistof waren onder 
detectielimiet, en vers long materiaal bevatte geen detecteerbare Ang I-genererende activiteit 
of angiotensinogeen. Ang I en II waren even potent in bronchoconstrictie, en captopril 
zorgde voor een shift van de Ang I curve, terwijl irbesartan volledig het effect van Ang II 
kon blokkeren. Dus, Ang II zorgt voor bronchoconstrictie, maar compound 48/80 zorgt niet 
voor voldoende Ang II om bronchoconstrictie te veroorzaken. Serotonine, een signaalstof 
die in mestcellen opgeslagen ligt, zorgde ook voor bronchoconstrictie, en de 5-HT
2A/C 
receptor antagonist ketanserine kon dit effect volledig blokkeren. Ketanserine kon ook de 
bronchoconstrictie veroorzaakt door compound 48/80 blokkeren, terwijl mestcelstabilisatie 
met cromoglicinezuur zorgde voor verminderde constrictie. Hieruit concluderen wij dat de 
bronchoconstrictie na compound 48/80 veroorzaakt wordt door serotonine, en niet door renine. 
Mestcellen zijn een onwaarschijnlijke bron van renine in zowel het hart als de longen. 
Hoofdstukken 5 en 6: Renine remming en renine/prorenine metingen
Het bloeddrukverlagende effect van de renine remmer aliskiren houdt langer aan dan verwacht 
werd op basis van de halfwaardetijd. Dit wordt mogelijk veroorzaakt door intracellulaire 
accumulatie van aliskiren in de juxtaglomerulaire cellen waarin renine opslagen ligt. Dit 
werd onderzocht met behulp van de renine-producerende HMC-1 cellen, die 7 dagen aan 
verschillende concentraties aliskiren blootgesteld werden. Daarna werden de cellen gewassen, 
en blootgesteld aan forskoline, wat zorgt voor afgifte van opgeslagen renine. 
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 Zonder aliskiren bevatte het kweekmedium vooral prorenine, lag er alleen renine 
opgeslagen in de cellen, en zorgde forskoline voor een verdubbeling van de renine afgifte. 
Aliskiren bond dosis-afhankelijk aan (pro)renine in het kweek medium en aan intracellulair 
renine, maar had geen effect op forskoline-geïnduceerde renine afgifte. De concentratie 
aliskiren die nodig was voor prorenine binding was tien- tot honderdvoudig die voor renine. 
Remming van de intracellulaire renine activiteit ging van 27±15% naar 79±5%, met oplopende 
concentraties aliskiren, en deze percentages waren identiek voor het renine dat na forskoline 
stimulatie afgegeven werd. Dit geeft aan dat ze uit dezelfde pool afkomstig waren, namelijk 
de intracellulaire opslagplaatsen voor renine.
 Ook zorgt renine remming voor een grotere stijging van de renine concentratie in 
het bloed dan andere renine-angiotensine systeem blokkers. Dit kan komen doordat prorenine 
binding aan aliskiren zorgt voor een conformatieverandering waardoor prorenine door renine-
specifieke antilichamen herkend wordt. Vergelijking van renine en prorenine metingen 
in bloed van vrijwilligers, behandeld met aliskiren, liet zien dat het percentage prorenine 
dat gedetecteerd werd in renine metingen, opliep tot wel 30% bij de hoogste concentratie 
aliskiren. Dus een gedeelte van de verhoogde renine concentratie na aliskiren behandeling, is 
eigenlijk prorenine wat foutief herkend wordt als renine.
 Een manier om dit probleem goed op te lossen is om prorenine direct te meten. 
Daarom evalueerden we een nieuwe prorenine meting die gebruik maakt van een antilichaam 
dat het prosegment van prorenine herkent. Resultaten met deze meting waren vergelijkbaar 
met de indirecte methode (na prorenine-renine conversie met trypsine, of na prorenine 
‘activatie’ met alsikiren) die gebruik maakt van renine-specifieke antilichamen. Zoals 
verwacht, zorgde trypsine behandeling dat prorenine bijna niet meer gedetecteerd werd in 
de directe prorenine assay, maar ook aliskiren behandeling zorgde voor een verminderde 
detectie. Dus de conformatieverandering die aliskiren teweeg brengt in prorenine, zorgt 
ervoor dat het prosegment minder goed herkend wordt door het antilichaam, waardoor de 
nieuwe meting niet geschikt is om prorenine concentraties te meten in patiënten die aliskiren 
gebruiken.  
Prorenine activatie door lage temperatuur (cryo-activatie), na opslag en ontdooien 
van plasma monsters, kan ervoor zorgen dat prorenine bijdraagt aan de Ang I-genererende 
activiteit van plasma. Echter, de Ang I-genererende activiteit in plasma van 6 vrijwilligers 
was identiek na directe meting en na bevriezen en ontdooien van dezelfde monsters. Dus, 
onder normale condities lijkt cryo-activatie niet tot meetbare prorenine activatie te leiden. 
Of dit ook geldt voor plasma monsters met hele hoge prorenine spiegels (zoals aanwezig bij 
diabeten met microvasculaire complicaties) moet nog onderzocht worden.
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